[
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7",
      "CK1\u03b1",
      "IKZF1",
      "W\u0399\u0396",
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "NEK7",
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "potent NEK7-directed MGD",
      "induces selective NEK7 degradation",
      "favorable ADME/DMPK properties"
    ],
    "safety": [
      "No inhibition of hERG",
      "Oral bioavailability"
    ],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1",
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent and Selective VAV1-directed MGD",
      "Induces selective VAV1 degradation",
      "Favorable ADME/DMPK profile"
    ],
    "safety": [
      "IC50 > 30 \u00b5M",
      "EC50 > 30 \u00b5M",
      "> 50%"
    ],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": [
      "CRBN",
      "CUL3",
      "VHL"
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "MRT-2359",
      "MRT-6160",
      "NEK7",
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "MYC-driven Malignancies",
      "Autoimmune Disease",
      "Inflammatory Diseases",
      "Ovarian Cancer",
      "Breast Cancer"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Inflammation"
    ],
    "clinical_phases": [
      "Discovery",
      "IND-Enabling",
      "Clinical"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Keystone2024_FINAL.pdf",
      "slide": 23
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase I"
    ],
    "claims": [
      "optimal PD modulation",
      "clinical activity",
      "favorable tolerability profile"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": "GSPT1",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase I"
    ],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "MYC-driven tumors"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent and Selective GSPT1 Degrader",
      "Induced selective GSPT1 degradation",
      "Favorable ADME/DMPK profile"
    ],
    "safety": [
      "CYP DDIs",
      "hERG inhibition patch clamp",
      "Oral bioavailability all species"
    ],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "Lung NE"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer (NSCLC & SCLC)",
      "DLBCL",
      "high-grade neuroendocrine tumors",
      "N-/L-MYC amplified solid tumors"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Demonstrate dose dependent PK",
      "Demonstrate significant GSPT1 degradation at safe dose levels in PBMCs and tissue biopsies (60% based on preclinical data)",
      "Share potential preliminary efficacy signals in biomarker positive patients"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Observed dose dependent PK after oral dosing",
      "Clinical data support that 0.5 mg starting dose was fully active based on pharmacodynamic (PD) assessment of peripheral blood mononuclear cells (PBMC) and tissue samples from patients, with optimal PD modulation across dose levels tested",
      "Encouraging initial clinical activity at all dose levels: 2 partial responses (PRs) (1 confirmed, 1 unconfirmed) and 1 stable disease (SD) in 6 evaluable, heavily pretreated patients identified with biomarker positive tumors; 1 SD in non-small cell lung cancer (NSCLC) with un-evaluable biomarker status"
    ],
    "safety": [
      "Favorable adverse event (AE) profile at 0.5 and 1 mg",
      "Grade 4 thrombocytopenia identified as dose limiting toxicity (DLT) at 2 mg",
      "No hypotension/cytokine release syndrome or clinically significant hypocalcemia observed at any dose level"
    ],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Dose dependent exposure in line with preclinical PK",
      "No food effect observed",
      "PD modulation in PBMCs observed across all dose levels; level of degradation (~ 60%) in line with maximal degradation observed in preclinical studies using the same method",
      "Level of degradation equivalent across all dose levels, suggesting saturated PD response from 0.5 to 2 mg"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "No observed clinically significant hypocalcemia or hypotension/cytokine release syndrome",
      "Thrombocytopenia",
      "Neutropenia",
      "Leukopenia",
      "Nausea",
      "Vomiting",
      "Diarrhea",
      "Hypokalemia",
      "Fatigue",
      "Decreased appetite",
      "Rash"
    ],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "High Grade Neuroendocrine Bladder Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed PR",
      "PR (-34% per RECIST 1.1)",
      "continued to improve at week 8 (-59% per RECIST 1.1)"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Unconfirmed PR in NSCLC with SCLC/NE Transformation",
      "Resolution of liver metastases (-41% per RECIST 1.1)"
    ],
    "safety": [
      "Frequent dose interruptions due to bowel obstruction unrelated to MRT-2359"
    ],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "bladder carcinoma",
      "NSCLC",
      "SCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "6/15 patients were identified as biomarker positive",
      "2 have experienced a PR (1 confirmed, 1 unconfirmed)",
      "1 patient has SD",
      "No clinical activity seen in biomarker negative patients"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Clinical data support that 0.5 mg starting dose was active based on PD assessment (PBMC and tissue), with optimal PD modulation across dose levels tested",
      "Encouraging initial clinical activity at all dose levels: 2 PRs (1 confirmed, 1 unconfirmed) and 1 SD in 6 evaluable, heavily pretreated patients identified with biomarker positive tumors; 1 SD in non-small cell lung cancer (NSCLC) with un-evaluable biomarker status",
      "Favorable AE profile at 0.5 and 1 mg",
      "Grade 4 thrombocytopenia identified as dose limiting toxicity (DLT) at 2 mg",
      "No hypotension/cytokine release syndrome or clinically significant hypocalcemia observed at any dose level"
    ],
    "safety": [
      "Favorable AE profile at 0.5 and 1 mg",
      "Grade 4 thrombocytopenia identified as dose limiting toxicity (DLT) at 2 mg",
      "No hypotension/cytokine release syndrome or clinically significant hypocalcemia observed at any dose level"
    ],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "VAV1",
      "NEK7",
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "MYC-driven Malignancies",
      "Autoimmune Disease",
      "Inflammatory Diseases",
      "Ovarian Cancer",
      "Breast Cancer",
      "SCD",
      "\u03b2-Thalassemia"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Inflammation",
      "Genetic diseases"
    ],
    "clinical_phases": [
      "Discovery",
      "IND-Enabling",
      "Clinical"
    ],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": "molecular glue degraders",
    "e3_ligase": null,
    "indications": [
      "MYC-driven cancers"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [
      "optimal pharmacodynamic modulation",
      "early signs of clinical activity"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa Company Call Presentation - October 17 2023.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": "cereblon",
    "indications": [
      "multiple sclerosis",
      "inflammatory bowel disease",
      "rheumatoid arthritis",
      "psoriasis"
    ],
    "therapeutic_areas": [
      "autoimmune diseases",
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "MRT-6160 inhibits T and B cell activation",
      "MRT-6160 reduces pro-inflammatory cytokine levels",
      "MRT-6160 reduces spinal cord immune cell infiltration",
      "MRT-6160 reduces demyelination",
      "MRT-6160 has oral bioavailability"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "FOCIS_2025_MRT6160_EAE.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "MYC-driven cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": "Molecular Glue Degraders",
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven Solid Tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "selective degradation of GSPT1",
      "Viability effects are cereblon-dependent",
      "MYC expression status governs cell sensitivity to primary hit"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "high selective effect (2.4 U)",
      "rationally designed to be in the ADMET sweet-spot",
      "good oral bioavailability"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "GSPT2"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly Optimized and Potent"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "IKZF1",
      "IKZF3",
      "SALL4",
      "ZFP91",
      "CK1a",
      "GAPDH"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly Selective",
      "Oral bioavailable",
      "Favorable ADMET profile"
    ],
    "safety": [
      "No activity observed in an in vitro panel of 44 safety targets"
    ],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-Driven NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Preferential antiproliferative activity in N-MYC high cell lines",
      "N-MYC overexpression sensitizes NCI-H2023 resistant cells to MRT-2359"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 preferentially impairs protein synthesis in tumor cells with high MYC expression",
      "MRT-2359 induces ribosome stalling at stop codon only in N-MYC high cell line",
      "MRT-2359 completely abrogates protein synthesis only in N-MYC high cell line"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "N-MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "NSCLC"
    ],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 induces GSPT1 degradation leading to N-MYC protein downregulation in NCI-H1155",
      "Degradation of GSPT1 leads to downregulation of N-MYC transcriptional output in NCI-H1155",
      "Transcriptional modulation of >200 MYC target genes"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "c-MYC",
      "N-MYC",
      "L-MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Preferential GSPT1 degradation",
      "Preferential inhibition of translation",
      "MYC down modulation"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "Lung NE"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer (NSCLC & SCLC)",
      "DLBCL",
      "high-grade neuroendocrine tumors",
      "N-/L-MYC amplified solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR2023__Owen_Final1.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Genetic disease",
      "Nervous system",
      "Musculoskeletal",
      "Urinary system",
      "Psychiatric disorder",
      "Respiratory system",
      "Neoplasm",
      "Endocrine system",
      "Metabolic disease",
      "Immune system"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metabolic pathologies",
      "cardiovascular diseases",
      "inflammatory issues",
      "neurologic disorders",
      "Cryopyrin-associated periodic syndromes (CAPS)"
    ],
    "therapeutic_areas": [
      "inflammatory disease"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Heart",
      "Metabolism",
      "Brain",
      "Intestine",
      "Lung",
      "Liver",
      "Kidney",
      "Joints"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "NEK7",
      "CDK2",
      "VAV1",
      "BCL11A"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "MYC-driven Malignancies",
      "Inflammatory Diseases",
      "Ovarian Cancer",
      "Breast Cancer",
      "T and B Cell Malignancies",
      "Autoimmune Disease",
      "SCD",
      "\u03b2-Thalassemia"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Autoinflammation",
      "Oncology / immunology",
      "Genetic diseases"
    ],
    "clinical_phases": [
      "Discovery",
      "IND-Enabling",
      "Clinical"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "2nd Annual TPD Europe Summit.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": "Molecular Glue Degraders (MGDs)",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Neuroscience"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "VAV1",
      "NEK7",
      "CDK2",
      "CCNE1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "other MYC-driven Malignancies",
      "Autoimmune Disease \u2013 Systemic and CNS",
      "IL-1\u03b2/NLRP3-driven Inflammatory Diseases",
      "Breast Cancer",
      "CCNE1 amplified tumors"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Neurological Diseases",
      "Immunology",
      "Inflammation"
    ],
    "clinical_phases": [
      "Discovery",
      "IND-Enabling",
      "Clinical"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "gout",
      "pericarditis",
      "cardiovascular disease",
      "neurodegenerative disease",
      "obesity"
    ],
    "therapeutic_areas": [
      "inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MGD",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "gout",
      "pericarditis",
      "cardiovascular disease",
      "neurodegenerative disease",
      "obesity"
    ],
    "therapeutic_areas": [
      "inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MGD",
    "targets": [
      "NEK7"
    ],
    "modality": "small molecule",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "potent",
      "selective",
      "durable"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": "MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent",
      "Selective",
      "Favorable Drug-like Profile",
      "Excellent selectivity profile in different cell lines",
      "Active in human and non-human primates",
      "Oral Bioavailability"
    ],
    "safety": [
      "Negative Mini-Ames",
      "No inhibition (EC50> 30 \u00b5M)"
    ],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NLRP3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NLRP3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Reduced IL-1\u03b2 in human and cynomolgus monkey whole blood",
      "Reduced ASC speck formation in human whole blood"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-8102 induces degradation of NEK7 in vivo over several days",
      "In vivo NEK7 degradation leads to inhibition of NLRP3 inflammasome in ex vivo stimulation assay"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8046",
    "targets": [
      "NEK7"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [
      "gout"
    ],
    "therapeutic_areas": [
      "inflammation"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "IL-1\u03b2",
      "IL-1\u03b1",
      "NLRP3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Pericarditis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 23
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "inflammation"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 24
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 25
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "CNS"
    ],
    "clinical_phases": [],
    "claims": [
      "Displays CNS-penetrance in cynomolgus monkey",
      "Significant NEK7 degradation in various cyno brain regions 24h post treatment"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 26
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "treatment + prevention of recurrent pericarditis",
      "treatment + prevention of acute myocardial infarction",
      "treatment of myocarditis",
      "prevention of heart failure",
      "treatment of Parkinson\u2019s disease",
      "treatment of Alzheimer\u2019s disease",
      "treatment + prevention of acute gouty arthritis",
      "treatment + prevention of obesity"
    ],
    "therapeutic_areas": [
      "immuno-cardiology",
      "neuro-immunology",
      "rheumatology",
      "metabolism"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 27
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "inflammatory disorders"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "selective",
      "potent",
      "durable NEK7 degrader",
      "inhibition of NLRP3 inflammasome",
      "therapeutic activity in rabbit gout model"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 28
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "NEK7 Inflammasome Summit_Monte Rosa.pdf",
      "slide": 29
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "Cereblon (CRBN)",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "IKZF1",
      "CK1a",
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6797",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "NEK7",
      "Neosubstrate 3",
      "Neosubstrate 4",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - AI Applications for Molecular Glue Degraders.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CRBN",
      "CK1\u03b1",
      "mTOR FRB"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "IKZF1",
      "W\u0399\u0396",
      "GSPT1",
      "NEK7",
      "CK1\u03b1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Immunology target"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Licenses inflammasome assembly",
      "Kinase-independent scaffolding function"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "NEK7-MGD",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone_FINAL.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metastatic castration resistant prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "achieved compelling clinical activity in a subset of heavily pre-treated mCRPC patients with AR mutations",
      "100% disease control rate in the AR mutant population",
      "overall disease control rate (DCR) of 64% in a total of 14 evaluable patients"
    ],
    "safety": [
      "well tolerated with mild or moderate manageable GI adverse events being the most frequent toxicities"
    ],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "AR",
      "MYC",
      "Cyclin D1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "therapy-resistant mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Prostate Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "AR",
      "MYC",
      "E2F"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 treatment significantly reduced AR-independent proteins",
      "AR pathway-relevant proteins",
      "CRPC-relevant oncoproteins",
      "AR abundance (WT and V7) and proteins regulated by AR were significantly reduced",
      "Other CRPC-relevant oncogenes such as MYC and Cyclin D1 were also significantly reduced",
      "MRT-2359 was more effective than enzalutamide at reducing AR activity"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 + enzalutamide drove tumor regressions in CDX models of CRPC with various AR alterations including LNCaP and VCaP",
      "MRT-2359 + Pluvicto improved activity over single agents in enzalutamide-resistant, AR-V7 expressing 22Rv1 model"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "lung cancer",
      "high-grade neuroendocrine tumors",
      "solid tumors with N-/L-MYC amplification",
      "metastatic castration resistant prostate cancer (CRPC)"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [
      "Well-tolerated dose level"
    ],
    "year": 2025,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase I"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "adverse_event": "Fatigue",
        "grade_1": 3,
        "grade_2": 5,
        "grade_3": 1,
        "grade_4": 0
      },
      {
        "adverse_event": "Diarrhea",
        "grade_1": 2,
        "grade_2": 2,
        "grade_3": 0,
        "grade_4": 0
      },
      {
        "adverse_event": "Nausea",
        "grade_1": 2,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0
      },
      {
        "adverse_event": "Arthralgia",
        "grade_1": 1,
        "grade_2": 1,
        "grade_3": 0,
        "grade_4": 0
      },
      {
        "adverse_event": "Decreased appetite",
        "grade_1": 1,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0
      },
      {
        "adverse_event": "Vomiting",
        "grade_1": 1,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0
      },
      {
        "adverse_event": "Neutropenia",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0
      },
      {
        "adverse_event": "Muscular weakness",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0
      }
    ],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Achieved Tumor Regressions in AR Mutant mCRPC",
      "Durable disease control noted in mutant and ARi na\u00efve patients"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "MYC",
      "E2F",
      "AR"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC with AR mutations"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metastatic castration resistant prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1/2",
      "Phase 2"
    ],
    "claims": [
      "100% PSA response",
      "Overall disease control rate (DCR) of 64%"
    ],
    "safety": [
      "well tolerated",
      "mild or moderate manageable GI adverse events"
    ],
    "year": 2026,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 23
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Castration-resistant Prostate Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 24
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 25
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-2359 Clincial Data Update.pdf",
      "slide": 26
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": "cereblon",
    "indications": [
      "Pericarditis",
      "Atherosclerosis"
    ],
    "therapeutic_areas": [
      "Cardiovascular Inflammation",
      "Cardiometabolic Diseases"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Inhibits IL-1 downstream of NLRP3 inflammasome activation",
      "Inhibits upstream pyroptosis & DAMP/cytokine release",
      "Suppresses cytokine release in ex vivo-stimulated whole blood"
    ],
    "safety": [
      "Safety and tolerability"
    ],
    "year": 2025,
    "source": {
      "document": "Monte Rosa AHA 2025 NEK7 Poster.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": "cereblon",
    "indications": [
      "collagen-induced arthritis",
      "rheumatoid arthritis",
      "multiple sclerosis",
      "inflammatory bowel disease",
      "psoriasis"
    ],
    "therapeutic_areas": [
      "autoimmune diseases",
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "preclinical"
    ],
    "claims": [
      "MRT-6160 reduces joint inflammation",
      "MRT-6160 reduces autoantibody production",
      "MRT-6160 attenuates T cell activation",
      "MRT-6160 attenuates B cell activation",
      "MRT-6160 reduces serum levels of pro-inflammatory cytokines"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "MRT_EULAR_2024_MRT6160_CIA_FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": "cereblon",
    "indications": [
      "multiple sclerosis",
      "inflammatory bowel disease",
      "rheumatoid arthritis",
      "psoriasis"
    ],
    "therapeutic_areas": [
      "autoimmune diseases",
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "completed testing in Healthy Subjects"
    ],
    "claims": [
      "MRT-6160 inhibits T and B cell activation and effector functions",
      "MRT-6160 inhibits EAE disease progression, severity, and incidence"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "MRT_ECTRIMS_2025_MRT6160_EAE_FINAL_PDF.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "MYC-driven Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "IKZF1",
      "IKZF3",
      "SALL4",
      "ZFP91",
      "CK1a",
      "GAPDH"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 is a selective GSPT1-directed MGD",
      "MRT-2359 is orally bioavailable",
      "MRT-2359 has favorable ADMET profile",
      "MRT-2359 does not inhibit or induce major CYPs",
      "MRT-2359 does not inhibit hERG"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Preferential antiproliferative activity in high N-MYC cell lines",
      "N-MYC overexpression sensitizes NCI-H2023 resistant cells to MRT-2359"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 induces ribosome stalling only in N-MYC high cell line",
      "MRT-2359 rapidly and completely abrogates protein synthesis only in N-MYC high cell line"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "N-MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "N-MYC High NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 induces GSPT1 degradation leading to N-MYC protein downregulation in NCI-H1155",
      "Degradation of GSPT1 leads to downregulation of N-MYC transcriptional output in NCI-H1155"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Synthetic lethality",
      "Oncogene addiction"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "Lung NE"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC High Lung Cancer",
      "Neuroendocrine Lung Cancer"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Demonstrates Preferential Anti-tumor Activity"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer (NSCLC & SCLC)",
      "DLBCL",
      "high-grade neuroendocrine tumors",
      "N-/L-MYC amplified solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [
      "MYC-driven lung cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "first-in-man"
    ],
    "claims": [
      "potent",
      "selective",
      "orally bioavailable",
      "impairs protein synthesis",
      "affects MYC and its downstream targets",
      "demonstrates robust anti-tumor activity preferentially in MYC-driven lung cancer models"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7",
      "NLRP3"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "Gout"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "gout",
      "pericarditis",
      "cardiovascular disease",
      "neurodegenerative disease",
      "obesity"
    ],
    "therapeutic_areas": [
      "inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": "Molecular Glue Degraders",
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Neuroscience"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7",
      "NLRP3"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "Gout"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": "MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Negative Mini-Ames",
      "No inhibition (EC50> 30 \u00b5M)"
    ],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NLRP3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7",
      "NLRP3"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "Gout"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7",
      "NLRP3"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "Gout"
    ],
    "therapeutic_areas": [
      "Inflammation"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NLRP3",
      "Caspase-1",
      "IL-1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Gout"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Inhibits NLRP3 Activation",
      "Reduces Caspase-1 activation",
      "Prevents IL-1 release"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "gout",
      "inflammatory disorders"
    ],
    "therapeutic_areas": [
      "inflammation"
    ],
    "clinical_phases": [],
    "claims": [
      "selective",
      "potent",
      "durable NEK7 degrader",
      "inhibition of the NLRP3 inflammasome"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "EULAR 2025 NEK7 Presentation.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-9643",
    "targets": [
      "CDK2"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": "CRBN",
    "indications": [
      "HR-Positive/HER2-Negative Breast Cancer"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "MRT-9643 inhibits proliferation of CDK2-dependent cancer cells",
      "MRT-9643 counteracts resistance to CDK4/6 inhibition in HR-positive cells",
      "MRT-9643 demonstrates activity and pathway suppression in combination with CDK4/6 inhibition",
      "MRT-9643 exhibits potency, selectivity, and favorable drug-like properties",
      "CDK2 degradation inhibits CDK2-dependent cancer cell proliferation",
      "CDK2 degradation delays resistance to CDK4/6 inhibition",
      "CDK2 degradation achieves equivalent efficacy compared to anti-CDK4/6 and anti-estrogen standard of care"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "P5-01-26_Ilic-Widlund.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": "Cereblon",
    "indications": [
      "autoimmune diseases",
      "inflammatory diseases",
      "inflammatory bowel disease"
    ],
    "therapeutic_areas": [
      "immunology"
    ],
    "clinical_phases": [
      "IND-enabling studies"
    ],
    "claims": [
      "inhibits TCR-induced activation",
      "reduces pro-inflammatory cytokine production",
      "prevents disease progression",
      "reduces colon inflammation"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "MRT_DDW_2024_MRT6160_IBD_FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "immune-mediated conditions"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "Safety, PK and PD Data from SAD and MAD Healthy Volunteers"
    ],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "Safety and tolerability"
    ],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Dose-Dependent VAV1 Degradation >90% in Peripheral Blood T Cells After Single and Multiple Dose Administration"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Significantly attenuated CD69 upregulation on T and B cells following TCR stimulation, reflecting functional inhibition",
      "Significantly (up to 99%) inhibited IL-2, IFN-\u03b3 and IL-17A secretion from whole blood derived T cells following ex vivo TCR stimulation",
      "Attenuated IL-6 production by 60-90% across dose levels following B-cell stimulation"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Resulted in Sustained Suppression of TCR-mediated CD69 Activation following Single or Multiple Dose Administration",
      "Marked suppression of CD69 upregulation (>90%) in peripheral blood T and B cells following TCR stimulation",
      "Similar results observed in peripheral blood B cells following BCR stimulation"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "MRT-6160 was well tolerated with no serious adverse events (SAE)",
      "Observed treatment-emergent adverse events (TEAE) were mild (82%) or moderate (18%) and self-limiting",
      "Overall TEAE frequency was similar between MRT-6160 and placebo",
      "TEAE observed in 2 or more subjects treated with MRT-6160: SAD: pain from vessel puncture (2), MAD: cough (2), diarrhea (3), feeling hot (4), headache (5), nasal congestion (2), oropharyngeal pain (3) and pyrexia (2)"
    ],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "immune-mediated diseases"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "significant effects on cytokine production",
      "highly favorable safety profile in humans"
    ],
    "safety": [
      "highly favorable safety profile in humans"
    ],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Peripheral Inflammatory Diseases",
      "High CRP",
      "Gout",
      "Pseudogout",
      "Osteoarthritis"
    ],
    "therapeutic_areas": [
      "Cardio-immunology"
    ],
    "clinical_phases": [
      "Phase 1 HV",
      "Planned Phase 1 (PoC)"
    ],
    "claims": [
      "Safety, tolerability, and pharmacokinetics in healthy volunteers",
      "Changes in levels of inflammatory cytokines",
      "Changes in CRP levels in subjects with high CRP",
      "Changes in gout/pseudogout flare pain or osteoarthritic pain",
      "Reduction in frequency of gout/pseudogout flares"
    ],
    "safety": [
      "Safety, and tolerability of 28-day dosing"
    ],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent degradation of NEK7",
      "Highly selective NEK7 degradation",
      "Prolonged pharmacodynamic effect"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "No MRT-8102 related clinical signs",
      "No changes in immunophenotyping",
      "No gross or clinical pathology findings at any dose level",
      "NOAEL was the highest dose tested, 150 mg/kg/day (rat) and 100 mg/kg/day (cyno)",
      ">200-fold exposure margin over projected human efficacious dose in both species",
      "No concerns related to in vitro off-targets",
      "No concerns related to mutagenicity",
      "No concerns related to phototoxicity",
      "No concerns related to hERG",
      "No concerns related to in vivo respiratory or CNS safety pharmacology (rat)",
      "No concerns related to CV safety pharmacology (cyno)"
    ],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 23
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 24
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 25
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 26
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 27
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "TNF",
      "IL-1",
      "IL-17",
      "IL-6"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [
      "immune",
      "blood"
    ],
    "clinical_phases": [],
    "claims": [
      "High degradation in immune and blood cells",
      "Catalytic MOA drives sustained PD effect",
      "Exquisite selectivity enables high therapeutic index",
      "Potential to deplete both membrane receptors and intracellular signaling nodes",
      "No MGD induced tox findings in 2 GLP tox studies (VAV1, NEK7)"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 28
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 29
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 30
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 31
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 32
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "N-MYC High",
      "L-MYC High",
      "SCLC L/N-MYC high",
      "Heme",
      "NSCLC N-MYC high SCLC/NE transformation",
      "Neuroendocrine lung cancer",
      "Neuroendocrine tumors",
      "L-/N-MYC amplified tumors",
      "c-MYC High",
      "Prostate cancer AR positive including AR-V7",
      "Breast cancer ER positive metastatic"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 33
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer",
      "high-grade neuroendocrine tumors",
      "solid tumors with N-/L-MYC amplification",
      "NSCLC",
      "SCLC",
      "HR+/Her2- Breast Cancer (+Fulv)",
      "Prostate cancer (+Enza)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [
      "Safety assessments initiated"
    ],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 34
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 35
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "AE": "Thrombocytopenia",
        "G1-2": 0,
        "G3": 0,
        "G4": 0
      },
      {
        "AE": "Neutropenia",
        "G1-2": 0,
        "G3": 0,
        "G4": 0
      },
      {
        "AE": "Leukopenia",
        "G1-2": 0,
        "G3": 0,
        "G4": 0
      },
      {
        "AE": "Anemia",
        "G1-2": 0,
        "G3": 0,
        "G4": 0
      },
      {
        "AE": "Nausea",
        "G1-2": 3,
        "G3": 0,
        "G4": 0
      },
      {
        "AE": "Vomiting",
        "G1-2": 1,
        "G3": 0,
        "G4": 0
      },
      {
        "AE": "Diarrhea",
        "G1-2": 1,
        "G3": 0,
        "G4": 0
      },
      {
        "AE": "Hypokalemia",
        "G1-2": 0,
        "G3": 0,
        "G4": 0
      },
      {
        "AE": "Fatigue",
        "G1-2": 0,
        "G3": 0,
        "G4": 0
      }
    ],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 36
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 37
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 38
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Castrate-Resistant Prostate Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "1 PR (confirmed, -57%)",
      "2 SDs",
      "1 PSA response (-90%)"
    ],
    "safety": [
      "Safety profile has been favorable"
    ],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 39
    }
  },
  {
    "company": "monte_rosa",
    "program": "AR H875Y Mutation",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Refractory CRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed PR"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 40
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 41
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CCNE1",
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 42
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CCNE1",
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Ovarian cancer",
      "Endometrial cancer",
      "ER-positive breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CCNE1 and CDK2 are key drivers of cancers with cyclin dependent kinase pathway alterations",
      "CCNE1 not druggable by conventional modalities",
      "CCNE1 and CDK2 MGDs are expected to achieve greater selectivity versus conventional CDK inhibitors",
      "more sustained pathway inhibition compared to inhibitors"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 43
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-50969",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CCNE1 amplified gastric cancer",
      "CCNE1 amplified breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 44
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-51443",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ Breast Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "induces robust tumor regression in combination with CDK4/6 inhibition and fulvestrant",
      "substantially reduces tumor growth vs. ribo + fulv"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 45
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 46
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 47
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Monte Rosa Pipeline Update - March 20, 2025.pdf",
      "slide": 48
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": "protein degradation",
    "e3_ligase": null,
    "indications": [
      "autoimmune diseases",
      "chronic inflammatory diseases",
      "rheumatoid arthritis",
      "inflammatory bowel disease",
      "multiple sclerosis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "autoimmune diseases",
      "chronic inflammatory diseases"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "molecular glue degraders",
    "e3_ligase": null,
    "indications": [
      "autoimmune diseases",
      "inflammatory diseases",
      "IBD",
      "RA"
    ],
    "therapeutic_areas": [
      "autoimmunity",
      "chronic inflammation"
    ],
    "clinical_phases": [],
    "claims": [
      "successful and specific degradation of VAV1 in vitro and in vivo",
      "inhibition of T cell proliferation",
      "inhibition of cytokine production in a dose-dependent manner",
      "promising preclinical activity in mouse models of T and T/B cell-mediated disease",
      "inhibiting disease progression in collagen-induced arthritis",
      "inhibiting disease progression in colitis"
    ],
    "safety": [
      "risk of serious and opportunistic infections",
      "inherent risk of malignancy"
    ],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Neurath Berg - VAV1 Trends Immunology.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "MRTx_AACR_2024_MRT2359_Prostate.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "LBA004",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Myc-driven cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-048",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Myc-driven Cancers"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-048",
    "targets": [
      "p4EBP1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Breast Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-048",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent anti-tumor activity",
      "Target engagement demonstrated"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-048",
    "targets": [
      "Myc"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Myc gene signatures are strongly down-regulated following treatment with MRT-048"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "AACR-NCI-EORTC Late Breaking Presentation.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "MYC-driven Malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "potent inducer of GSPT1-cereblon proximity",
      "selective GSPT1-directed MGD",
      "oral bioavailability all species"
    ],
    "safety": [
      "CYP DDIs",
      "hERG inhibition patch clamp"
    ],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-Driven NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Preferential antiproliferative activity in N-MYC high cell lines",
      "N-MYC overexpression sensitizes NCI-H2023 resistant cells to MRT-2359"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Synthetic lethality",
      "Oncogene addiction"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "N-MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "N-MYC High NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Induces GSPT1 degradation leading to N-MYC protein downregulation",
      "Degradation of GSPT1 leads to downregulation of N-MYC transcriptional output"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC high Lung Cancer",
      "Neuroendocrine Lung Cancer"
    ],
    "therapeutic_areas": [
      "NSCLC",
      "SCLC"
    ],
    "clinical_phases": [],
    "claims": [
      "Demonstrates Preferential Anti-tumor Activity"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer (NSCLC & SCLC)",
      "DLBCL",
      "high-grade neuroendocrine tumors",
      "N-/L-MYC amplified solid tumors"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "lung cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "first-in-man"
    ],
    "claims": [
      "rationally designed",
      "potent",
      "selective",
      "orally bioavailable",
      "robust antitumor activity"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "34th EORTC-NCI-AACR Symposium.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "IKZF1",
      "IKZF3",
      "SALL4",
      "ZFP91",
      "CK1a",
      "GAPDH"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 is a selective GSPT1-directed MGD",
      "MRT-2359 is orally bioavailable",
      "MRT-2359 has favorable ADMET profile",
      "MRT-2359 is neither an inhibitor, nor an inducer of major CYPs",
      "MRT-2359 doesn\u2019t inhibit hERG"
    ],
    "safety": [
      "CYP DDIs > 30 \u00b5M",
      "hERG inhibition patch clamp",
      "EC50 > 30 \u00b5M"
    ],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-Driven NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Preferential antiproliferative activity in N-MYC high cell lines",
      "N-MYC overexpression sensitizes NCI-H2023 resistant cells to MRT-2359"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven Tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Synthetic lethality",
      "Oncogene addiction"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "N-MYC high NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 induces ribosome stalling only in N-MYC high cell line",
      "MRT-2359 rapidly and completely abrogates protein synthesis only in N-MYC high cell line"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "N-MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "N-MYC High NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Induces GSPT1 degradation leading to N-MYC protein downregulation",
      "Degradation of GSPT1 leads to downregulation of N-MYC transcriptional output"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "GSPT2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Ph I",
      "Phase I/Ib"
    ],
    "claims": [],
    "safety": [
      "CYP2C19 @ 1.5 uM",
      "hERG (patch clamp)",
      "Caco2 (Efflux Ratio)"
    ],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven Cancer Cell Lines"
    ],
    "therapeutic_areas": [
      "NSCLC",
      "SCLC",
      "Lymphoma"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "Lung NE"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC High Lung Cancer",
      "Neuroendocrine Lung Cancer"
    ],
    "therapeutic_areas": [
      "NSCLC",
      "SCLC"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer (NSCLC & SCLC)",
      "DLBCL",
      "high-grade neuroendocrine tumors",
      "N-/L-MYC amplified solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 23
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase I",
      "Phase I",
      "Phase I",
      "Phase I",
      "Phase I",
      "Phase I"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 24
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "MRT-2359 KOL Webinar, October 24, 2022.pdf",
      "slide": 25
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "GSPT1",
    "targets": [
      "Myc"
    ],
    "modality": "molecular glue degraders",
    "e3_ligase": null,
    "indications": [
      "Myc-driven cancers"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "powerful and differentiated approach to eradicate disease-causing proteins",
      "clinically validated",
      "favorable drug-like properties",
      "broad therapeutic application"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Target X",
      "Target Y",
      "Target Z"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-048",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "NEK7",
      "CDK2",
      "VAV1",
      "BCL11A"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung Cancer (NSCLC, SCLC)",
      "Inflammatory Diseases",
      "Ovarian Cancer",
      "Breast Cancer",
      "T and B Cell Malignancies",
      "Autoimmune Disease",
      "SCD",
      "\u03b2-Thalassemia"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Autoinflammation",
      "Oncology / immunology",
      "Genetic diseases"
    ],
    "clinical_phases": [
      "Discovery",
      "IND-Enabling",
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7",
      "GSPT1",
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "inflammatory disorders",
      "MYC-driven cancers",
      "solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Selectivity confirmed biochemically and by proteomics profiling",
      "MGDs are biochemically selective for NEK7",
      "MGDs promotes NEK7-CRBN proximity",
      "MGDs promotes selective degradation of NEK7"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Inflammation",
      "Metabolic disorders",
      "Neurodegeneration",
      "Genetic diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "European Protein Degradation Congress - September 21, 2021.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-50969",
    "targets": [
      "Cyclin E1"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": "CRBN",
    "indications": [
      "Ovarian cancer",
      "Endometrial cancer",
      "Gastric cancer",
      "Breast cancer"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "First-in-class cyclin E1 degrader for cyclin E1 amplified cancers",
      "MRT-50969 shows superior differential activity in CCNE1 dependent cell lines compared to clinical-stage CDK2 inhibitors",
      "MRT-50969 is a potent and highly selective cyclin E1-directed MGD",
      "MRT-50969 induces robust G1/S cell cycle arrest",
      "MRT-50969 is orally bioavailable and shows anti-tumor activity in a dose dependent manner in CCNE1-amplified cell line-derived xenograft models"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "ENA_2024_CCNE1_poster.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ASCVD",
      "cardiovascular diseases",
      "cardiometabolic diseases",
      "chronic inflammatory diseases",
      "gout",
      "recurrent pericarditis",
      "immune-mediated diseases",
      "CRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "MRT-8102 to transform the treatment of ASCVD",
      "MRT-8102 as an oral best-in-class therapeutic among agents targeting the NRLP3/ IL-1/IL-6 pathway",
      "MRT-8102 has significant potential in multiple chronic inflammatory diseases",
      "MRT-6160 in immune-mediated diseases",
      "MRT-2359 in combination with a second-generation androgen receptor inhibitor"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "chronic inflammatory diseases",
      "ASCVD",
      "MASH"
    ],
    "therapeutic_areas": [
      "cardiovascular disease"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "induced rapid and compelling reduction in hsCRP",
      "favorable AE profile",
      "85% sustained reduction of hsCRP",
      "94% subjects achieved reduction of hsCRP levels to <2 mg/L",
      "31% reduction of fibrinogen"
    ],
    "safety": [
      "no adverse safety signals",
      "no SAEs",
      "no severe AEs"
    ],
    "year": 2025,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NLRP3",
      "NEK7"
    ],
    "modality": "Neosubstrate-directed MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "induces catalytic NEK7 degradation",
      "prevents pyroptotic cell death-mediated release of inflammatory cytokines and DAMPs"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NLRP3",
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ASCVD"
    ],
    "therapeutic_areas": [
      "Cardiovascular"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase I"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potency, selectivity, and long-lasting pharmacodynamics differentiate from other IL-1/NLRP3 inflammasome approaches",
      "MRT-8102 potently degraded NEK7",
      "MRT-8102 induced highly selective NEK7 degradation",
      "MRT-8102 exposure resulted in prolonged PD effect",
      "MRT-8102 has potential to avoid on-off pharmacodynamics and off-target toxicities of NLRP3 inhibitors"
    ],
    "safety": [
      "No degradation of other known CRBN neosubstrates"
    ],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase I"
    ],
    "claims": [],
    "safety": [
      "Safety and tolerability"
    ],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "SAD",
      "MAD",
      "CRP PoC"
    ],
    "claims": [
      "Achieved 80 \u2013 90% NEK7 Degradation in Peripheral Blood T Cells After Single and Multiple Dose Administration"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "55% reduction of endogenous IL-6 plasma levels",
      "Rapid and sustained reduction of IL-1\u03b2 after ex-vivo stimulation",
      "~80% inhibition in IL-1\u03b2 secretion noted in subjects with elevated CRP at baseline at doses ranging from 5 \u2013 200 mg",
      "Significant reduction in median IL-6 levels to below CV risk threshold noted in subjects with elevated CRP"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "85% decrease of hsCRP after 4 weeks of dosing",
      "94% of subjects show suppression of hsCRP to <2 mg/L",
      "Up to 31% reduction in fibrinogen after 4 weeks of treatment"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Well tolerated with favorable safety profile with no SAEs",
      "Treatment-emergent AEs were mild to moderate",
      "No evidence of increased infection risk",
      "No dose dependency"
    ],
    "year": 2025,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "CVD"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "Safety and tolerability of 28 days dosing"
    ],
    "year": 2020,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Cardio-Immuno-Metabolic",
      "Rheumatology",
      "Allergic Diseases",
      "Metabolic dysfunction-associated steatohepatitis",
      "Gout",
      "Asthma",
      "Recurrent pericarditis",
      "Osteoarthritis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-8102",
    "targets": [
      "NEK7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "high-risk CVD",
      "ASCVD"
    ],
    "therapeutic_areas": [
      "cardiovascular"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "~80-90% NEK7 degradation noted in T cells",
      "85% sustained reduction of hsCRP",
      "94% subjects achieved reduction of hsCRP levels to <2 mg/L",
      "31% reduction of fibrinogen"
    ],
    "safety": [
      "No SAEs",
      "no severe AEs"
    ],
    "year": 2026,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 23
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 24
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 25
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "MRT-8102 Phase 1 Clinical Data Update_.pdf",
      "slide": 26
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-51443",
    "targets": [
      "CDK2"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": "CRBN",
    "indications": [
      "HR-Positive/HER2-Negative Breast Cancer"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "MRT-51443 is a potent and highly selective CDK2-directed molecular glue degrader.",
      "MRT-51443 counteracts resistance to CDK4/6 inhibition in HR+ breast cancer models.",
      "MRT-51443 exhibits favorable PK and PD profiles.",
      "MRT-51443 inhibits proliferation of CDK2-dependent cancer cells.",
      "MRT-51443 displays superior selectivity compared to clinical CDK2 inhibitors.",
      "MRT-51443 induces robust tumor regression in combination with CDK4/6 inhibition and Fulvestrant."
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Selective Targeting of CDK2 Using Molecular Glue Degraders.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "immune-mediated diseases"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "SLE",
      "Sj\u00f6gren\u2019s disease",
      "rheumatoid arthritis",
      "IBD"
    ],
    "therapeutic_areas": [
      "immune-mediated diseases"
    ],
    "clinical_phases": [
      "clinical trial"
    ],
    "claims": [
      "deep VAV1 degradation of greater than 90%",
      "significant T and B cell functional inhibition",
      "significant inhibition of cytokines commonly associated with multiple immune-mediated diseases"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Collagen-Induced Arthritis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Inhibits disease progression",
      "Reduces secretion of key disease-associated serum cytokines"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-6160 reversed disease progression resulting in lower overall disease burden than standard of care",
      "MRT-6160 reduced expression of cytokines, tissue damage, and T cell pathway expression in the spinal cord"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-6160 inhibited disease progression and colon weight:length ratio",
      "MRT-6160 reduced expression of key disease-associated cytokines and tissue damage in the colon"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Inhibits disease progression",
      "Reduces kidney histopathology including lupus and interstitial nephritis"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Degradation by MRT-6160 exceeds 90%",
      "Significant functional inhibition of T and B cells following a single dose administration"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "autoimmune/inflammatory disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Keystone Symposia - MRT-6160.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": "Cereblon",
    "indications": [
      "rheumatoid arthritis",
      "multiple sclerosis",
      "inflammatory bowel disease",
      "psoriasis"
    ],
    "therapeutic_areas": [
      "autoimmune diseases",
      "inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "attenuates antigen receptor-mediated activation and effector functions of T- and B-cells",
      "rapidly degrades Vav1 in vivo",
      "attenuates disease progression in the CIA autoimmune disease model"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "MRT_ACR_2023_MRT6160_CIA_FINAL_PDF.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": "CRBN",
    "indications": [
      "Cancers with MYC-induced Translational Addiction"
    ],
    "therapeutic_areas": [
      "Lung Cancer",
      "Non-small Cell Lung Cancer (NSCLC)",
      "Small Cell Lung Cancer (SCLC)",
      "Neuroendocrine Lung Cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "Potent",
      "Selective",
      "Orally Bioavailable",
      "Induces degradation of GSPT1",
      "Downregulates N-MYC",
      "Preferential anti-tumor activity in MYC-driven tumors"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Monte Rosa AACR Poster April 2022.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": "Molecular Glue Degraders",
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Clinically validated"
    ],
    "safety": [
      "Favorable drug-like properties"
    ],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "VAV1",
      "NEK7",
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "other MYC-driven Malignancies",
      "Autoimmune Disease",
      "Inflammatory Diseases",
      "Ovarian Cancer",
      "Breast Cancer"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Inflammation"
    ],
    "clinical_phases": [
      "Discovery",
      "IND-Enabling",
      "Clinical"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": [
      "CRBN",
      "VHL",
      "CUL3"
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER positive breast cancer",
      "ovarian cancer",
      "endometrial cancer"
    ],
    "therapeutic_areas": [
      "solid tumors"
    ],
    "clinical_phases": [],
    "claims": [
      "CDK2 is a key driver of cancers with cyclin dependent kinase pathway alterations",
      "MGDs will achieve greater selectivity against other CDKs and kinases in general, as well as more sustained pathway inhibition compared to inhibitors"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CDK2 degradation results in reduction of E2F pathway proteins",
      "CDK2 degradation arrests CDK2-dependent cells in G1 phase",
      "CDK2 degradation blocks proliferation"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 23
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": [
      "CRBN",
      "VHL",
      "CUL3"
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 24
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "E3 ligase Y",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 25
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 26
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 27
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "2024.01.31.Dolgikh_MGD_Develop_Summit_final.pdf",
      "slide": 28
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2",
      "Cyclin E1"
    ],
    "modality": null,
    "e3_ligase": [
      "CRBN"
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HR+ breast cancer",
      "Cyclin E1 (CCNE1) amplified cancers"
    ],
    "therapeutic_areas": [
      "ovarian",
      "endometrial",
      "gastric",
      "breast"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-9643",
    "targets": [
      "CDK2"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent and Highly Selective CDK2-directed MGD",
      "Induces highly selective CDK2 degradation",
      "Favorable ADME/DMPK profile",
      "No degradation of other known CRBN neosubstrates"
    ],
    "safety": [
      "IC50 15 - >50 \u00b5M",
      "hERG inhibition patch clamp"
    ],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-9643",
    "targets": [
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-9643",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-9643",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-9643",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ Breast Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "induces strong TGI in combination with CDK4/6 inhibitor in vivo",
      "induces robust tumor regression in combination with CDK4/6 inhibition and fulvestrant"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-9643",
    "targets": [
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ Breast Cancer"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Induces Strong Pathway Suppression",
      "Readily degrades CDK2 in vivo",
      "Induces robust pathway suppression in combination with breast cancer SoC"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-9643",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ Breast Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "induces strong TGI in combination with CDK4/6 inhibitors in vivo",
      "induces robust tumor regression in combination with CDK4/6 inhibition and fulvestrant"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2"
    ],
    "modality": "molecular glue degraders",
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly selective CDK2-targeting",
      "Best in CDK2-class potential",
      "RB-dependent activity indicates on-target effects",
      "Efficacy observed in combination with CDK4/6 inhibitors"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CCNE1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ovarian cancer",
      "endometrial cancer",
      "gastric cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-50969",
    "targets": [
      "Cyclin E1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-50969",
    "targets": [
      "E2F targets",
      "Cyclin E1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-50969",
    "targets": [
      "Cyclin E1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Loss of RB blunts growth suppression induced by MRT-50969",
      "Induction of senescence by cyclin E1 degradation is RB-dependent"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-50969",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Ovarian cancer",
      "Gastric cancer",
      "Breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 23
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-50969",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 24
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-50969",
    "targets": [
      "cyclin E1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "inhibits tumor growth",
      "degrades cyclin E1"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 25
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-50969",
    "targets": [
      "cyclin E1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CCNE1 amplified gastric cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-50969 inhibits tumor growth in CCNE1 amplified gastric cancer model",
      "MRT-50969 degrades cyclin E1 and inhibits downstream pathway activity in vivo"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 26
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "cyclin E1"
    ],
    "modality": "molecular glue degraders",
    "e3_ligase": null,
    "indications": [
      "ovarian cancer",
      "endometrial cancer",
      "gastric cancer",
      "breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "First-in-class, highly selective cyclin E1-targeting molecular glue degraders",
      "Sensitivity to cyclin E1 MGD parallels genetic dependency",
      "Monotherapy efficacy seen in CCNE1-amplified cancer models in vivo"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 27
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 28
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Monte Rosa CDK2_CCNE1 TPD Summit Oct 2024.pdf",
      "slide": 29
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": "cereblon",
    "indications": [
      "Sj\u00f6gren\u2019s disease",
      "systemic lupus erythematosus",
      "rheumatoid arthritis"
    ],
    "therapeutic_areas": [
      "autoimmune diseases",
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "Phase I"
    ],
    "claims": [
      "attenuates T and B cell effector functions",
      "inhibits disease progression",
      "reduces kidney glomerular and interstitial nephritis"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "MRT_ACR_2025_MRT6160_SjD_FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "Cereblon (CRBN)",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Genetic disease",
      "Nervous system",
      "Musculoskeletal",
      "Urinary system",
      "Psychiatric disorder",
      "Respiratory system",
      "Neoplasm",
      "Endocrine system",
      "Metabolic disease",
      "Immune system"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "sickle cell disease",
      "hematologic malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "CDK2"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "NEK7",
      "CDK2",
      "VAV1",
      "BCL11A"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung Cancer",
      "Inflammatory Diseases",
      "Ovarian Cancer",
      "Breast Cancer",
      "T and B Cell Malignancies",
      "Autoimmune Disease",
      "SCD",
      "\u03b2-Thalassemia",
      "Multiple"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Autoinflammation",
      "Oncology / immunology",
      "Genetic diseases"
    ],
    "clinical_phases": [
      "Discovery",
      "IND-Enabling"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "4th Annual TPD Summit.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Neuroscience"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "Target 1",
      "Target 2",
      "Target 3",
      "Target 4",
      "Target N"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [
      "oncology",
      "immunology/inflammation"
    ],
    "clinical_phases": [],
    "claims": [
      "Unique Target Space",
      "Unprecedented Selectivity",
      "Catalytic Mechanism of Action"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1",
      "VAV1",
      "NEK7",
      "CDK2",
      "CCNE1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "NSCLC",
      "SCLC",
      "MYC-driven Malignancies",
      "Autoimmune Disease",
      "Systemic and CNS",
      "IL-1\u03b2/NLRP3 driven Inflammatory Diseases",
      "Breast Cancer",
      "CCNE1 amplified tumors"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Immunology",
      "Inflammation"
    ],
    "clinical_phases": [
      "Discovery",
      "IND-Enabling",
      "Clinical"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC-driven tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "GSPT1 is a therapeutic vulnerability of MYC-driven tumors leading to preferential activity of GSPT1 MGDs"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent and Highly Selective GSPT1-directed MGD",
      "Induces selective GSPT1 degradation",
      "Shows favorable ADME/DMPK profile",
      "No degradation of other known cereblon neosubstrates"
    ],
    "safety": [
      "CYP DDIs > 30 \u00b5M",
      "hERG inhibition patch clamp EC50 > 30 \u00b5M",
      "Oral bioavailability all species ~50%"
    ],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "N-Myc high / NDRG1 low NSCLC"
    ],
    "therapeutic_areas": [
      "Non-small Cell Lung Cancer"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "MYC",
      "CCND1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AR positive prostate cancer"
    ],
    "therapeutic_areas": [
      "prostate cancer"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Castration Resistant Prostate Cancer",
      "ARV7-driven Prostate Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lung cancer",
      "high-grade neuroendocrine tumors",
      "solid tumors with N-/L-MYC amplification",
      "HR+/Her2- Breast cancer (+Fulv)",
      "Prostate cancer (+Enza)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": "2024",
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 reduced GSPT1 protein expression in human tissue biopsies"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HG NE bladder carcinoma",
      "NSCLC with SCLC/NE transformation",
      "SCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "2 patients experienced a PR (1 confirmed, 1 unconfirmed)",
      "1 patient has SD",
      "1 patient with NSCLC and unclear biomarker status remains on therapy for > 7 months with stable disease",
      "No clinical activity seen in biomarker negative patients"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 17
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "inflammatory bowel disease",
      "rheumatoid arthritis",
      "multiple sclerosis",
      "myasthenia gravis"
    ],
    "therapeutic_areas": [
      "autoimmune diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 18
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 19
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "No degradation of other known cereblon neosubstrates",
      "IC50 > 30 \u00b5M",
      "EC50 > 30 \u00b5M",
      "> 50% oral bioavailability all species"
    ],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 20
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 21
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "T Cell Transfer-Induced Colitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-6160 Ameliorates T Cell Transfer-Induced Colitis Better than Standard of Care"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 22
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Ulcerative Colitis"
    ],
    "therapeutic_areas": [
      "Inflammation"
    ],
    "clinical_phases": [],
    "claims": [
      "Reduces inflammation-mediated damage of the colon",
      "Reduces cytokine production in the mesenteric lymph node and colon"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 23
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-6160",
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "early insights into safety"
    ],
    "year": 2025,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 24
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "VAV1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "autoimmune/inflammatory disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 25
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 26
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 27
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Monte Rosa TPD Summit MGDs from Bench to Clinic.pdf",
      "slide": 28
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "lung cancers"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 1
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 2
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": "molecular glue degrader",
    "e3_ligase": null,
    "indications": [
      "MYC-driven tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 3
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "MGD",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "CYP DDIs (7 isoforms)",
      "CEREP (Safety panel 44)",
      "hERG inhibition (patch clamp)"
    ],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 4
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly Selective Recruiter and Degrader of GSPT1",
      "Potent inducer of GSPT1-cereblon proximity",
      "Highly selective against common neosubstrates of CRBN"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 5
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 6
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 7
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 8
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 9
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 10
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 preferentially impairs protein synthesis in tumor cells with high MYC expression",
      "MRT-2359 induces ribosome stalling at stop codon only in N-MYC high cell line",
      "MRT-2359 completely abrogates protein synthesis only in N-MYC high cell line"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 11
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "N-MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "N-MYC High NSCLC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MRT-2359 induces GSPT1 degradation leading to N-MYC protein downregulation in NCI-H1155",
      "Degradation of GSPT1 leads to downregulation of N-MYC transcriptional output in NCI-H1155"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 12
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1",
      "N-MYC"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Induces Tumor Regressions in N-MYC-driven Xenograft Models",
      "Oral dosing shows anti-tumor activity and regressions"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 13
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYC High Lung Cancer",
      "Neuroendocrine Lung Cancer"
    ],
    "therapeutic_areas": [
      "NSCLC",
      "SCLC"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 14
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 15
    }
  },
  {
    "company": "monte_rosa",
    "program": "MRT-2359",
    "targets": [
      "GSPT1"
    ],
    "modality": "MGD",
    "e3_ligase": null,
    "indications": [
      "MYC-driven Tumors"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [
      "Best-in-Class",
      "highly selective",
      "orally bioavailable",
      "optimal degradation kinetics",
      "preferential activity in MYC-driven cancer cells"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 16
    }
  },
  {
    "company": "monte_rosa",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR 2023_Gerald.pdf",
      "slide": 17
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 1
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 2
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 3
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 4
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 5
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 6
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 7
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 8
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 9
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "STAT3",
      "MDM2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD",
      "cHL",
      "MCC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "IRAK4 Degradation leads to Early POC in HS and AD",
      "STAT3 Degradation Leads to Major Response in cHL Patient",
      "Degradation of IRAK4 and Ikaros/Aiolos in Humans was Well Tolerated",
      "MDM2 Degradation Leads to Major Response in MCC Patient with no Heme-tox"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 10
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 11
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 12
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 13
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD",
      "RA",
      "Asthma",
      "COPD",
      "IBD"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Best-in-pathway profile opportunity",
      "Superiority in Phase 1/2"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 14
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Strong PK/PD Correlation",
      "Safety",
      "Early Signs of Clinical Activity",
      "Differentiated vs. SMI"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 15
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "excellent preclinical to clinical translation and predictability of IRAK4 degradation"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 16
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IL-4/13 Transcription Factor",
      "IL-23/IFN Scaffolding Kinase",
      "STAT6",
      "TYK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 17
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "CRSwNP",
      "EoE",
      "PN",
      "others"
    ],
    "therapeutic_areas": [
      "Allergic Th2 Inflammation"
    ],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [
      "Dupilumab-like activity with oral small molecule profile",
      "Best-in-pathway profile opportunity"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 18
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 19
    }
  },
  {
    "company": "kymera",
    "program": "KT-294",
    "targets": [
      "TYK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Type I IFN & IL-23 inflammation",
      "IBD",
      "PsO",
      "PsA",
      "Lupus"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Best-in-pathway profile opportunity",
      "recapitulates LOF phenotype: biologic-like activity and convenience of oral pill"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 20
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 21
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "STAT6",
      "TYK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Th1/Th2/Th17 Inflammation",
      "Allergic Th2 Inflammation",
      "Type I IFN & IL-23 inflammation"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 22
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4 (KT-474)",
      "STAT6 (KT-621)",
      "TYK2 (KT-294)"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD",
      "RA",
      "Asthma",
      "COPD",
      "IBD",
      "others",
      "AD",
      "Asthma",
      "COPD",
      "CRSwNP",
      "EoE",
      "PN",
      "others",
      "IBD",
      "PsO",
      "PsA",
      "Lupus",
      "others"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "First-in-class broad anti-inflammatory oral degrader",
      "Dupilumab-like activity",
      "Biologic-like activity in a pill"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 23
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 24
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": "Oral Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 25
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 26
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "RA",
      "CAPS",
      "HS",
      "AD",
      "Gout",
      "Macrophage Activation Syndrome",
      "Generalized Pustular Psoriasis",
      "Asthma"
    ],
    "therapeutic_areas": [
      "immune-inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 27
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Dermatology",
      "Respiratory",
      "GI",
      "Rheumatology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 28
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [
      "inflammation"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Only Degrader Can Fully Block Inflammation",
      "IRAK4 degradation reduces signs and symptoms of HS and AD, while IRAK4 SMI inactive in Phase 2 HS trial",
      "IRAK4 blocks inflammation in blood and skin of HS and AD patients"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 29
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Selective and Potent IRAK4 Degrader Active in Multiple Cell Types",
      "Selectivity in PBMC",
      "Potent degradation in PBMC subsets and skin cells including fibroblasts, with single-digit nM DC50",
      "Associated with functional inhibition of TLR- and IL-1b-stimulated cytokine production",
      "Comprehensive understanding of degradation kinetics across cell types to enable human translation"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 30
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Hidradenitis Suppurativa",
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [
      "Dermatology"
    ],
    "clinical_phases": [],
    "claims": [
      "Potential for broad anti-inflammatory effect",
      "Competitive efficacy vs. pathway biologics",
      "Convenience of once-daily oral dosing"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 31
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "hidradenitis suppurativa",
      "atopic dermatitis"
    ],
    "therapeutic_areas": [
      "dermatology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Compelling Data and Early POC",
      "Robust IRAK4 degradation",
      "Promising clinical activity"
    ],
    "safety": [
      "Generally well-tolerated across all dose groups",
      "Safety, PK and PD comparable to healthy volunteers"
    ],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 32
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 33
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Hidradenitis Suppurativa",
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 34
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "HiSCR50 response rate of up to 50% and pain reduction of up to 66% in moderate to severe HS patients"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 35
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "EASI score reduction of up to 36% and pruritus reduction of up to 63% in moderate to severe AD patients"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 36
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": "oral degrader",
    "e3_ligase": null,
    "indications": [
      "inflammatory diseases"
    ],
    "therapeutic_areas": [
      "anti-inflammatory"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Robust IRAK4 degradation",
      "Favorable safety profile",
      "Systemic suppression of proinflammatory cytokines and chemokines",
      "Early signs of strong clinical activity"
    ],
    "safety": [
      "Favorable safety profile"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 38
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "Oral Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Dupilumab-like activity"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 39
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 40
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "allergic diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "STAT6 degradation can achieve dupilumab\u2013like pathway inhibition"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 41
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Asthma",
      "PN",
      "COPD",
      "CRSwNP",
      "EoE"
    ],
    "therapeutic_areas": [
      "DERMATOLOGY",
      "RESPIRATORY",
      "ENT",
      "GI"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 42
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Allergic Th2 Inflammation"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 43
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "TH2 diseases",
      "asthma",
      "COPD",
      "EoE",
      "AD",
      "CPG",
      "CU"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 44
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Complete STAT6 degradation selectivity in human PBMC proteome at 100 x DC90",
      "No other STATs are degraded to any extent"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 45
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 46
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "IL-4",
      "IL-13"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 47
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieves Dose Dependent Deep Degradation of STAT6 in vivo with Low Oral Doses",
      "potently degrades STAT6 across multiple preclinical species",
      "can degrade STAT6 to depletion with low oral doses"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 48
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Deep degradation of STAT6 in NHP after 14 days of daily oral dosing",
      "STAT6 is degraded in key disease-relevant tissues: blood, spleen, skin and lung"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 49
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "atopic dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Comparable in vivo efficacy to IL-4R\u03b1 saturating dose of Dupilumab"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 50
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 51
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "oral small molecule",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "atopic dermatitis",
      "lung inflammation"
    ],
    "clinical_phases": [
      "FIH: 2H 2024"
    ],
    "claims": [
      "Dupilumab-like efficacy",
      "Full IL-4 and IL-13 functional inhibition with picomolar IC50s superior to dupilumab",
      "Robust efficacy shown in in vivo models equal or superior to dupilumab"
    ],
    "safety": [
      "Well-tolerated in multiple preclinical safety studies at >40x efficacious concentration"
    ],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 52
    }
  },
  {
    "company": "kymera",
    "program": "KT-294",
    "targets": [
      "TYK2"
    ],
    "modality": "Oral",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 53
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 54
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "TYK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "autoimmune diseases",
      "inflammatory diseases"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 55
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Dermatology",
      "Gastroenterology",
      "Rheumatology",
      "CNS"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 56
    }
  },
  {
    "company": "kymera",
    "program": "KT-294",
    "targets": [
      "TYK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Inflammatory Bowel Disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Only TYK2 degradation recapitulates the human LOF phenotype of full pathway inhibition of Type I IFN, IL-12 and IL-23 and sparing of IL-10",
      "KT-294 does not inhibit IL-10, which is important in IBD",
      "KT-294 fully inhibits Type I IFN",
      "Full TYK2 degradation demonstrated by KT-294 leads to superior pathway inhibition to existing SMIs and potentially reach biologic-like activity"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 57
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 58
    }
  },
  {
    "company": "kymera",
    "program": "KT-294",
    "targets": [
      "TYK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly Selective Picomolar TYK2 Degrader",
      "Fully Inhibits Type I IFN and IL-12/23 and Spares IL-10/22"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 59
    }
  },
  {
    "company": "kymera",
    "program": "KT-294",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 60
    }
  },
  {
    "company": "kymera",
    "program": "KT-294",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 61
    }
  },
  {
    "company": "kymera",
    "program": "KT-294",
    "targets": [
      "TYK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Dose Dependent Deep Degradation of TYK2 in vivo with Low Oral Doses",
      "KT-294 potently degrades TYK2 across multiple preclinical species",
      "In NHP, KT-294 can degrade TYK2 to depletion with low oral doses"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 62
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 63
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 64
    }
  },
  {
    "company": "kymera",
    "program": "KT-294",
    "targets": [
      "TYK2"
    ],
    "modality": "oral degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "FIH"
    ],
    "claims": [
      "Potential Best-in-Class Opportunity with Biologic-like Profile",
      "Mega-blockbuster potential for oral degrader with biologic-like activity that is superior to TYK2 SMI"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 65
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 66
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 67
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 69
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "STAT6",
      "TYK2"
    ],
    "modality": "Oral QD Small Molecule Degraders",
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD",
      "RA",
      "Asthma",
      "IBD",
      "COPD",
      "PN",
      "CRSwNP",
      "EoE",
      "Psoriasis",
      "PsA",
      "Lupus"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Ph2",
      "Ph1"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 70
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": "Oral QD Small Molecule Degraders",
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD",
      "RA",
      "Asthma",
      "IBD",
      "other1"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Ph2"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 71
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 72
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 73
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 74
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "Kymera R.pdf",
      "slide": 75
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 1
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 2
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 3
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 4
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 5
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 6
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 7
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 8
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 9
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 10
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "S T A T 6",
      "I R F 5",
      "I R A K 4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 11
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 12
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6",
      "IRF5",
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Dermatology",
      "Respiratory",
      "GI",
      "Rheumatology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 13
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "CRSwNP",
      "EoE",
      "CSU",
      "PN",
      "SLE",
      "RA",
      "UC",
      "CD",
      "Sj\u00f6grens",
      "SSc",
      "DM",
      "HS"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 14
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6",
      "IRF5",
      "IRAK4"
    ],
    "modality": "Oral Small Molecule Degraders",
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "PN",
      "CRSwNP",
      "EoE",
      "BP",
      "CSU",
      "Lupus",
      "Sj\u00f6gren's",
      "RA",
      "IBD",
      "SSc",
      "DM"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Ph1",
      "Ph1b",
      "Ph2b"
    ],
    "claims": [],
    "safety": [
      "Safety",
      "degradation"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 15
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Dupilumab-like Activity in a Pill"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 16
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "CRSwNP",
      "CSU",
      "EoE",
      "PN"
    ],
    "therapeutic_areas": [
      "Allergic Th2 Inflammation"
    ],
    "clinical_phases": [],
    "claims": [
      "Only STAT6 degradation has the potential to fully block IL-4/IL-13 signaling with an oral daily drug"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 17
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "dermatology",
      "respiratory",
      "gastroenterology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 18
    }
  },
  {
    "company": "kymera",
    "program": "KT-6",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Excellent Degradation Potency and Selectivity",
      "Complete STAT6 Degradation Selectivity in Human PBMC Proteosome at 100 x DC90",
      "Picomolar Potency and Consistent Degradation Across all Disease-Relevant Cell Types Evaluated"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 19
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "IL-4",
      "IL-13"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Asthma"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Fully Blocks IL-4/13 Pathway",
      "Blocks Th2 Inflammation in Vivo",
      "IC50\u2019s Lower than Dupilumab"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 20
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Degrades STAT6 at Low Oral Doses in All Relevant Tissues",
      "Dose Responsive STAT6 Degradation in Dog Blood",
      "STAT6 Degradation in All Relevant Tissues in NHP"
    ],
    "safety": [
      "No adverse safety findings in any doses of 4-week GLP tox studies in NHP and rodents"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 21
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Moderate/Severe Atopic Dermatitis",
      "Asthma"
    ],
    "therapeutic_areas": [
      "Dermatology",
      "GI",
      "Respiratory"
    ],
    "clinical_phases": [
      "Ph1",
      "Ph1b",
      "Ph2b",
      "Ph3"
    ],
    "claims": [
      "Safety & tolerability",
      "Efficacy and safety in two initial Th2 diseases",
      "Ph3 dose selection for clinical activity franchise"
    ],
    "safety": [
      "Dosing for 28 days"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 22
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "robustly degrade STAT6 in blood and skin at doses that are safe and well-tolerated"
    ],
    "safety": [
      "Safety & tolerability of escalating single and multiple doses of KT-621"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 23
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [
      "Dermatology"
    ],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [
      "Demonstrate that KT-621 has a dupilumab-like biomarker signature in blood and skin lesions"
    ],
    "safety": [
      "Safety, PK, STAT6 degradation, Th2 biomarkers in blood and skin lesions, clinical activity (EASI, pruritus, IGA)"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 24
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Asthma"
    ],
    "therapeutic_areas": [
      "Th2 diseases"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 2b"
    ],
    "claims": [
      "Dupilumab-like activity",
      "Well-tolerated in preclinical studies"
    ],
    "safety": [
      "Well-tolerated in multiple preclinical safety studies at >40x efficacious concentration"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 25
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": "Oral Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 26
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "I&I"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 27
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": "oral degrader",
    "e3_ligase": null,
    "indications": [
      "Lupus",
      "Rheumatoid Arthritis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "potent",
      "selective",
      "well-tolerated"
    ],
    "safety": [
      "well-tolerated in safety studies up to 200-fold above the predicted human efficacious concentration"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 28
    }
  },
  {
    "company": "kymera",
    "program": "IRF5 Degrader",
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "LE",
      "j\u00f6gren\u2019s",
      "RA",
      "IB",
      "c1",
      "c2"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 29
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 30
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 31
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE",
      "Sj\u00f6gren\u2019s",
      "RA",
      "IBD"
    ],
    "therapeutic_areas": [
      "autoimmune diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "Blocking IRF5 activity has the potential for more effective, tolerated and durable responses"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 32
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 33
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "pro-inflammatory cytokines",
      "Type-I IFN",
      "Autoantibodies"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lupus",
      "Rheumatoid Arthritis"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degradation and selectivity",
      "Inhibition of pro-inflammatory cytokines",
      "Type-I IFN inhibition"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 34
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "pro-inflammatory cytokines",
      "Type-I IFN",
      "Autoantibodies"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lupus",
      "Rheumatoid Arthritis"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degradation and selectivity",
      "Inhibition of pro-inflammatory cytokines",
      "Type-I IFN inhibition"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 35
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 36
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Degrades all Cytoplasmic and Nuclear IRF5 (but not IRF3/7)",
      "Selectively depletes TLR7/8 induced IRF5 nuclear translocation, while sparing IRF7 and IRF3"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 37
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 38
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Systemic Lupus Erythematosus (SLE)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-579 blocks Type I IFN dependent genes at least as effectively as an anti-TLR7/8 drug (Afimetoran)",
      "KT-579 inhibits TLR7/8 induced ISGs that are associated with increased disease activity in SLE"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 39
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "pro-inflammatory cytokines",
      "Type-I IFN",
      "Autoantibodies"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lupus",
      "Rheumatoid Arthritis"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degradation and selectivity",
      "Inhibition of pro-inflammatory cytokines",
      "Type-I IFN inhibition"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 40
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "TNF\u03b1",
      "IL-12p40",
      "IL-6",
      "IL-1\u03b2",
      "IFN\u03b2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE"
    ],
    "therapeutic_areas": [
      "autoimmune diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 41
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Inhibits IgG Levels After TLR9 Activation (CpG-B)",
      "Reduces TLR9 (CpG-B) induced plasmablast differentiation",
      "Inhibits IgG production in SLE derived B cells"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 42
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "pro-inflammatory cytokines",
      "Type-I IFN",
      "Autoantibodies"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lupus",
      "Rheumatoid Arthritis"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degradation and selectivity",
      "Inhibition of pro-inflammatory cytokines",
      "Type-I IFN inhibition"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 43
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Effectively Blocks Circulating Cytokines In Mouse Model",
      "Leads to Significant Dose-dependent Inhibition of TLR7-R848 and TLR9-CpG-B Cytokine Production in Mouse"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 44
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lupus"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Demonstrated Generally Better Outcomes than Approved or Clinically Active Drugs",
      "Reduced proteinuria",
      "Prevented disease associated mortality better than all other approved or clinically active agents tested"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 45
    }
  },
  {
    "company": "kymera",
    "program": "IRF5 Degrader",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Decreased Proteinuria",
      "Early, Sustained and Complete Reduction in Anti-dsDNA Abs",
      "Superior Activity Reducing Anti-dsDNA at Week 37"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 46
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IFR5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Rheumatoid Arthritis"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Reduces Joint Swelling",
      "Significant Reduction in Circulating Pro-inflammatory Cytokines"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 47
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potently degrades IRF5",
      "Excellent safety profile",
      "No adverse effects at up to 200-fold predicted human efficacious exposure"
    ],
    "safety": [
      "Completed non-GLP toxicity studies in NHP and rodents with no adverse effects"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 48
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": "oral degrader",
    "e3_ligase": null,
    "indications": [
      "Lupus",
      "Sjogren's disease",
      "dermatomyositis",
      "RA",
      "IBD"
    ],
    "therapeutic_areas": [
      "autoimmune diseases",
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "first-in-class",
      "best-in-class profile",
      "highly selective",
      "potent"
    ],
    "safety": [
      "favorable safety profile",
      "no AEs in non-GLP tox studies"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 49
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6",
      "IRF5",
      "IRAK4"
    ],
    "modality": "Oral Small Molecule Degraders",
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "PN",
      "CRSwNP",
      "EoE",
      "BP",
      "CSU",
      "Lupus",
      "Sj\u00f6gren's",
      "RA",
      "IBD",
      "SSc",
      "DM"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Ph1",
      "Ph1b",
      "Ph2b"
    ],
    "claims": [],
    "safety": [
      "Safety",
      "degradation"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 50
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 51
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics Immunology Innovation Day Presentation_May 2025.pdf",
      "slide": 52
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 1
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 2
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 3
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 4
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 5
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 6
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 7
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT 6",
      "IRF 5",
      "IRAK 4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 8
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRF 5",
      "IRAK 4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "EoE",
      "CRSwNP",
      "CSU",
      "PN",
      "BP",
      "SLE",
      "RA",
      "UC",
      "CD",
      "Sj\u00f6grens",
      "SSc",
      "DM",
      "HS"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 9
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6",
      "IRF5",
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "HS",
      "CSU",
      "PN",
      "BP",
      "Vitiligo",
      "AA",
      "Asthma",
      "COPD",
      "CRSwNP",
      "IBD",
      "EoE",
      "RA",
      "SLE",
      "SSc",
      "Sj\u00f6gren\u2019s",
      "DM",
      "Myositis",
      "MG",
      "CIDP",
      "GD",
      "ITP"
    ],
    "therapeutic_areas": [
      "Dermatology",
      "Respiratory",
      "GI",
      "Rheumatology",
      "Other"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 10
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6",
      "IRF5",
      "IRAK4",
      "CDK23"
    ],
    "modality": "Oral Small Molecule Degraders",
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "EoE",
      "CRSwNP",
      "CSU",
      "PN",
      "BP",
      "Lupus",
      "Sj\u00f6gren's",
      "RA",
      "IBD",
      "SSc",
      "DM",
      "Breast cancer",
      "other solid tumors"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "IND-Enabling",
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 11
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 12
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Asthma",
      "Allergic Rhinitis"
    ],
    "therapeutic_areas": [
      "Type 2 diseases"
    ],
    "clinical_phases": [
      "Phase 1b",
      "Phase 2b"
    ],
    "claims": [
      "Dupilumab-like activity",
      "Deep STAT6 degradation",
      "Robust reductions in Type 2 biomarkers",
      "Meaningful improvements on clinical endpoints and PROs",
      "Favorable safety profile"
    ],
    "safety": [
      "Favorable safety profile"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 13
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Allergic Type 2 Inflammation"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 14
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "dermatology",
      "gastroenterology",
      "respiratory"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 15
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "atopic dermatitis",
      "asthma"
    ],
    "therapeutic_areas": [
      "Type 2 diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "has the potential to offer 'what patients want'",
      "transforming the treatment of AD, asthma, and other Type 2 diseases"
    ],
    "safety": [
      "no side effects or safety issues"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 16
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Type 2 Diseases",
      "AD",
      "Asthma",
      "EoE",
      "CSU",
      "PN",
      "BP",
      "COPD",
      "CRSwNP"
    ],
    "therapeutic_areas": [
      "dermatology",
      "GI",
      "respiratory"
    ],
    "clinical_phases": [
      "Ph1",
      "Ph1b",
      "Ph2b",
      "Ph3"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 17
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "allergic rhinitis",
      "asthma",
      "atopic dermatitis"
    ],
    "therapeutic_areas": [
      "immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Relieves allergic rhinitis symptoms (TNSS, RQLQ)",
      "Blocked IL-4 and IL-13 signaling in human cells and in vivo systems equally or more potently than dupilumab",
      "Robust activity in asthma and AD in mouse models",
      "Blocks Type 2 inflammation in skin and impacts AD lesions (EASI, vIGA-AD, and skin transcriptomic changes)",
      "Deep STAT6 degradation >95% in HV & patients with AD in blood",
      "Blocks Type 2 inflammation in lungs (FeNO) and relieves asthma symptoms (ACQ-5)",
      "Deep STAT6 degradation >94/95% in HV & patients with AD in skin",
      "Robust and consistent reductions in itch (PPNRS, SCORAD Itch, IL-31)"
    ],
    "safety": [
      "No AEs at any doses in: 4 weeks rat and NHP GLP tox",
      "4 months rat and NHP GLP tox",
      "Embryofetal development tox in rat, rabbit and NHP"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 18
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [
      "Dermatological",
      "Gastrointestinal"
    ],
    "clinical_phases": [
      "Phase 2b"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 19
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Moderate to Severe Eosinophilic Asthma"
    ],
    "therapeutic_areas": [
      "Respiratory"
    ],
    "clinical_phases": [
      "Phase 2b"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 20
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 21
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Compelling Clinical Profile",
      "Potential for Dupilumab-like Activity in a Pill",
      "Robust STAT6 Degradation in Blood and Skin Following Low Daily Oral Doses",
      "Reductions in Multiple Disease-Relevant Type 2 Biomarkers"
    ],
    "safety": [
      "Favorable safety profile: well-tolerated across all dose levels with safety profile undifferentiated from placebo"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 22
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Asthma",
      "Allergic Rhinitis"
    ],
    "therapeutic_areas": [
      "Type 2 Diseases"
    ],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [
      "Deep STAT6 degradation in blood and skin",
      "Robust reductions in Type 2 biomarkers",
      "Meaningful improvements of clinical endpoints and patient-reported outcomes"
    ],
    "safety": [
      "Well-tolerated and favorable safety profile"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 23
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [],
    "safety": [
      "Safety"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 24
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Deep STAT6 Degradation in Blood and Skin",
      "Degradation Maintained for 28 Days Across Both Dose Cohorts",
      "Median STAT6 degradation of 98% in blood in both dose groups maintained throughout the treatment period",
      "Deep skin degradation of 94% in both dose groups with multiple patients\u2019 STAT6 levels below the LLOQ"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 25
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 26
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "CCL26/Eotaxin-3",
      "CCL17/TARC",
      "CCL18/PARC",
      "CCL13/MCP-4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 27
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Rapid and Robust Reductions in EASI and SCORAD Across All Patients",
      "Reductions seen as early as Day 8 without apparent plateau during treatment duration",
      "Achieved robust clinical improvement across EASI-50 (76% overall), EASI-75 (29% overall) and vIGA-AD (19% overall)"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 28
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 29
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 30
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Asthma",
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "56% median FeNO reduction at Day 29",
      "100% responder rate in ACQ-5"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 31
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Allergic Rhinitis",
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved mean changes of \u20130.9 points in TNSS",
      "Achieved mean changes of -0.8 points in RQLQ",
      "TNSS responder rate was 57%",
      "RQLQ responder rate was 33%"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 32
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 33
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [],
    "safety": [
      "Well-tolerated with favorable safety at both 100 mg and 200 mg",
      "No SAEs or Severe AEs",
      "No dose-dependent pattern in the TEAEs",
      "No related TEAEs or TEAEs leading to discontinuation",
      "No AEs of conjunctivitis (or of any ocular disorder), herpes infections, or arthralgias",
      "No clinically relevant changes in vital signs, laboratory tests or ECGs"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 34
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Type 2 inflammation"
    ],
    "therapeutic_areas": [
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [
      "safely and deeply degraded STAT6",
      "blocked IL-4/13 biomarkers equally or numerically better than dupilumab",
      "demonstrated meaningful improvements on Type 2 biomarkers in blood and skin",
      "improvements on FeNO in AD and comorbid asthma patients",
      "improvements on clinical endpoints in patients with AD, comorbid asthma and allergic rhinitis",
      "results in line with or in some cases numerically exceeded published data for dupilumab at week 4"
    ],
    "safety": [
      "safely"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 35
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 36
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": "oral small molecule",
    "e3_ligase": null,
    "indications": [
      "lupus",
      "RA"
    ],
    "therapeutic_areas": [
      "autoimmune diseases"
    ],
    "clinical_phases": [
      "Phase 1 HV"
    ],
    "claims": [
      "first-in-class",
      "potent",
      "selective",
      "fully degrades IRF5",
      "favorable safety profile"
    ],
    "safety": [
      "de-risk safety"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 37
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 38
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SLE",
      "Sj\u00f6gren\u2019s",
      "RA",
      "IBD"
    ],
    "therapeutic_areas": [
      "autoimmune diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "Blocking IRF5 activity has the potential for more effective, tolerated and durable responses"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 39
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 40
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Rheumatology",
      "Gastroenterology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 41
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 42
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 43
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "TLR7",
      "TLR8",
      "TLR9"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Systemic Lupus Erythematosus"
    ],
    "therapeutic_areas": [
      "Autoimmune Diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "Effectively Blocks TLR Induced Pro-inflammatory Cytokines",
      "Reduces Total IgG levels in SLE PBMC Samples"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 44
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lupus"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Sustained Reduction of Serum Anti-dsDNA",
      "All KT-579 Treated Mice Survived Length of Study",
      "KT-579 administered once daily for 63 days was well tolerated and prevented mortality more effectively than all other approved or clinically active comparator agents tested",
      "KT-579 led to sustained reduction of serum anti-dsDNA levels and reduction in splenic plasmablasts, differentiated B cells, and plasma cells, achieving effects comparable to, or better than, standard of care"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 45
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Significantly Decreases IgG, Complement 3 (C3) and Renal Disease Progression",
      "Clear reduction in IgG/complement glomeruli staining indicating reduced kidney disease involvement in SLE MRL/lpr mouse model with IRF5 degrader as compared to standard of care"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 46
    }
  },
  {
    "company": "kymera",
    "program": "IRF5 Degrader",
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Lupus"
    ],
    "therapeutic_areas": [
      "Autoimmune Diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "Decreased Proteinuria",
      "Early, Sustained and Complete Reduction in Anti-dsDNA Abs",
      "Superior Activity Reducing Anti-dsDNA at Week 37"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 47
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IFR5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Rheumatoid Arthritis"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Reduces Joint Swelling",
      "Leads to Significant Reduction in Joint Swelling Comparable to Tofacitinib",
      "Results in significant reduction of circulating pro-inflammatory cytokines",
      "Results in significant reduction of pathogenic infiltrating T cells"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 48
    }
  },
  {
    "company": "kymera",
    "program": "KT-579",
    "targets": [
      "IRF5"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potently degrades IRF5 across multiple preclinical species with low oral doses",
      "Completed non-GLP toxicity studies in NHP and rodents with no adverse effects at up to 200-fold predicted human efficacious exposure"
    ],
    "safety": [
      "Excellent safety profile"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 49
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 50
    }
  },
  {
    "company": "kymera",
    "program": "KT-485",
    "targets": [
      "IRAK4"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "highly selective",
      "potent",
      "oral"
    ],
    "safety": [
      "absence of any QTc signal"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 51
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "CDK2"
    ],
    "modality": "Molecular Glue Degrader",
    "e3_ligase": null,
    "indications": [
      "breast cancer",
      "solid tumors"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "potential best-in-class profile",
      "exquisite selectivity for CDK2",
      "selectively degrade CDK2 while sparing closely related kinases"
    ],
    "safety": [
      "potentially broader therapeutic index",
      "minimal impact on healthy tissue"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 52
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [
      "asthma",
      "AD"
    ],
    "therapeutic_areas": [
      "immunology"
    ],
    "clinical_phases": [
      "Phase 2b",
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 53
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 54
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 55
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "IL-4",
      "IL-13",
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Compelling Preclinical Profile",
      "Potential for Dupilumab-like Activity",
      "Exquisite Selectivity",
      "Robust Degradation in Relevant Cell Types",
      "Full Inhibition of IL-4/IL-13 Pathways, More Potent than Dupilumab",
      "Excellent Preclinical Activity Comparable or Superior to Dupilumab"
    ],
    "safety": [
      "Favorable safety profile: well-tolerated in multiple preclinical species and safety studies at concentrations 40-fold above efficacious dose with up to 4 months of dosing"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 56
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a"
    ],
    "claims": [],
    "safety": [
      "Well Tolerated Across All Doses Evaluated and Safety Profile Undifferentiated from Placebo",
      "No Serious Adverse Events",
      "No Severe Adverse Events",
      "No dose dependent pattern in Treatment Emergent Adverse Events (TEAEs)",
      "No Treatment Related AE (TRAE) reported in >1 participant",
      "No related TEAEs leading to discontinuation",
      "No clinically relevant changes in vital signs, laboratory tests, and ECGs"
    ],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 57
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 58
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 59
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Severe AD"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 60
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 61
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 62
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 63
    }
  },
  {
    "company": "kymera",
    "program": "KT-485",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "RA",
      "CAPS",
      "HS",
      "AD",
      "RP",
      "Gout",
      "Macrophage Activation Syndrome",
      "Generalized Pustular Psoriasis",
      "Asthma",
      "COPD"
    ],
    "therapeutic_areas": [
      "immune-inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 64
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 65
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 66
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "Kymera Therapeutics Corporate Presentation_January 2026_R.pdf",
      "slide": 67
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 1
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 2
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 3
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 4
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 5
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 6
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 7
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 8
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 9
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 10
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Immunology/Inflammation",
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 11
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "IL-1R/TLR",
      "MYD88MT",
      "JAK/STAT",
      "STAT3",
      "p53",
      "MDM2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Immuno-inflammatory Diseases: HS, AD, RA, others",
      "Liquid & Solid Tumors",
      "Autoimmune & Fibrotic Diseases"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Immunology-Inflammation"
    ],
    "clinical_phases": [
      "Discovery",
      "IND Enabling",
      "Phase 1",
      "Phases 2/3"
    ],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 12
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "FIRST randomized, placebo-controlled trial in healthy volunteers",
      "FIRST Hetero-bifunctional degrader against an undrugged transcription factor in clinic"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 13
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 14
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 15
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 16
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 17
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 18
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 19
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Rheumatoid Arthritis",
      "CAPS",
      "Hidradenitis Suppurativa",
      "Atopic Dermatitis",
      "Gout",
      "Macrophage Activation Syndrome",
      "Generalized Pustular Psoriasis"
    ],
    "therapeutic_areas": [
      "autoimmune inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Adult humans with IRAK4 Null Mutation are healthy"
    ],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 20
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Hidradenitis Suppurativa",
      "Rheumatoid Arthritis",
      "Lupus",
      "IBD",
      "Gout",
      "Psoriasis",
      "Atopic Dermatitis",
      "Asthma",
      "COPD",
      "CRSwNP"
    ],
    "therapeutic_areas": [
      "Th1-Th17",
      "Th2"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 21
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 22
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS"
    ],
    "therapeutic_areas": [
      "inflammation"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 23
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-474 DC50 = 2.1 nM in human immune cells",
      "KT-474 only degraded IRAK4 in human immune cells at concentration 10-fold above the DC90",
      "KT-474 better able to inhibit IL-6 under both LPS and LPS + IL-1\u03b2 than clinically active IRAK4 SM kinase inhibitor PF-06550833"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 24
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Sclerosis",
      "Gout",
      "Psoriasis"
    ],
    "therapeutic_areas": [
      "immune-inflammatory"
    ],
    "clinical_phases": [],
    "claims": [
      "IRAK4 knockdown of \u226585% in whole blood achieved anti-inflammatory effect comparable to potent corticosteroids or approved standard of care drugs"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 25
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "HS"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "Safety & tolerability"
    ],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 26
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 27
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 28
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "TLRs",
      "IRAK3",
      "MyD88",
      "IRAK4",
      "IRAK1",
      "IRAK2",
      "TRAF6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 29
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 30
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 31
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "description": "No SAEs",
        "cohort": null
      },
      {
        "description": "Treatment-related AEs observed only in SAD 5 and SAD 6; all were self-limiting and resolved",
        "cohort": [
          "SAD 5",
          "SAD 6"
        ]
      },
      {
        "description": "No treatment-related AEs in SAD 7",
        "cohort": "SAD 7"
      },
      {
        "description": "No significant ECG changes",
        "cohort": null
      },
      {
        "description": "Headache",
        "cohort": [
          "SAD 5",
          "SAD 6"
        ],
        "severity": "Moderate",
        "number_of_subjects": 2
      },
      {
        "description": "Nausea",
        "cohort": [
          "SAD 5"
        ],
        "severity": "Mild",
        "number_of_subjects": 2
      },
      {
        "description": "Nausea",
        "cohort": [
          "SAD 6"
        ],
        "severity": "Mild",
        "number_of_subjects": 2
      }
    ],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 32
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 33
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Near Complete and Sustained IRAK4 Degradation with Multiple Daily Oral Doses (14 Days)",
      "Steady state IRAK4 reduction achieved between Days 7 and 14",
      "Recovery towards baseline by Day 28 (2 weeks after last dose)",
      "MAD 2 through 4 approached Lower Limit of Quantitation (LLOQ)"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 34
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved >98% IRAK4 Degradation",
      "Plateau in IRAK4 Reduction after 14 days in PBMC after 100 mg"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 35
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 36
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 37
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Reduced IRAK4 to Near LLOQ in the Skin",
      "Dose-dependent IRAK4 degradation in skin",
      "Mean IRAK4 levels at 200 mg dose nearing LLOQ by Day 14, with knockdown up to 90% at 200 mg"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 38
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 39
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 40
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "adverse_event": "Headache",
        "subjects": 6,
        "severity": "Moderate, Mild",
        "cohort": "MAD2"
      },
      {
        "adverse_event": "Palpitations",
        "subjects": 3,
        "severity": "Mild",
        "cohort": "MAD 3"
      },
      {
        "adverse_event": "Nausea",
        "subjects": 2,
        "severity": "Mild",
        "cohort": "MAD 4"
      }
    ],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 41
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "proof of mechanism (IRAK4 degradation)",
      "proof of biology (broad inhibition of cytokine induction)",
      "marked reduction of IRAK4 protein in blood and skin",
      "strong and broad inhibition of whole blood ex vivo cytokine induction",
      "prolonged suppression of IRAK4 in blood and skin"
    ],
    "safety": [
      "shown to be safe and well-tolerated"
    ],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 42
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 43
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 44
    }
  },
  {
    "company": "sanofi",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "Sanofi_R_D_Approach_Presentation.pdf",
      "slide": 45
    }
  },
  {
    "company": "kymera",
    "program": "SAR444656",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 46
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 47
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": "protein degrader",
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Hidradenitis Suppurativa"
    ],
    "therapeutic_areas": [
      "immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degradation of IRAK4 protein abolishes its kinase activity and scaffold function",
      "SAR444656 inhibits pNFkB and pro-inflammatory cytokines"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 48
    }
  },
  {
    "company": "kymera",
    "program": "KT-413",
    "targets": [
      "IRAK1"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 49
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "Ikaros",
      "Aiolos"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [
      "DLBCL"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 50
    }
  },
  {
    "company": "kymera",
    "program": "IRAKIMiD",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYD88-mutant DLBCL",
      "Waldenstr\u00f6m\u2019s Macroglobulinemia",
      "Primary Central Nervous System Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 51
    }
  },
  {
    "company": "kymera",
    "program": "KT-413",
    "targets": [
      "IRAK4",
      "Ikaros",
      "Aiolos"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYD88MT DLBCL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent Degrader of IRAK4 and IMiD Substrates",
      "Profound antitumor effect in vitro and in vivo",
      "More active in MYD88MT DLBCL cells than CC-220 and KTX-545"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 52
    }
  },
  {
    "company": "kymera",
    "program": "KT-413",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly Active on Intermittent Dosing Regimens",
      "Superior Anti-tumor activity",
      "Complete or partial regressions",
      "Extended tumor exposure",
      "Strong degradation of both IRAK4 and IMiD substrates"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 53
    }
  },
  {
    "company": "kymera",
    "program": "KT-413",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "KT-413 administered on intermittent schedules leads to strong regressions in combination with the BTK inhibitor Ibrutinib",
      "KT-413 administered on intermittent schedules leads to deep and durable regressions in combination with the BCL-2 inhibitor, Venetoclax",
      "KT-413 administered on intermittent schedules leads to deep and durable regressions in combination with Rituxan"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 54
    }
  },
  {
    "company": "kymera",
    "program": "KT-413",
    "targets": [
      "IRAK4",
      "Ikaros",
      "Aiolos"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R B-cell lymphoma",
      "MYD88 mutant R/R DLBCL",
      "MYD88 wild-type R/R DLBCL",
      "Waldenstr\u00f6m\u2019s Macroglobulinemia",
      "Primary CNS Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [],
    "safety": [
      "safety",
      "tolerability",
      "MTD/RP2D"
    ],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 55
    }
  },
  {
    "company": "kymera",
    "program": "KT-413",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Waldenstrom\u2019s",
      "PCNSL",
      "R/R MYD88mut DLBCL",
      "R/R MYD88mut DLBCL + SOC",
      "1st line + SOC DLBCL",
      "Wild Type DLBCL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "First US Approval (Accelerated)",
      "Second US Approval (Full)"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 56
    }
  },
  {
    "company": "kymera",
    "program": "KT-413",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYD88MT DLBCL",
      "PCNSL",
      "WM"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "monotherapy",
      "combinations"
    ],
    "claims": [
      "Potential to be First Precision Medicine in DLBCL to Target a Genetically-defined Population"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 57
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 58
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "T cell malignancies",
      "DLBCL",
      "AML",
      "TKI resistant oncogene-driven solid tumors"
    ],
    "therapeutic_areas": [
      "oncology",
      "immuno-oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "First-in-class opportunity to address STAT3 driven pathology across large and diverse indications"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 59
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Peripheral T-cell Lymphoma (PTCL)",
      "Cutaneous T-cell Lymphoma (CTCL)",
      "Large Granular Lymphocytic Leukemia (LGL-L)",
      "Solid Tumors PD-1 Combo: e.g. Stage IV CRC \u2013 MSI-H"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 60
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly Selective Degradation of STAT3",
      "Selective degradation of only STAT3 protein"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 61
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 62
    }
  },
  {
    "company": "kymera",
    "program": "KTX-201",
    "targets": [
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Immuno-Oncology"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "synergizes with anti-PD-1 leading to 60% complete responses",
      "complete responders reject tumor rechallenge demonstrating development of long-term immune memory",
      "combination extends survival"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 63
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R B-cell lymphoma",
      "Advanced solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [],
    "safety": [
      "Safety",
      "Tolerability"
    ],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 64
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "\u22652nd Line R/R PTCL",
      "1st Line PTCL",
      "LGL-L",
      "Solid Tumor CRC MSI-H"
    ],
    "therapeutic_areas": [
      "PTCL",
      "CTCL"
    ],
    "clinical_phases": [
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Accelerated Approval",
      "Full Approval"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 65
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [
      "STAT3"
    ],
    "modality": "heterobifunctional degrader",
    "e3_ligase": null,
    "indications": [
      "liquid tumor",
      "solid tumors"
    ],
    "therapeutic_areas": [
      "heme malignancies"
    ],
    "clinical_phases": [
      "clinical development"
    ],
    "claims": [
      "First-in-class Opportunity",
      "Profound single agent activity",
      "Promising combo activity with anti-PD1"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 66
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 67
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 68
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Systemic Sclerosis",
      "Idiopathic Pulmonary Fibrosis",
      "Atopic Dermatitis",
      "Rheumatoid Arthritis"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 69
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 70
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 71
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 72
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 73
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "MDM2",
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "IND",
      "IND",
      "IND"
    ],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 74
    }
  },
  {
    "company": "kymera",
    "program": "KT-253",
    "targets": [
      "MDM2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Solid Tumors",
      "Liquid Tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 75
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": "MDM2",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 76
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "MDM2",
      "p53"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "MDM2 small molecule inhibitors of MDM2/p53 interaction show activity in the clinic",
      "MDM2 degraders can overcome the p53-dependent feedback loop that upregulates MDM2",
      "MDM2 degrader can induce an acute apoptotic response in tumor cells, increasing efficacy and therapeutic index vs a small molecule inhibitor"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 77
    }
  },
  {
    "company": "kymera",
    "program": "KT-253",
    "targets": [
      "MDM2",
      "p53"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "IND enabling"
    ],
    "claims": [
      "Superior to MDM2/p53 Small Molecule Inhibitors",
      "Potent MDM2 degrader",
      "Strongly stabilizes p53",
      "Superior tumor cell killing (pM range)",
      ">200-fold more potent in tumor cell killing assays than SMI's due to its mechanism of action",
      "Selective degradation of KT-253"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 78
    }
  },
  {
    "company": "kymera",
    "program": "KT-253",
    "targets": [
      "MDM2",
      "p53"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 79
    }
  },
  {
    "company": "kymera",
    "program": "KT-253",
    "targets": [
      "MDM2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "4 hr target coverage by KT-253 is sufficient to induce apoptosis",
      "Intermittent dosing schedule of KT-253 can drive efficacy while increasing therapeutic index"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 80
    }
  },
  {
    "company": "kymera",
    "program": "KT-253",
    "targets": [
      "MDM2",
      "p53",
      "p21",
      "PUMA"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Single Dose of KT-253 Leads to Sustained Tumor Regression",
      "Single Dose of KT-253 Achieves Sustained Tumor Regression",
      "MDM2 Degradation (KT-253, 1 mg/kg) Leads to Fast Increase in p53, p21, and PUMA (Key Apoptotic Biomarker)"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 81
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Liquid Tumors",
      "Solid Tumors"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 82
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Mesothelioma",
      "Melanoma",
      "DLBCL",
      "Prostate cancer",
      "Cholangiocarcinoma",
      "Cervical cancer",
      "AML",
      "Renal cell cancer",
      "Uveal melanoma",
      "Thyroid cancer",
      "Liposarcoma",
      "HCC",
      "Lymphomas"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 83
    }
  },
  {
    "company": "kymera",
    "program": "KT-253",
    "targets": [
      "MDM2",
      "p53"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AML",
      "Uveal melanoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent MDM2 Degrader",
      "Best-in-Class p53 Stabilizer",
      "Inhibits tumor cell growth with picomolar potency",
      "More than 200-fold more potent than clinically active MDM2 small molecule inhibitors",
      "Blocks the feedback loop which up-regulates MDM2 production",
      "Induces apoptosis in cell lines and in vivo xenografts",
      "Ensures high activity and improved therapeutic index vs SMI\u2019s"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 84
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 85
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 86
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "MDM2",
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": [
      "E3-1",
      "E3-2"
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 87
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 88
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 89
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 90
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 91
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 92
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 93
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 94
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 95
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 96
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "MDM2",
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 97
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 98
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [
      "immune-inflammatory"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Ph1"
    ],
    "claims": [
      "best-in-class"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 99
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Immuno-inflammatory Diseases: HS, AD, RA",
      "Liquid & Solid Tumors",
      "Autoimmune & Fibrotic Diseases"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Immunology-Inflammation"
    ],
    "clinical_phases": [
      "Discovery",
      "IND Enabling",
      "Phase 1",
      "Phases 2/3"
    ],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 100
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 101
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 102
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 103
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 104
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "KYM_R_D_Day_Deck_Final_Dec_2021.pdf",
      "slide": 105
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "Oral Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 1
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 2
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "asthma",
      "atopic dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2b"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 3
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 4
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 5
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 6
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 7
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 8
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Allergic Type 2 Inflammation"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 9
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 10
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "IL-4",
      "IL-13",
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Compelling Preclinical Profile",
      "Potential for Dupilumab-like Activity",
      "Exquisite Selectivity",
      "Robust Degradation in Relevant Cell Types",
      "Full Inhibition of IL-4/IL-13 Pathways, More Potent than Dupilumab",
      "Excellent Preclinical Activity Comparable or Superior to Dupilumab"
    ],
    "safety": [
      "Favorable safety profile: well-tolerated in multiple preclinical species and safety studies at concentrations 40-fold above efficacious dose with up to 4 months of dosing"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 11
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Type 2 Inflammatory Diseases"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Compelling Clinical Profile",
      "Potential for Dupilumab-like Activity",
      "Robust STAT6 Degradation"
    ],
    "safety": [
      "Favorable safety profile",
      "Well-tolerated across all dose levels",
      "Safety profile undifferentiated from placebo"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 12
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Asthma",
      "Eosinophilic Esophagitis",
      "Chronic Spontaneous Urticaria",
      "Prurigo Nodularis",
      "Bullous Pemphigoid",
      "Chronic Obstructive Pulmonary Disease",
      "Chronic Rhinosinusitis with Nasal Polyps"
    ],
    "therapeutic_areas": [
      "Dermatology",
      "Gastrointestinal",
      "Respiratory"
    ],
    "clinical_phases": [
      "Ph1",
      "Ph1b",
      "Ph2b",
      "Ph3"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 13
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "atopic dermatitis",
      "asthma",
      "allergic rhinitis"
    ],
    "therapeutic_areas": [
      "dermatology",
      "respiratory"
    ],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [
      "Strong fidelity of translation from Phase 1a healthy volunteer study to AD patients",
      "Deep STAT6 degradation in blood and skin",
      "Robust reductions in Type 2 biomarkers in blood, skin lesions and lung (FeNO)",
      "Meaningful improvements of clinical endpoints and patient-reported outcomes"
    ],
    "safety": [
      "Well-tolerated and favorable safety profile similar to Phase 1a healthy volunteer study"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 14
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 15
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 16
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 17
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 18
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 19
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 20
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 21
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Median STAT6 degradation of 98% in blood in both dose groups after 4 weeks of treatment",
      "Deep degradation maintained throughout dosing period",
      "Plasma PK profile at 100 and 200 mg similar to healthy volunteer study",
      "Strong translation from healthy volunteer study"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 22
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Median STAT6 degradation of 94% in skin in both dose groups after 4 weeks of treatment using targeted Mass Spec",
      "Deep skin degradation with multiple patients\u2019 STAT6 levels below the LLOQ"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 23
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 24
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 25
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 26
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 27
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 28
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Median TARC Reduction of 74% in Patients with TARC Levels Comparable to Dupilumab AD Studies",
      "Rapid and robust reduction of TARC across both dose cohorts",
      "74% median TARC reduction similar to dupilumab at week 4 when stratifying for patients with similar baseline TARC levels",
      "KT-621 reached dupilumab-like TARC inhibition"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 29
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Median Serum Eotaxin-3 Reduction of up to 73%",
      "Reduction exceeds the dupilumab 52-week results of 51% median reduction in CRSwNP trial and 38% in asthma trial"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 30
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Median Serum IgE Reduction of up to 14%",
      "IgE reduction comparable to dupilumab data in AD studies at week 41"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 31
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "IL-31"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [
      "Dermatology"
    ],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [
      "Robust reduction of pruritogenic cytokine IL-31"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 32
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved up to 33% Reduction in FeNO in AD Patients",
      "First known demonstration of FeNO reduction in AD patients"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 33
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 34
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "CCL26/Eotaxin-3",
      "CCL17/TARC",
      "CCL18/PARC",
      "CCL13/MCP-4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [
      "Dermatology"
    ],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 35
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "CCL26/Eotaxin-3",
      "CCL17/TARC",
      "CCL18/PARC",
      "CCL13/MCP-4",
      "CXCL1/GRO-\u237a",
      "PI3/Peptidase inhibitor 3",
      "KRT16/Keratin 16",
      "MMP12",
      "POSTN/Periostin",
      "OSMR/Oncostatin-M receptor",
      "S100A12",
      "TSLP"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [
      "Dermatology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 36
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 37
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 38
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 39
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Robust Clinical Improvement Across EASI-50, EASI-75, and vIGA-AD 0/1 Measures"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 40
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 41
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Robust and Consistent Reductions in Itch Across Independent Clinical Measures",
      "Mean % Change from Baseline at D29 for KT-621 100 mg QD: -47%",
      "Mean % Change from Baseline at D29 for KT-621 200 mg QD: -35%",
      "Mean % Change from Baseline at D29 Overall: -40%",
      "Rapid and robust mean Peak Pruritus NRS and SCORAD-Itch reduction in both dose cohorts"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 42
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 43
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved 76% Overall Mean Reduction in SCORAD-Sleeplessness",
      "Rapid and robust mean SCORAD-Sleeplessness reduction in both dose cohorts"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 44
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 45
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 46
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Severe AD"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 47
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Asthma",
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "56% median FeNO reduction at Day 29",
      "100% responder rate in ACQ-5"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 48
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Allergic Rhinitis",
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved mean changes of \u20130.9 in TNSS",
      "Achieved mean changes of -0.8 in RQLQ",
      "TNSS responder rate was 57%",
      "RQLQ responder rate was 33%"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 49
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 50
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 51
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Well-tolerated with favorable safety at both 100 mg and 200 mg with a profile similar to what was observed in the Phase 1a healthy volunteer trial",
      "No SAEs or Severe AEs",
      "No dose-dependent pattern in the TEAEs",
      "No related TEAEs or TEAEs leading to discontinuation",
      "No AEs of conjunctivitis (or of any ocular disorder), herpes infections, or arthralgias",
      "No clinically relevant changes in vital signs, laboratory tests or ECGs"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 52
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Type 2 Allergic Diseases"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [
      "Deep STAT6 Degradation in Blood and Skin",
      "IL-4/IL-13 Pathway Inhibition",
      "Dupilumab-like reductions in TARC, Eotaxin-3 and IgE",
      "Reduction of IL-31",
      "Dupilumab-like reductions in core Type 2 inflammation and AD disease-relevant gene sets in skin lesions",
      "First known demonstration of FeNO reduction in AD patients",
      "Dupilumab-like impact on EASI, SCORAD and multiple measures of pruritus",
      "No rescue therapy required during treatment period",
      "Similar effect in patients with low or high baseline EASI/TARC",
      "Early evidence of activity in asthma and allergic rhinitis"
    ],
    "safety": [
      "Well tolerated",
      "Safety profile similar to Phase 1a healthy volunteer trial"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 53
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 54
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Type 2 inflammation",
      "Atopic Dermatitis",
      "asthma",
      "allergic rhinitis"
    ],
    "therapeutic_areas": [
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [
      "safely and deeply degraded STAT6",
      "blocked IL-4/13 biomarkers equally or numerically better than dupilumab",
      "demonstrated meaningful improvements on Type 2 biomarkers in blood and skin",
      "improvements on FeNO in AD and comorbid asthma patients",
      "improvements on clinical endpoints in patients with AD, comorbid asthma and allergic rhinitis",
      "results in line with or in some cases numerically exceeded published data for dupilumab at week 4"
    ],
    "safety": [
      "safely and deeply degraded STAT6"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 55
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Alzheimer's Disease",
      "asthma"
    ],
    "therapeutic_areas": [
      "Type 2 market"
    ],
    "clinical_phases": [
      "Phase 1b",
      "Phase 2b"
    ],
    "claims": [
      "oral, biologics-like profile",
      "potential to broaden clinical access",
      "disrupt a biologics-dominated market"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 56
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera KT-621 BroADen Phase 1b Presentation_December 2025.pdf",
      "slide": 57
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 1
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 2
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 3
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [
      "Immunology",
      "Inflammation",
      "Oncology"
    ],
    "clinical_phases": [
      "clinical stage"
    ],
    "claims": [
      "demonstrating degrader vs. small molecule inhibitors (SMI) biological differentiation",
      "potential best in class profile in I/I"
    ],
    "safety": [
      "demonstrated fidelity of translation of PK, PD and safety across three clinical programs in I/I and oncology patients"
    ],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 4
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "IL-1R/TLR",
      "IRAKIMiD",
      "MYD88MT",
      "JAK/STAT",
      "STAT3",
      "KT-413",
      "KT-333",
      "p53",
      "MDM2",
      "KT-253"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Immuno-inflammatory Diseases: HS, AD, RA, others",
      "Liquid & Solid Tumors",
      "Autoimmune & Fibrotic Diseases"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Immunology-Inflammation"
    ],
    "clinical_phases": [
      "Discovery",
      "IND Enabling",
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 5
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "demonstrating PK/PD consistent with pre-clinical models",
      "No dose-limiting toxicities observed to date"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 6
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 7
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Peripheral T-cell lymphoma (PTCL)",
      "Cutaneous T-cell lymphoma (CTCL)",
      "Large granular lymphocyte leukemia (LGL-L)",
      "Solid Tumors, PD-1 Combo (e.g. Stage IV MSI-H CRC)"
    ],
    "therapeutic_areas": [
      "oncology",
      "immuno-oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 8
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ALK+ ALCL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Complete Tumor Regressions Associated with Robust STAT3 KD for \u223c48h in Preclinical Models",
      "10 mg/kg sufficient to drive full tumor regression in SU-DHL-1 that was durable for multiple weeks after the last dose"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 9
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "PTCL",
      "CTCL",
      "LGL-L",
      "Solid Tumors"
    ],
    "therapeutic_areas": [
      "Lymphoma",
      "Leukemia"
    ],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [
      "Safety/Tolerability and MTD and RP2D",
      "Safety/Tolerability at RP2D in Patients with Lymphoma/Leukemia and Solid Tumors",
      "PK Parameters of KT-333",
      "Preliminary Estimates of Activity",
      "Preliminary Clinical Activity (ORR, DoR, PFS, DCR, OS)",
      "PD Effects of KT-333"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 10
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "No DLTs",
      "no treatment-related SAEs",
      "no AEs leading to discontinuation"
    ],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 11
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 12
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 13
    }
  },
  {
    "company": "kymera",
    "program": "KT-333",
    "targets": [
      "STAT3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Initial Proof-of-Mechanism demonstrated",
      "STAT3 degradation consistent with preclinical predictions",
      "At least 48h of target degradation observed"
    ],
    "safety": [
      "DL1 level generally well-tolerated with no DLTs or treatment-related SAEs"
    ],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 14
    }
  },
  {
    "company": "kymera",
    "program": "IRAKIMiD (KT-413)",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 15
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "Ikaros",
      "Aiolos"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "MYD88MT DLBCL",
      "MYD88MT Waldenstr\u00f6m\u2019s Macroglobulinemia",
      "MYD88MT PCNS Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 16
    }
  },
  {
    "company": "kymera",
    "program": "KT-413",
    "targets": [
      "IRAK4",
      "Ikaros"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Complete Tumor Regressions",
      "Strong antitumor activity",
      "Superior activity compared to IMiD CC-220"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 17
    }
  },
  {
    "company": "kymera",
    "program": "KT-413",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R DLBCL",
      "R/R B-cell NHL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [
      "Safety/Tolerability and MTD and RP2D",
      "Safety/Tolerability at RP2D in Patients with DLBCL",
      "PK Parameters of KT-413",
      "Preliminary Estimates of Activity",
      "Preliminary Clinical Activity (ORR, DoR, PFS, DCR, OS)",
      "PD Effects of KT-413"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 18
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "B-cell lymphoma",
      "Follicular lymphoma",
      "DLBCL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "No DLTs",
      "No treatment-related SAEs",
      "No AEs leading to discontinuation",
      "No neutropenia in first two dose levels"
    ],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 19
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 20
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4",
      "Ikaros",
      "Aiolos"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 21
    }
  },
  {
    "company": "kymera",
    "program": "KT-413",
    "targets": [
      "Ikaros",
      "Aiolos",
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Up to 95/100% KD of Ikaros/Aiolos",
      "40% KD of IRAK4 in blood",
      "At least 72h target degradation observed"
    ],
    "safety": [
      "First 2 dose levels generally well-tolerated",
      "No DLTs",
      "No treatment-related SAEs",
      "No neutropenia observed"
    ],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 22
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 23
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Rheumatoid Arthritis",
      "CAPS",
      "Hidradenitis Suppurativa",
      "Atopic Dermatitis",
      "Gout",
      "Macrophage Activation Syndrome",
      "Generalized Pustular Psoriasis"
    ],
    "therapeutic_areas": [
      "autoimmune inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 24
    }
  },
  {
    "company": "kymera",
    "program": "PF-06550833",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 25
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Hidradenitis Suppurativa",
      "Rheumatoid Arthritis",
      "Lupus",
      "IBD",
      "Gout",
      "Psoriasis",
      "Atopic Dermatitis",
      "Asthma",
      "COPD",
      "CRSwNP"
    ],
    "therapeutic_areas": [
      "Th1-Th17",
      "Th2"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 26
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Healthy Volunteers",
      "Hidradenitis Suppurativa",
      "Atopic Dermatitis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "IRAK4 degradation of 80-90% in PBMC using Flow Cytometry",
      "Reduction to near lower limit of quantification with Mass Spectrometry",
      "Associated with up to 85% inhibition of multiple disease-relevant cytokines and chemokines in ex vivo TLR stimulation assay at 100 mg dose",
      "Dose-dependent IRAK4 degradation in skin of >50%",
      "Generally well tolerated at doses up to 200 mg with no SAEs",
      "Non-adverse, self-limiting QTcF prolongation in 10-20 msec range was neither dose- nor exposure-dependent"
    ],
    "safety": [
      "Generally well tolerated at doses up to 200 mg with no SAEs",
      "Non-adverse, self-limiting QTcF prolongation in 10-20 msec range"
    ],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 27
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 28
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 29
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 30
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 31
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 32
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 33
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 34
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Hidradenitis Suppurativa"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 35
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 36
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "adverse_event": "Headache",
        "number_of_patients": 6,
        "severity": {
          "mild": 5,
          "severe": 1
        },
        "outcome": {
          "recovered": 6
        }
      },
      {
        "adverse_event": "Fatigue",
        "number_of_patients": 4,
        "severity": {
          "mild": 4
        },
        "outcome": {
          "recovered": 4
        }
      },
      {
        "adverse_event": "Diarrhea",
        "number_of_patients": 2,
        "severity": {
          "mild": 2
        },
        "outcome": {
          "recovered": 2
        }
      }
    ],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 37
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 38
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 39
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 40
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IL-6",
      "CRP",
      "IL-1\u03b2",
      "SAA"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 41
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 42
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 43
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 44
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 45
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 46
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 47
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 48
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 49
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 50
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 51
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 52
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 53
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 54
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 55
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 56
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 57
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 58
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 59
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 60
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [
      "inflammatory diseases"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "safety, PK and PD comparable to healthy volunteers",
      "modest, non-adverse QTcF prolongation observed",
      "robust degradation of IRAK4 associated with systemic anti-inflammatory effect",
      "promising clinical activity exceeding benchmark placebo rates",
      "superior clinical potential over SMI"
    ],
    "safety": [
      "safety, PK and PD comparable to healthy volunteers",
      "modest, non-adverse QTcF prolongation observed to spontaneously resolve"
    ],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 61
    }
  },
  {
    "company": "kymera",
    "program": "KT-474",
    "targets": [
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "HS",
      "AD"
    ],
    "therapeutic_areas": [
      "immune-inflammatory diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "potential best in class oral drug"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 62
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "Kymera_December_2022_Investor_Webcast_Presentation.pdf",
      "slide": 63
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "Oral Small Molecule Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 1
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 2
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 3
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 4
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 5
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 6
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "S T A T 6",
      "I R F 5",
      "I R A K 4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 7
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [
      "STAT6",
      "IRF5",
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "AD",
      "Asthma",
      "COPD",
      "PN",
      "CRSwNP",
      "EoE",
      "BP",
      "CSU",
      "Lupus",
      "Sj\u00f6gren's",
      "RA",
      "IBD",
      "SSc",
      "DM"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Ph1",
      "Ph1b",
      "Ph2b"
    ],
    "claims": [],
    "safety": [
      "Safety",
      "degradation"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 8
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 9
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 10
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 11
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Allergic Th2 Inflammation"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 12
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "immunology"
    ],
    "clinical_phases": [],
    "claims": [
      "Only STAT6 Degradation Has the Potential to Lead to Dupilumab-Like Pathway Inhibition"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 13
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 14
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Asthma"
    ],
    "therapeutic_areas": [
      "Dermatology",
      "Respiratory"
    ],
    "clinical_phases": [
      "Ph1",
      "Ph1b",
      "Ph2b",
      "Ph3"
    ],
    "claims": [
      "Safety and tolerability",
      "Clinical activity",
      "Efficacy and safety in two initial Th2 diseases"
    ],
    "safety": [
      "Dosing for 28 days"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 15
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Complete STAT6 degradation selectivity in human PBMC at 100xDC90",
      "Full inhibition of IL-4/IL-13 pathways more potent than dupilumab",
      "90% STAT6 degradation leads to comparable or superior in vivo efficacy to dupilumab in asthma models"
    ],
    "safety": [
      "Well tolerated in multiple preclinical species and safety studies at concentrations 40-fold above efficacious dose"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 16
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Dupi-like profile",
      "Robust inhibition of several biomarkers, comparable/superior to published dupilumab data"
    ],
    "safety": [
      "Well tolerated at 90%+ degradation",
      "No SAEs",
      "No TRAEs >1 subject"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 17
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Asthma"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 2b"
    ],
    "claims": [
      ">90% STAT6 degradation in blood in all doses above 1.5 mg",
      "Complete STAT6 degradation achieved in both blood and skin in all doses \u22655 mg",
      "Results in line or superior to published data for dupilumab, with strong TARC and Eotaxin-3 reductions",
      "KT-621 was well-tolerated with a safety profile undifferentiated from placebo"
    ],
    "safety": [
      "Well-tolerated",
      "Safety profile undifferentiated from placebo"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 18
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Dupilumab-like Activity"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 19
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 20
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a"
    ],
    "claims": [],
    "safety": [
      "Safety & tolerability of escalating single and multiple doses of KT-621"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 21
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 22
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 23
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Single doses of KT-621 achieved rapid, deep and prolonged STAT6 degradation in blood",
      "Maximal degradation seen as quickly as 4 hours after single dose",
      "Robust degradation maintained as long as 4 days after single dose with recovery by Day 14",
      "Multiple subjects with STAT6 levels below LLOQ at doses of 75 mg or greater"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 24
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      ">90% STAT6 Degradation in Blood Across All Dose Levels",
      ">95% Mean STAT6 Degradation Achieved at Doses of 75 mg or Greater"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 25
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Complete STAT6 Degradation in Blood",
      "Robust STAT6 degradation observed at first time point measured (8hr) for all doses above 1.5 mg",
      "Steady-state maximum degradation achieved as early as 8hr post-first dose with recovery starting at 4 days post-last dose",
      "Most subjects with STAT6 levels below LLOQ at doses of \u22655 mg"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 26
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved >90% STAT6 Degradation in Blood at All Dose Levels Above 1.5 mg",
      "Complete Degradation Achieved at Doses of 50 mg or Greater"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 27
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved Complete STAT6 Degradation in Skin"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 28
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Complete STAT6 degradation achieved at doses \u22655 mg",
      "\u226595% mean STAT6 degradation at doses \u22655 mg"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 29
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 30
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 31
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 32
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 33
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 34
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 35
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Well Tolerated Across All Doses Evaluated Undifferentiated from Placebo",
      "No SAEs",
      "No Severe AEs",
      "No dose dependent pattern in the TEAEs",
      "No treatment related AE reported in >1 participant",
      "No related TEAEs leading to discontinuation",
      "No clinically relevant changes in vital signs, laboratory tests, and ECGs"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 36
    }
  },
  {
    "company": "kymera",
    "program": "KT-621",
    "targets": [
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Atopic Dermatitis",
      "Asthma"
    ],
    "therapeutic_areas": [
      "Immunology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 2b"
    ],
    "claims": [
      ">90% STAT6 degradation in blood in all doses above 1.5 mg",
      "Complete STAT6 degradation achieved in both blood and skin in all doses \u22655 mg",
      "Results in line or superior to published data for dupilumab, with strong TARC and Eotaxin-3 reductions",
      "KT-621 was well-tolerated with a safety profile undifferentiated from placebo"
    ],
    "safety": [
      "Well-tolerated",
      "Safety profile undifferentiated from placebo"
    ],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 37
    }
  },
  {
    "company": "kymera",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Kymera Therapeutics KT-621 Phase 1 Healthy Volunteer Data Announcement_June 2025.pdf",
      "slide": 38
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma",
      "non-Hodgkin\u2019s lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "potentially be best-in-class IKZF1/3 degrader"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Relapsed Refractory Multiple Myeloma",
      "Non-Hodgkin's Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "First-in-Human"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3",
      "IRF4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma",
      "non-Hodgkin\u2019s lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "on-target neutropenia"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed refractory multiple myeloma",
      "relapsed refractory non-Hodgkin\u2019s lymphoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "best-in-class IKZF1/3 degrader",
      "demonstrated monotherapy anti-myeloma and immunomodulatory effects",
      "compelling anti-lymphoma activity"
    ],
    "safety": [
      "well-tolerated with manageable neutropenia",
      "low rates of infections and febrile neutropenia",
      "wide therapeutic index"
    ],
    "year": 2024,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "potentially best-in-class profile",
      "potent anti-myeloma activity",
      "differentiated safety profile",
      "immunomodulatory effects"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "Grade 4 neutropenia lasting >7 days"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Well-tolerated",
      "Manageable neutropenia",
      "1 DLT (Grade 4 neutropenia lasting >7 days at the 62.5 \u00b5g dose level)",
      "No TEAEs lead to dose reductions",
      "TEAEs leading to dose interruption: 32% (15/47)",
      "TEAEs leading to discontinuation: 4% (2/47)",
      "Common (>20% All Grades) TEAEs: Neutropenia (22), Infections (18), Anemia (10), Fatigue (10), Thrombocytopenia (9), Diarrhea (7), Lymphopenia (6), Febrile neutropenia (3)",
      "Grade 5 AEs: 2 patients experienced Grade 5 AEs (septic shock and subdural hematoma), both deemed unrelated to cemsidomide"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "adverse_event": "Neutropenia",
        "grade": "\u22653",
        "incidence": "38%"
      },
      {
        "adverse_event": "Anemia",
        "grade": "\u22653",
        "incidence": "21%"
      },
      {
        "adverse_event": "Infections",
        "grade": "\u22653",
        "incidence": "17%"
      },
      {
        "adverse_event": "Upper respiratory tract infection",
        "grade": "\u22653",
        "incidence": "2%"
      },
      {
        "adverse_event": "Pneumonia",
        "grade": "\u22653",
        "incidence": "11%"
      },
      {
        "adverse_event": "Septic shock",
        "grade": "\u22653",
        "incidence": "2%"
      },
      {
        "adverse_event": "Thrombocytopenia",
        "grade": "\u22653",
        "incidence": "11%"
      },
      {
        "adverse_event": "Lymphopenia",
        "grade": "\u22653",
        "incidence": "13%"
      },
      {
        "adverse_event": "Febrile neutropenia",
        "grade": "\u22653",
        "incidence": "6%"
      }
    ],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "description": "Only 26% (12/47) of pts received G-CSF across the study",
        "grade_3_neutropenia": "Only one patient experienced Grade >3 neutropenia for the first time after completing cycle 2",
        "grade_3_infection": "One patient experienced a Grade \u22653 infection in a Cycle >8",
        "gcsf_use": "No patients received G-CSF after Cycle 7"
      }
    ],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "36% ORR",
      "45% CBR"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "36% ORR at the highest dose level evaluated to date (75 \u00b5g QD)",
      "26% ORR across all dose levels",
      "well-tolerated with a compelling safety profile"
    ],
    "safety": [
      "38% of patients experienced Grade 3/4 neutropenia, which was manageable, and no cases resulted in cemsidomide discontinuation"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 23
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Non-Hodgkin\u2019s Lymphoma (NHL)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 24
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 25
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 27
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Well-tolerated",
      "Manageable incidents of on-target neutropenia",
      "2 DLTs occurred at 100 \u00b5g QD (Grade 4 thrombocytopenia and Grade 3 febrile neutropenia)",
      "TEAEs leading to discontinuation: 9% (2/23)",
      "39% (9/23) of patients received G-CSF"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 28
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "adverse_event": "Neutropenia",
        "grade": "\u22653",
        "occurrences": {
          "25 \u00b5g MWF": 0,
          "50 \u00b5g MWF": 0,
          "37.5 \u00b5g QD": 5,
          "62.5 \u00b5g QD": 4,
          "100 \u00b5g QD": 0,
          "Total": 11
        }
      },
      {
        "adverse_event": "Infections",
        "grade": "\u22653",
        "occurrences": {
          "25 \u00b5g MWF": 0,
          "50 \u00b5g MWF": 0,
          "37.5 \u00b5g QD": 3,
          "62.5 \u00b5g QD": 0,
          "100 \u00b5g QD": 0,
          "Total": 6
        }
      },
      {
        "adverse_event": "Pneumonia",
        "grade": "\u22653",
        "occurrences": {
          "25 \u00b5g MWF": 0,
          "50 \u00b5g MWF": 0,
          "37.5 \u00b5g QD": 1,
          "62.5 \u00b5g QD": 0,
          "100 \u00b5g QD": 0,
          "Total": 2
        }
      },
      {
        "adverse_event": "Sepsis",
        "grade": "\u22653",
        "occurrences": {
          "25 \u00b5g MWF": 0,
          "50 \u00b5g MWF": 0,
          "37.5 \u00b5g QD": 1,
          "62.5 \u00b5g QD": 0,
          "100 \u00b5g QD": 0,
          "Total": 1
        }
      },
      {
        "adverse_event": "Urinary tract infection",
        "grade": "\u22653",
        "occurrences": {
          "25 \u00b5g MWF": 0,
          "50 \u00b5g MWF": 0,
          "37.5 \u00b5g QD": 1,
          "62.5 \u00b5g QD": 0,
          "100 \u00b5g QD": 0,
          "Total": 1
        }
      },
      {
        "adverse_event": "Bacteremia",
        "grade": "\u22653",
        "occurrences": {
          "25 \u00b5g MWF": 0,
          "50 \u00b5g MWF": 0,
          "37.5 \u00b5g QD": 1,
          "62.5 \u00b5g QD": 0,
          "100 \u00b5g QD": 0,
          "Total": 1
        }
      },
      {
        "adverse_event": "Skin infection",
        "grade": "\u22653",
        "occurrences": {
          "25 \u00b5g MWF": 0,
          "50 \u00b5g MWF": 0,
          "37.5 \u00b5g QD": 0,
          "62.5 \u00b5g QD": 0,
          "100 \u00b5g QD": 0,
          "Total": 0
        }
      },
      {
        "adverse_event": "Anemia",
        "grade": "\u22653",
        "occurrences": {
          "25 \u00b5g MWF": 0,
          "50 \u00b5g MWF": 0,
          "37.5 \u00b5g QD": 0,
          "62.5 \u00b5g QD": 1,
          "100 \u00b5g QD": 0,
          "Total": 4
        }
      },
      {
        "adverse_event": "Febrile neutropenia",
        "grade": "\u22653",
        "occurrences": {
          "25 \u00b5g MWF": 0,
          "50 \u00b5g MWF": 0,
          "37.5 \u00b5g QD": 0,
          "62.5 \u00b5g QD": 0,
          "100 \u00b5g QD": 0,
          "Total": 0
        }
      },
      {
        "adverse_event": "Thrombocytopenia",
        "grade": "\u22653",
        "occurrences": {
          "25 \u00b5g MWF": 0,
          "50 \u00b5g MWF": 0,
          "37.5 \u00b5g QD": 1,
          "62.5 \u00b5g QD": 0,
          "100 \u00b5g QD": 0,
          "Total": 1
        }
      },
      {
        "adverse_event": "Maculopapular rash",
        "grade": "\u22653",
        "occurrences": {
          "25 \u00b5g MWF": 0,
          "50 \u00b5g MWF": 0,
          "37.5 \u00b5g QD": 0,
          "62.5 \u00b5g QD": 0,
          "100 \u00b5g QD": 0,
          "Total": 0
        }
      }
    ],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 29
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 30
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 31
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 32
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 33
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma",
      "non-Hodgkin\u2019s lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "potentially be a best-in-class therapy",
      "potential backbone therapy",
      "well-tolerated with a compelling safety profile",
      "compelling anti-tumor activity across a range of dose levels"
    ],
    "safety": [
      "well-tolerated",
      "compelling safety profile"
    ],
    "year": 2030,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 34
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_ASH Investor Presentation_FINAL_FINAL_12.9.24__v4.pdf",
      "slide": 35
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "protein degrader",
    "e3_ligase": "cereblon",
    "indications": [
      "multiple myeloma",
      "non-Hodgkin lymphoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "safety and tolerability of CFT7455 as monotherapy and in combination with dexamethasone"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 ASH Trial-in-Progress Poster Presentation.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600"
    ],
    "modality": "BiDAC\u2122 degrader",
    "e3_ligase": "cereblon",
    "indications": [
      "melanoma",
      "colorectal cancer",
      "non-small cell lung cancer",
      "anaplastic thyroid carcinoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "C4_356a_ASCO_2023_Trial_in_progress_poster.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "Mutant BRAF"
    ],
    "modality": "Selective Degrader",
    "e3_ligase": null,
    "indications": [
      "BRAF Driven Cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600E"
    ],
    "modality": "BiDAC",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT1946 degrades BRAF-V600E in a dose dependent manner",
      "HiBiT assay shows BRAF-V600E degradation with CFT1946 treatment in dose-dependent manner",
      "pERK loss aligns with loss of BRAF-V600E protein demonstrating MAPK pathway inhibition"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Causes BRAF-V600E Degradation",
      "Potent Inhibition of MAPK Signaling",
      "Loss of Viability in BRAF-V600E Cells"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600E",
      "NRAS-Q61K"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "mBRAF"
    ],
    "modality": "targeted protein degradation",
    "e3_ligase": null,
    "indications": [
      "non-V600X mBRAF Driven Cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT1946 provides proof of concept for degradation of selected non-V600E mBRAF of both Class II and Class III",
      "CFT1946 treatment of Class III mBRAF model cell line shows proof of concept for TPD-mediated growth inhibition superior to BRAFi",
      "CFT1946 treatment demonstrates degradation of HA-tagged mBRAF in a dose-dependent manner",
      "CFT1946 treatment of H1666 cells shows modest growth inhibition, superior to inhibition alone"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600X",
      "BRAF-V600E",
      "NRAS-Q61K"
    ],
    "modality": "BiDACTM degrader",
    "e3_ligase": null,
    "indications": [
      "BRAF-V600X\u2013driven cancers",
      "inhibitor-resistant BRAF-V600X\u2013driven cancers"
    ],
    "therapeutic_areas": [
      "mBRAF Class II and Class III driven cancers"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT1946 Preclinical Evaluation.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Relapsed/Refractory Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "Small Molecule",
    "e3_ligase": "CRBN",
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Class-leading catalytic activity",
      "High binding affinity",
      "Selective to reduce off-target liabilities",
      "Pharmacologic profile that enables sustained IKZF1/3 degradation"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "monoDAC",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "monoDAC",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "CRBN",
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Catalytic activity enhancement resulted in >1000-fold improvement in potency vs. Pom"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Demonstrates high potency in MM cell lines and xenografts",
      "Has broad antiproliferative activity",
      "Promotes durable tumor regression"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Durable Tumor PK",
      "Deep IKZF3 degradation",
      "Regression in MM xenograft models"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "CRBN",
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT7455 is efficacious in MM models resistant or insensitive to IMiDs",
      "CFT7455 retains activity in Len- & Pom-Resistant MM cells",
      "CFT7455 promotes regression in tumors insensitive to Pom"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [
      "R/R MM",
      "non-Hodgkin\u2019s lymphoma"
    ],
    "therapeutic_areas": [
      "multiple myeloma"
    ],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [
      "High CRBN binding affinity (KD = 0.9 nM)",
      "Rapid, selective, and deep degradation of IKZF1/3 that is associated with apoptosis",
      "Broad, potent antiproliferative activity in a panel of MM cell lines",
      "Regression in the treatment-na\u00efve H929 MM tumor models at doses \u226510 \u00b5g/kg/day",
      "Durable antitumor responses consistent with long-lived pharmacodynamic activity",
      "Single-agent efficacy in models unresponsive to approved IMiDs"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT7455 Discovery and Characterization.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Solid Tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1/3",
      "BRAF V600 Mutant",
      "EGFR L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma & Non-Hodgkin\u2019s Lymphoma",
      "V600 Mutant Cancers",
      "Non-Small Cell Lung Cancer"
    ],
    "therapeutic_areas": [
      "Cancer",
      "Autoimmune",
      "Neurological"
    ],
    "clinical_phases": [
      "Discovery",
      "Preclinical",
      "Early Phase Development",
      "Late Phase Development"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "BRAF V600 mutant driven solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Proof of Mechanism",
      "Proof of Degrader Concept",
      "Well tolerated and highly selective degrader",
      "Increased drug exposure observed with dose escalation",
      "Degraded BRAF V600E protein in all available post-treatment biopsies",
      "Early evidence of monotherapy anti-tumor activity in patients who progressed after treatment with BRAF inhibitors",
      "Anti-tumor activity seen across multiple BRAF V600 mutants",
      "Degradation of mutant BRAF protein overcomes resistance mechanisms",
      "Potentially deeper and more durable responses than BRAF inhibitors",
      "Potential to disrupt the treatment landscape and become an important option for patients"
    ],
    "safety": [
      "No Grade \u2265 3 cutaneous adverse events"
    ],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600 Mutants"
    ],
    "modality": "BiDAC degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Prevents BRAF V600 mutant mono/heterodimer formation",
      "Avoids paradoxical activation seen with approved inhibitors",
      "Addresses MAPK pathway alterations resulting from BRAF inhibitor resistance",
      "Specifically targets BRAF V600 mutations, which includes BRAF V600 mutations beyond BRAF V600E",
      "Spares wild-type BRAF, likely avoiding AEs associated with inhibition of wild-type BRAF",
      "Enables deep elimination of mutant BRAF signaling to create potential durable responses through degrader molecule recycling and catalytic effect"
    ],
    "safety": [
      "Likely avoiding AEs associated with inhibition of wild-type BRAF"
    ],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "melanoma",
      "colorectal cancer",
      "non-small cell lung cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "BRAF V600 mutant driven solid tumors",
      "melanoma",
      "colorectal cancer (CRC)",
      "anaplastic thyroid cancer (ATC)",
      "non-small cell lung cancer (NSCLC)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1/2",
      "Phase 1B"
    ],
    "claims": [
      "Safety and tolerability",
      "Determine RP2D/MTD",
      "Estimate anti-tumor activity",
      "Assess PK and PD"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "description": "No Discontinuations, Dose Interruptions or Reductions Due to CFT1946 Treatment-related Adverse Events",
        "total_patients": 36,
        "patients_with_any_TEAEs": 31,
        "grade_3_TEAEs": 14,
        "TEAEs_related_to_CFT1946": 16,
        "grade_3_TEAEs_related_to_CFT1946": 1,
        "any_TESAEs": 9,
        "TESAEs_related_to_CFT1946": 0,
        "TEAEs_leading_to_discontinuation": 3,
        "TEAEs_leading_to_interruption": 8,
        "TEAEs_leading_to_reduction": 9,
        "TEAEs_leading_to_death": 1,
        "TRAEs_leading_to_discontinuation_interruption_reduction_death": 0,
        "patients_with_DLTs": 11
      }
    ],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "No DLTs",
      "Majority of TEAEs observed were mild to moderate",
      "No treatment-related SAEs",
      "No Grade > 3 treatment-related cutaneous adverse events",
      "No new primary malignancies"
    ],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "preferred_term": "Hyperkeratosis",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 2,
        "grade_5": 2
      },
      {
        "preferred_term": "Alopecia",
        "grade_1": 1,
        "grade_2": 1,
        "grade_3": 1,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "PPES",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 1,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Rash#",
        "grade_1": 0,
        "grade_2": 1,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Dry skin",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Pruritus",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Photosensitivity reaction",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Acne",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Dermatitis acneiform",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Ephelides",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      }
    ],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF",
      "TP53",
      "TERT",
      "MEK2",
      "MEK1",
      "APC",
      "RNF43",
      "NRAS"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Melanoma",
      "Colorectal cancer (CRC)",
      "Non-small cell lung cancer (NSCLC)",
      "Other Indications"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "BRAF V600K melanoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Confirmed Partial Response"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "BRAF V600E pancreatic carcinoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Confirmed Partial Response"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "BRAF V600 Mutant Solid Tumors",
      "Colorectal cancer (CRC)"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Well tolerated safety profile in an advanced and metastatic patient population",
      "No Grade \u2265 3 cutaneous adverse events commonly seen with wild-type BRAF inhibition",
      "No drug interruptions, reductions, or discontinuations due to treatment-related adverse events",
      "Dose-dependent bioavailability",
      "CFT1946 degrades BRAF V600E protein in all post-treatment biopsies to date",
      "Monotherapy anti-tumor activity in patients refractory to BRAF inhibitors",
      "Tumor reduction in 16/27 patients",
      "8/11 melanoma patients demonstrated tumor reduction",
      "Tumor reductions observed in patients with various V600 mutation types",
      "Intrinsic resistance in CRC patients supports CFT1946 in combination with cetuximab"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "melanoma",
      "CRC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 2024_TPD_Summit (ESMO encore)_30Oct2024_Final_Approved-24Oct_210pm.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma",
      "non-small cell lung cancer"
    ],
    "therapeutic_areas": [
      "inflammation",
      "neuroinflammation",
      "neurodegeneration"
    ],
    "clinical_phases": [
      "clinical"
    ],
    "claims": [
      "potential best-in-class IKZF1/3 degrader for MM",
      "EGFR L858R degrader for NSCLC"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "potential best-in-class profile",
      "potential path to AA"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1/3",
      "EGFR L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "4L+ Multiple Myeloma",
      "2L+ Multiple Myeloma",
      "Non-Small Cell Lung Cancer"
    ],
    "therapeutic_areas": [
      "Clinical Oncology",
      "Inflammation",
      "Neuroinflammation",
      "Neurodegeneration"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "KRAS",
      "IRAK4",
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "autoimmune diseases",
      "oncology"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "On-target neutropenia"
    ],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Potential Best-in-Class Next-generation IKZF1/3 Degrader"
    ],
    "safety": [
      "No dose discontinuations related to cemsidomide",
      "Grade 3/4 neutropenia: 59%",
      "Only 6% dose reductions due to TEAEs"
    ],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Cemsidomide has the potential to capture a valuable portion of the large global multiple myeloma market",
      "Estimated peak revenue for initial cemsidomide opportunity is $2.5-$4B",
      "Cemsidomide has potential for multibillion dollar opportunities across multiple lines of therapy"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "anti-myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [
      "Combination is safe",
      "Early evidence of anti-myeloma activity",
      "Differentiated safety profile",
      "Compelling anti-myeloma activity",
      "T-cell activation observed across all cemsidomide dose levels"
    ],
    "safety": [
      "Differentiated safety profile"
    ],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2",
      "Phase 3",
      "Phase 1b"
    ],
    "claims": [
      "Accelerated Approval",
      "Full Approval"
    ],
    "safety": [
      "Characterize safety and tolerability"
    ],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Potential best-in-class profile",
      "53% ORR at the highest dose level (100 \u00b5g)",
      "40% ORR at the second highest dose level (75 \u00b5g)",
      "36% ORR across all doses evaluated",
      "No discontinuations related to cemsidomide",
      "Minimal disruptive adverse events"
    ],
    "safety": [
      "Differentiated safety & tolerability profile"
    ],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Non-Small Cell Lung Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR"
    ],
    "modality": "Allosteric Degrader",
    "e3_ligase": null,
    "indications": [
      "Non-small cell lung cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potent and selective against L858R regardless of secondary mutations",
      "Does not hit wild-type, potentially resulting in better tolerability"
    ],
    "safety": [
      "Toxicities associated with inhibition of wild-type EGFR limit tolerability"
    ],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR L858R",
      "EGFR Exon 21 Mutants",
      "EGFR C797S",
      "EGFR-L861Q"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 23
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 24
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 25
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 26
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "inflammation",
      "neuroinflammation",
      "neurodegeneration"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 27
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Inflammation",
      "Neuroinflammation",
      "Neurodegeneration"
    ],
    "clinical_phases": [],
    "claims": [
      "Degraders have the potential to outperform inhibitors in efficacy and safety in CNS diseases",
      "Fast path to clinical proof-of-concept, including early validation based on PD markers in healthy volunteers",
      "Normalize elevated protein levels without the need for complete elimination of the target",
      "Deploying TPD where the MOA is uniquely positioned to have an advantage over inhibitors to help benefit patients in a large market"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 28
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 29
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Alzheimer\u2019s Disease",
      "Psoriasis",
      "Multiple Sclerosis",
      "Down Syndrome",
      "Parkinson\u2019s Disease",
      "Rheumatoid Arthritis",
      "Multiple Myeloma",
      "Lupus Nephritis",
      "Systemic Lupus Erythematosus",
      "Inflammatory Bowel Disease",
      "Asthma",
      "Autosomal Dominant Polycystic Kidney Disease",
      "Chronic Kidney Disease",
      "Metabolic Dysfunction Associated Steatohepatitis",
      "Idiopathic Pulmonary Fibrosis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 30
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "2026 January Deck_FINAL_1.18.26.pdf",
      "slide": 31
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "clinic"
    ],
    "claims": [
      "potent CRBN binder",
      "fast, selective degradation of IKZF1/3"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "G-Loop"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 23
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 24
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 25
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target 1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 26
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 27
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 28
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target 2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 29
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 30
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target 2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Compound 1 demonstrates selective on-target, on-mechanism degradation of Target 2",
      "No degradation of IKZF1 or SALL4"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 31
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 32
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_Discovery_on_Target_2022_FINAL.pdf",
      "slide": 33
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "small molecule",
    "e3_ligase": "CRBN",
    "indications": [
      "non-Hodgkin\u2019s lymphoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [
      "demonstrates potent anti-tumor activity",
      "greater efficacy compared to pomalidomide",
      "synergistic activity with rituximab, ibrutinib, and romidepsin",
      "activity in CNS models of lymphoma"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "2023_ICML_Poster_CFT-7455_NHL-FINAL_approved (002).pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "class-leading efficacy",
      "differentiated safety & tolerability profile"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1/3",
      "EGFR L858R",
      "BRAF V600"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma",
      "Non-Hodgkin\u2019s Lymphoma",
      "Non-Small Cell Lung Cancer",
      "V600 Mutant Cancers",
      "CRC",
      "Melanoma",
      "Other BRAF V600 Mutant Cancers"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Non-oncology"
    ],
    "clinical_phases": [
      "Phase 1b",
      "Registrational Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma",
      "Non-Hodgkin\u2019s Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degrading IKZF1/3 leads to myeloma cell death",
      "Degrading IKZF1/3 supports T-cell activation"
    ],
    "safety": [
      "On-target neutropenia"
    ],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "RRMM",
      "R/R MM",
      "4L+ RRMM",
      "2L+ RRMM"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1B",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Potential accelerated approval",
      "Potential accelerated and full approval (2L+)",
      "Potential full approval (4L+)"
    ],
    "safety": [
      "differentiated safety & tolerability profile"
    ],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "3 DLTs at 100 \u00b5g QD",
      "1 DLT at 62.5 \u00b5g QD due to Grade 4 neutropenia lasting >7 days",
      "5 DLT events at 100 \u00b5g QD (G4 neutropenia, G3 pneumonia in 2 patients, G3 ALT increase, G3 febrile neutropenia)"
    ],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "TEAE": "Neutropenia",
        "All Grades": 44,
        "Grade 3": 17,
        "Grade 4": 24,
        "Grade 5": 0
      },
      {
        "TEAE": "Infections",
        "All Grades": 42,
        "Grade 3": 10,
        "Grade 4": 10,
        "Grade 5": 1
      },
      {
        "TEAE": "Pneumonia",
        "All Grades": 27,
        "Grade 3": 26,
        "Grade 4": 0,
        "Grade 5": 0
      },
      {
        "TEAE": "Upper Respiratory Tract Infection",
        "All Grades": 21,
        "Grade 3": 14,
        "Grade 4": 0,
        "Grade 5": 1
      },
      {
        "TEAE": "Septic Shock",
        "All Grades": 13,
        "Grade 3": 0,
        "Grade 4": 0,
        "Grade 5": 0
      },
      {
        "TEAE": "Sepsis",
        "All Grades": 0,
        "Grade 3": 0,
        "Grade 4": 0,
        "Grade 5": 0
      },
      {
        "TEAE": "Anemia",
        "All Grades": 8,
        "Grade 3": 3,
        "Grade 4": 2,
        "Grade 5": 1
      },
      {
        "TEAE": "Fatigue",
        "All Grades": 0,
        "Grade 3": 0,
        "Grade 4": 0,
        "Grade 5": 0
      },
      {
        "TEAE": "Diarrhea",
        "All Grades": 0,
        "Grade 3": 0,
        "Grade 4": 0,
        "Grade 5": 0
      },
      {
        "TEAE": "Leukopenia",
        "All Grades": 0,
        "Grade 3": 0,
        "Grade 4": 0,
        "Grade 5": 0
      },
      {
        "TEAE": "Thrombocytopenia",
        "All Grades": 0,
        "Grade 3": 0,
        "Grade 4": 0,
        "Grade 5": 0
      },
      {
        "TEAE": "Lymphopenia",
        "All Grades": 0,
        "Grade 3": 0,
        "Grade 4": 0,
        "Grade 5": 0
      },
      {
        "TEAE": "Febrile Neutropenia",
        "All Grades": 0,
        "Grade 3": 0,
        "Grade 4": 0,
        "Grade 5": 0
      }
    ],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Dose proportional exposure",
      "Achieves >50% degradation of IKZF1",
      "Achieves >80% degradation of IKZF3"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "50% of Multiple Myeloma Patients With Elevated Light Chains Achieved at Least a 50% Decrease in dFLC"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Cemsidomide + dex continued to be well-tolerated",
      "TEAEs were manageable",
      "Dose reductions remained at 6% (4/73)",
      "No discontinuations related to cemsidomide",
      "No additional febrile neutropenia events",
      "Two additional occurrences of grade \u22653 infections",
      "One patient with viral pneumonia not related to cemsidomide",
      "One patient who had chronic infections prior to starting study had a recurrent infection",
      "Neutropenia rate relatively consistent with IMS data",
      "Updated grade 3/4 neutropenia is 63% (12/19)"
    ],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 23
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 24
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 25
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 26
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "RRMM"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Potential for accelerated approval"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 27
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [],
    "safety": [
      "Characterize the safety and tolerability of cemsidomide in combination with elranatamab"
    ],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 28
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 29
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "immunology",
      "neuroinflammation",
      "neurodegeneration"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 30
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "neuroinflammation",
      "immunology",
      "genetic disorders"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "first-in-class opportunities"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 31
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Alzheimer\u2019s Disease",
      "Psoriasis",
      "Multiple Sclerosis",
      "Down Syndrome",
      "Parkinson\u2019s Disease",
      "Rheumatoid Arthritis",
      "Multiple Myeloma",
      "Lupus Nephritis",
      "Systemic Lupus Erythematosus",
      "Inflammatory Bowel Disease",
      "Asthma",
      "Autosomal Dominant Polycystic Kidney Disease",
      "Chronic Kidney Disease",
      "Metabolic Dysfunction Associated Steatohepatitis",
      "Idiopathic Pulmonary Fibrosis"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 32
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "October 8K Deck_10.15.2025_FINAL.pdf",
      "slide": 33
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8634",
    "targets": [
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "SMARCB1-Perturbed Cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "synovial sarcoma",
      "SMARCB1-deficient cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Synthetic lethal dependency on BRD9 in synovial sarcoma and other SMARCB1-deficient cancers"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Synovial Sarcoma",
      "Malignant Rhabdoid Tumor"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8634",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8634",
    "targets": [
      {
        "name": "BRD9",
        "dc50": "5 nM",
        "emax": "5%"
      },
      {
        "name": "BRD4",
        "dc50": "130 nM",
        "emax": "30%"
      },
      {
        "name": "BRD9",
        "dc50": "3 nM",
        "emax": "4%"
      },
      {
        "name": "BRD4",
        "dc50": ">10 \u00b5M",
        "emax": "75%"
      }
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT-8634",
    "targets": [
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8634",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8634",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Synovial Sarcoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8634",
    "targets": [],
    "modality": "BiDAC\u2122 degrader",
    "e3_ligase": null,
    "indications": [
      "synovial sarcoma",
      "SMARCB1-null solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [
      "potent",
      "selective",
      "orally bioavailable"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4T_AACR 2022_CFT8634 Discovery and Characterization.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR L858R"
    ],
    "modality": "selective, allosteric degrader",
    "e3_ligase": null,
    "indications": [
      "brain metastases",
      "EGFR patients who develop resistance to osimertinib"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Active in vitro and in vivo in models with secondary EGFR mutations",
      "Demonstrates intracranial activity indicating potential to prevent or treat brain metastases in patients with EGFR L858R-driven tumors",
      "25-45% of mutant EGFR NSCLC is driven by L858R activating mutation; these patients are not adequately addressed with current EGFR therapies",
      "Pre-clinical data suggests CFT8919 has path to registration in EGFR patients who develop resistance to osimertinib"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1/3",
      "BRD9",
      "EGFR",
      "BRAF V600E",
      "RET"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma & Lymphoma",
      "Synovial Sarcoma & SMARCB1 Deleted Tumors",
      "Drug-Resistant EGFR+ NSCLC",
      "Drug-Resistant BRAF mutant Tumors",
      "Drug-Resistant RET-Altered Tumors"
    ],
    "therapeutic_areas": [
      "Cancer"
    ],
    "clinical_phases": [
      "Clinical"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR"
    ],
    "modality": "targeted protein degradation",
    "e3_ligase": null,
    "indications": [
      "Non-Small Cell Lung Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR-L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR-L861Q",
      "EGFR-L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR-L858R-T790M"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR L858R"
    ],
    "modality": "Oral, Allosteric, Mutant-selective Degrader",
    "e3_ligase": null,
    "indications": [
      "NSCLC"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Active in vitro and in vivo in models with secondary mutations",
      "Demonstrates intracranial activity",
      "Potential to prevent or treat brain metastases",
      "May combine with approved EGFR inhibitors",
      "Potential for single agent activity in the front-line setting"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT8919_Pre_Clinical_Data.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8634",
    "targets": [
      "BRD9"
    ],
    "modality": "bifunctional degradation activating compound",
    "e3_ligase": "cereblon",
    "indications": [
      "synovial sarcoma",
      "SMARCB1-null tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [
      "Frequency and severity of AEs and SAEs of CFT8634"
    ],
    "year": 2022,
    "source": {
      "document": "C4_2206598_CTOS 2022_Final.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "synovial sarcoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9",
      "BRD7"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Potently degrades BRD9",
      "Selective over BRD4 & BRD7",
      "Drug-like properties",
      "Plasma stability",
      "Mouse PK"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": "Cereblon",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": [
      "CRBN"
    ],
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD7",
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRD4",
      "BRD7",
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 23
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "GSPT1",
      "SALL4",
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 24
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Compound 27",
    "targets": [
      "BRD9"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Synovial Sarcoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Degrades Endogenous BRD9",
      "Inhibits Synovial Sarcoma Cell Growth"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 25
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 26
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 27
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8634",
    "targets": [
      "BRD9"
    ],
    "modality": "BiDAC degrader",
    "e3_ligase": null,
    "indications": [
      "synovial sarcoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 28
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_BRD9_TPD_Summit_Presentation.pdf",
      "slide": 29
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide (CFT7455)",
    "targets": [],
    "modality": "MonoDAC\u00ae Degrader",
    "e3_ligase": null,
    "indications": [
      "Relapsed/Refractory Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide (CFT7455)",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "MonoDAC\u00ae degrader",
    "e3_ligase": "cereblon",
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "catalytic activity enabling rapid and deep target degradation",
      "high binding affinity to overcome resistance due to low cereblon levels",
      "pharmacologic profile to promote tumor residence time and sustained IKZF1/3 degradation"
    ],
    "safety": [
      "on-target neutropenia"
    ],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "adverse_event": "grade 4 neutropenia",
        "dose": "62.5 \u00b5g",
        "relation": "possibly related to cemsidomide"
      },
      {
        "adverse_event": "grade 3 ALT increase",
        "dose": "100 \u00b5g",
        "relation": "possibly related to cemsidomide"
      },
      {
        "adverse_event": "grade 3 febrile neutropenia",
        "dose": "100 \u00b5g",
        "relation": "possibly related to cemsidomide"
      },
      {
        "adverse_event": "grade 3 pneumonia",
        "dose": "100 \u00b5g",
        "relation": "possibly related to cemsidomide"
      },
      {
        "adverse_event": "grade 4 thrombocytopenia",
        "dose": "75 \u00b5g",
        "relation": "possibly related to cemsidomide"
      },
      {
        "adverse_event": "grade 5 AE of septic shock",
        "dose": "75 \u00b5g",
        "relation": "unrelated to cemsidomide"
      },
      {
        "adverse_event": "grade 3 neutropenia",
        "dose": "100 \u00b5g",
        "relation": "possibly related to cemsidomide"
      },
      {
        "adverse_event": "pseudomonal bacteremia",
        "dose": "100 \u00b5g",
        "relation": "unrelated to cemsidomide"
      }
    ],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "adverse_event": "Neutropenia",
        "grade": "All Grades",
        "percentage": 61
      },
      {
        "adverse_event": "Infections",
        "grade": "All Grades",
        "percentage": 58
      },
      {
        "adverse_event": "Anemia",
        "grade": "All Grades",
        "percentage": 38
      },
      {
        "adverse_event": "Fatigue",
        "grade": "All Grades",
        "percentage": 36
      },
      {
        "adverse_event": "Diarrhea",
        "grade": "All Grades",
        "percentage": 36
      },
      {
        "adverse_event": "Leukopenia",
        "grade": "All Grades",
        "percentage": 29
      },
      {
        "adverse_event": "Thrombocytopenia",
        "grade": "All Grades",
        "percentage": 19
      },
      {
        "adverse_event": "Lymphopenia",
        "grade": "All Grades",
        "percentage": 18
      },
      {
        "adverse_event": "Febrile Neutropenia",
        "grade": "All Grades",
        "percentage": 24
      },
      {
        "adverse_event": "Pneumonia",
        "grade": "Grade 3",
        "percentage": 14
      },
      {
        "adverse_event": "Upper Respiratory Tract Infection",
        "grade": "Grade 3",
        "percentage": 14
      },
      {
        "adverse_event": "Septic Shock",
        "grade": "Grade 3",
        "percentage": 1
      },
      {
        "adverse_event": "Sepsis",
        "grade": "Grade 3",
        "percentage": 3
      },
      {
        "adverse_event": "Neutropenia",
        "grade": "Grade 4",
        "percentage": 33
      },
      {
        "adverse_event": "Febrile Neutropenia",
        "grade": "Grade 4",
        "percentage": 11
      },
      {
        "adverse_event": "Thrombocytopenia",
        "grade": "Grade 4",
        "percentage": 4
      },
      {
        "adverse_event": "Lymphopenia",
        "grade": "Grade 4",
        "percentage": 3
      },
      {
        "adverse_event": "Septic Shock",
        "grade": "Grade 5",
        "percentage": 1
      },
      {
        "adverse_event": "Subdural Hematoma",
        "grade": "Grade 5",
        "percentage": 1
      }
    ],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide 14/14 + Dex",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed/refractory multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ORR (\u2265 PR) of 34% (23/67) was achieved across all dose levels with a clinical benefit rate (\u2265 MR) of 49%",
      "ORR at the highest dose level of cemsidomide 100\u00b5g was 50% with a clinical benefit rate of 64%",
      "MRD negativity achieved in 1 patient with a CR at the highest dose level of cemsidomide (100\u00b5g)"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 2",
      "Phase 1b"
    ],
    "claims": [
      "50% ORR at highest dose",
      "34% ORR across all dose levels",
      "well tolerated",
      "durable anti-myeloma activity"
    ],
    "safety": [
      "manageable TEAEs",
      "minimal treatment discontinuations or reductions"
    ],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "Dhakal_IMS 2025_Cemsi_Oral_Final 09152025 (002) (1).pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Solid Tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1/3",
      "BRAF V600 Mutant",
      "EGFR L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma",
      "Non-Hodgkin\u2019s Lymphoma",
      "V600 Mutant Cancers",
      "Non-Small Cell Lung Cancer"
    ],
    "therapeutic_areas": [
      "Cancer",
      "Autoimmune",
      "Neurological"
    ],
    "clinical_phases": [
      "Discovery",
      "Preclinical",
      "Early Phase Development",
      "Late Phase Development"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed or refractory multiple myeloma",
      "relapsed or refractory non-Hodgkin lymphoma",
      "colorectal cancer",
      "non-small cell lung cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": "targeted protein degradation",
    "e3_ligase": null,
    "indications": [
      "BRAF V600 mutant driven solid tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Proof of Mechanism",
      "Proof of Degrader Concept",
      "Well tolerated and highly selective degrader",
      "Increased drug exposure observed with dose escalation",
      "Degraded BRAF V600E protein in all available post-treatment biopsies",
      "Early evidence of monotherapy anti-tumor activity",
      "Anti-tumor activity seen across multiple BRAF V600 mutants",
      "Degradation of mutant BRAF protein overcomes resistance mechanisms"
    ],
    "safety": [
      "No Grade \u2265 3 cutaneous adverse events"
    ],
    "year": 2024,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600 Mutants"
    ],
    "modality": "BiDAC degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Prevents BRAF V600 mutant mono/heterodimer formation",
      "Avoids paradoxical activation seen with approved inhibitors",
      "Addresses MAPK pathway alterations resulting from BRAF inhibitor resistance",
      "Specifically targets BRAF V600 mutations, which includes BRAF V600 mutations beyond BRAF V600E",
      "Spares wild-type BRAF, likely avoiding AEs associated with inhibition of wild-type BRAF",
      "Enables deep elimination of mutant BRAF signaling to create potential durable responses through degrader molecule recycling and catalytic effect"
    ],
    "safety": [
      "likely avoiding AEs associated with inhibition of wild-type BRAF"
    ],
    "year": 2024,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "BRAF V600 mutant driven solid tumors",
      "melanoma",
      "colorectal cancer (CRC)",
      "anaplastic thyroid cancer (ATC)",
      "non-small cell lung cancer (NSCLC)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1/2",
      "Phase 1B"
    ],
    "claims": [
      "Safety and tolerability",
      "Determine RP2D/MTD",
      "Estimate anti-tumor activity",
      "Assess PK and PD"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "No DLTs",
      "Majority of TEAEs observed were mild to moderate",
      "No treatment-related SAEs",
      "No Grade > 3 treatment-related cutaneous adverse events",
      "No new primary malignancies"
    ],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "preferred_term": "Hyperkeratosis",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 2,
        "grade_5": 2
      },
      {
        "preferred_term": "Alopecia",
        "grade_1": 1,
        "grade_2": 1,
        "grade_3": 1,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "PPES",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Rash#",
        "grade_1": 1,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Dry skin",
        "grade_1": 0,
        "grade_2": 1,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Pruritus",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 1,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Photosensitivity reaction",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Acne",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Dermatitis acneiform",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "preferred_term": "Ephelides",
        "grade_1": 0,
        "grade_2": 0,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      }
    ],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF",
      "TP53",
      "TERT",
      "MEK2",
      "MEK1",
      "APC",
      "RNF43",
      "NRAS"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Melanoma",
      "Colorectal cancer (CRC)",
      "Non-small cell lung cancer (NSCLC)",
      "Other Indications"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Ongoing"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "BRAF V600K melanoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Confirmed Partial Response"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "BRAF V600E pancreatic carcinoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Confirmed Partial Response in BRAF V600E Pancreatic Cancer"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "BRAF V600 Mutant Solid Tumors",
      "Colorectal cancer (CRC)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Well tolerated safety profile in an advanced and metastatic patient population",
      "No Grade \u2265 3 cutaneous adverse events commonly seen with wild-type BRAF inhibition",
      "No drug interruptions, reductions, or discontinuations due to treatment-related adverse events",
      "Dose-dependent bioavailability",
      "CFT1946 degrades BRAF V600E protein in all post-treatment biopsies to date",
      "Monotherapy anti-tumor activity in patients refractory to BRAF inhibitors",
      "Tumor reduction in 16/27 patients",
      "8/11 melanoma patients demonstrated tumor reduction",
      "Tumor reductions observed in patients with various V600 mutation types",
      "Intrinsic resistance in CRC patients supports CFT1946 in combination with cetuximab"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "melanoma",
      "CRC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 23
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 Investor Presentation_Phase 1 _ 9.13.24_FINAL_2.pdf",
      "slide": 24
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target A",
      "Target B"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "MonoDAC Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF3"
    ],
    "modality": "MonoDAC Degrader",
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly Potent and Selective",
      "Linear, Durable Tumor PK",
      "48 hr Degradation Kinetics",
      "Deep IKZF3 degradation and regression in MM xenograft models"
    ],
    "safety": [
      "CC-92480 is not detectable after 4 hours"
    ],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "Target A"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Identified hit reduces tagged and endogenous Target A protein levels"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 23
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "GSPT1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Compound 3 demonstrates selective on-target, on-mechanism degradation of Target A"
    ],
    "safety": [
      "No degradation of IKZF1 and SALL4"
    ],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 24
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 25
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "C4_2022_TPD_Summit_Final_v2.pdf",
      "slide": 26
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1/3",
      "BRD9",
      "BRAF V600X",
      "EGFR L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma & Lymphoma",
      "Synovial Sarcoma & SMARCB1-null Solid Tumors",
      "Melanoma, CRC & NSCLC",
      "NSCLC",
      "Various Cancers",
      "Various Cancers",
      "Neurological Conditions",
      "Diseases of Aging, including Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Discovery",
      "Preclinical",
      "Phase 1",
      "Phase 2/3"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3",
      "BRD9",
      "Mutant BRAF"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed/refractory multiple myeloma",
      "SMARCB1-Perturbed Cancers",
      "BRAF Driven Cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1/2"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "Small Molecule",
    "e3_ligase": "CRBN",
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Potent small molecule IKZF1/3 degrader",
      "Enhanced catalytic & pharmacologic properties"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      ">1000-fold improvement in potency vs. Pomalidomide"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT7455 achieves equivalent efficacy at 1/100th of the dose compared to CC-92480",
      "CFT7455 results in durable tumor regressions in the NCI-H929 xenograft model"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Systemic Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Highly Efficacious"
    ],
    "safety": [
      "Mouse missing in CFT7455 100 \u00b5g/kg group due to changes unrelated to treatment or disease"
    ],
    "year": 2022,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Significant Potency Advantage over Other IKZF1/3 Degraders"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R Multiple Myeloma",
      "Non-Hodgkin\u2019s Lymphoma",
      "Mantle Cell Lymphoma",
      "Peripheral T-Cell Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "The 50 \u00b5g dose achieved exposures which were active (and superior to pomalidomide) in pre-clinical models",
      "CFT7455 was rapidly absorbed, with a plasma half-life of approximately two days",
      "Accumulation of drug was observed up to four-fold by day 15 (360 hours)",
      "Predicted efficacious exposure (plasma 0.097 ng/mL)"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Neutropenia",
      "Thrombocytopenia",
      "Anemia",
      "Leukopenia",
      "Aspartate aminotransferase increased",
      "Alanine aminotransferase increased",
      "Diarrhea",
      "Fatigue",
      "Pyrexia",
      "Rhinitis",
      "Upper respiratory tract infection",
      "Balance disorder",
      "Headache",
      "Nephrolithiasis"
    ],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "On-target Neutropenia Seen Across Patients; Most Severe at Day 21",
      "Neutropenia tended to worsen following day 15 and recovery was incomplete during the 7-day drug holiday",
      "Two DLTs were observed at the 50 \u03bcg per day dose, both consistent with on-target activity: Grade 4 neutropenia lasting more than 5 days, A delay (more than 7 days) in initiating treatment in Cycle 2, in the setting of persistent Grade 3 neutropenia"
    ],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "increased activity in vivo compared to CC-92480",
      "sustained IKZF1/3 degradation",
      "durable tumor regressions after drug discontinuation",
      "well absorbed with a plasma T1/2 of approximately 2 days",
      "accumulation of drug up to 4-fold by day 15",
      "substantial potency and deeper degradation of IKZF1 and IKZF3",
      "meaningful decreases in dFLC"
    ],
    "safety": [
      "on-target neutropenia",
      "3 patients with Grade 4 neutropenia",
      "2 DLTs"
    ],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 23
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R Multiple Myeloma",
      "Non-Hodgkin\u2019s Lymphoma",
      "Mantle Cell Lymphoma",
      "Peripheral T-Cell Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 24
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455_Phase_1_2_Cohort_A_Data_Investor_Call.pdf",
      "slide": 25
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Relapsed Refractory Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1/3",
      "BRAF-V600",
      "EGFR L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma & Non-Hodgkin\u2019s Lymphoma",
      "V600 Mutant Cancers",
      "Non-Small Cell Lung Cancers"
    ],
    "therapeutic_areas": [
      "Various Cancers",
      "Various Cancers",
      "Various Cancers"
    ],
    "clinical_phases": [
      "Discovery",
      "Pre-clinical",
      "Early phase development",
      "Late phase development"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Relapsed/Refractory multiple myeloma (R/R MM)",
      "Synovial Sarcoma",
      "SMARCB1-null tumors"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 1/2"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Established Safety Profile and Dosing Schedule",
      "Demonstrated Monotherapy Activity",
      "Promising Responses with CFT7455 + Dexamethasone"
    ],
    "safety": [
      "CFT7455 is well tolerated with no DLTs resulting in treatment discontinuations"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma",
      "Non-Hodgkin\u2019s Lymphoma"
    ],
    "therapeutic_areas": [
      "Hematopoietic Biology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degrading IKZF1/3 is a Validated Therapeutic Strategy in MM and NHL"
    ],
    "safety": [
      "On-target Neutropenia"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma",
      "Non-Hodgkin\u2019s lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Grade 3/4 Neutropenia Rate: 33% (Iberdomide), 41-48% (Mezigdomide), 45%, 76%"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma",
      "Non-Hodgkin\u2019s Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Reduce off-target toxicity and provide versatile combo potential",
      "Overcome resistance by maintaining efficacy at low cereblon levels",
      "Excellent catalytic efficiency and enhanced PK profile leads to enhanced efficacy due to predictable suppression of IKZF1/3 between doses",
      "Metabolize through the liver to be better tolerated and potentially avoid kidney clearance"
    ],
    "safety": [
      "Modest on-target degradation and off-target liabilities",
      "Acquired resistance to approved IKZF1/3 degraders",
      "Many MM/NHL therapies require onerous delivery (e.g., frequent dosing, IV administration)",
      "High-risk MM, including extramedullary disease, remains difficult to treat",
      "~50% of MM patients suffer from renal impairment, decreasing tolerability of renally cleared drugs"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Differentiated PK and Class-leading Catalytic Activity of CFT7455 Leads to Sustained Degradation Compared to Other Agents in this Class",
      "Extended Plasma and Tumor Exposure",
      "Leads to Optimized Degradation Kinetics"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R MM",
      "R/R NHL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "Safety and tolerability",
      "Determine the maximum tolerated doses"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "DLT associated with febrile neutropenia",
      "DLT associated with Grade 4 neutropenia >7 days"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R MM"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Death was not related to CFT7455",
      "Adverse event was a Grade 2 rash in the setting of early disease progression at the 50 \u03bcg dose on the MWF 14/14 schedule so there was limited benefit to continuing therapy"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R MM"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Manageable neutropenia was the most common side effect",
      "no DLTs resulted in discontinuations"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 23
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 24
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT7455 induces CD8+ T-cell activation by increasing effector memory T-cell subset",
      "T-cell activation is observed at well tolerated monotherapy clinical doses",
      "The clinical data consistent with the preclinical in vitro data reported for CFT7455"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 25
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 26
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Well tolerated",
      "Demonstrates anti-myeloma activity",
      "Immunomodulatory effects"
    ],
    "safety": [
      "manageable neutropenia"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 27
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R MM"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 28
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Relapsed/Refractory multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 29
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 30
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Anemia",
      "Neutropenia",
      "Febrile neutropenia",
      "Thrombocytopenia",
      "Leukopenia",
      "Lymphocyte count decreased",
      "Pneumonia",
      "Blood creatinine increased",
      "Mental impairment",
      "Hypocalcemia",
      "Acute kidney injury",
      "Epistaxis",
      "Pulmonary oedema",
      "Intracranial mass"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 31
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 32
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "sCR achieved in a pre-treated MM patient"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 33
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multi-refractory MM patients"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1 dose escalation",
      "Phase 1 dose expansion"
    ],
    "claims": [
      "well tolerated",
      "promising efficacy signals",
      "manageable neutropenia"
    ],
    "safety": [
      "well tolerated",
      "manageable neutropenia"
    ],
    "year": 2023,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 34
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 35
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 36
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma",
      "Multi-Refractory MM",
      "Early Line MM",
      "Post-Transplant MM"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Registrational Study",
      "Monotherapy",
      "Post-Transplant Maintenance Study"
    ],
    "claims": [
      "Accelerated Approval in Multi-Refractory MM",
      "Numerous Approvals in Early Line MM",
      "Maintenance Approval in Post-Transplant MM"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 37
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma",
      "relapsed/refractory multiple myeloma",
      "relapsed/refractory non-Hodgkin lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Established Safety Profile and Dosing Schedule",
      "Demonstrated Monotherapy Activity",
      "Promising Responses + Dexamethasone",
      "Well tolerated with no DLTs resulting in treatment discontinuations",
      "Optimal 14 days on/14 days off schedule",
      "Anti-myeloma activity and immunomodulatory effects observed at well tolerated doses",
      "Multiple patients achieved IMWG responses at low doses with best responses in patients refractory to BCMA therapies",
      "Opportunity in combination with novel MM agents for early-line patients and as a maintenance therapy option",
      "Opportunity in combination with dexamethasone for multi-refractory patients"
    ],
    "safety": [
      "Well tolerated with no DLTs resulting in treatment discontinuations"
    ],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 38
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT7455 Data Presentation _FINAL_12.12.23_.pdf",
      "slide": 39
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600X"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Prevents BRAF V600 mutant mono/heterodimer formation",
      "Avoids paradoxical activation seen with approved inhibitors",
      "Addresses MAPK pathway alterations resulting from BRAF inhibitor resistance",
      "Specifically targets BRAF V600X mutations, which includes BRAF V600 mutations beyond BRAF V600E",
      "Spares wild-type BRAF, likely avoiding AEs associated with inhibition of wild-type BRAF",
      "Enables deep elimination of mutant BRAF signaling to create potential durable responses through degrader molecule recycling and catalytic effect"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Melanoma",
      "Colorectal cancer",
      "Non-small cell lung cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "BRAF V600 mutant measurable solid tumors",
      "Melanoma",
      "Colorectal cancer (CRC)",
      "Anaplastic thyroid cancer (ATC)",
      "Non-small cell lung cancer (NSCLC)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "Safety and tolerability"
    ],
    "year": null,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Advanced or Metastatic BRAF V600 Mutant Solid Tumors"
    ],
    "therapeutic_areas": [
      "Colorectal cancer",
      "Non-small cell lung cancer",
      "Melanoma"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      {
        "subjects_with_any_teaes": 31,
        "grade_3_teaes": 14,
        "teaes_related_to_program": 16,
        "grade_3_teaes_related_to_program": 1,
        "any_tesaes": 9,
        "tesaes_related_to_program": 0,
        "teaes_leading_to_discontinuation": 3,
        "teaes_leading_to_interruption": 9,
        "teaes_leading_to_reduction": 1,
        "teaes_leading_to_death": 1,
        "traes_leading_to_discontinuation_interruption_reduction_death": 0,
        "subjects_with_dlts": 0
      }
    ],
    "year": null,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      {
        "term": "Anemia",
        "grade_1": 3,
        "grade_2": 14,
        "grade_3": 11,
        "grade_4": 2,
        "grade_5": 1
      },
      {
        "term": "Abdominal Pain",
        "grade_1": 1,
        "grade_2": 4,
        "grade_3": 2,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "term": "Peripheral edema",
        "grade_1": 4,
        "grade_2": 1,
        "grade_3": 2,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "term": "Pyrexia",
        "grade_1": 5,
        "grade_2": 1,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "term": "Fatigue",
        "grade_1": 4,
        "grade_2": 2,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "term": "Lipase increased",
        "grade_1": 1,
        "grade_2": 4,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "term": "Back pain",
        "grade_1": 3,
        "grade_2": 2,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "term": "Hypophosphatemia",
        "grade_1": 1,
        "grade_2": 2,
        "grade_3": 1,
        "grade_4": 0,
        "grade_5": 0
      },
      {
        "term": "Constipation",
        "grade_1": 1,
        "grade_2": 3,
        "grade_3": 0,
        "grade_4": 0,
        "grade_5": 0
      }
    ],
    "year": null,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "melanoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Proof of mechanism supported by BRAF V600E degradation"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "cholangiocarcinoma",
      "non-small cell lung cancer",
      "pancreatic carcinoma",
      "small intestine cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "cholangiocarcinoma",
      "non-small cell lung cancer",
      "pancreatic carcinoma",
      "small intestine cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Early Evidence of Anti-Tumor Activity",
      "Ongoing SD at 16.6 months",
      "Subject had confirmed PR after data cut off"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "BRAF V600E Pancreatic Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Early Evidence of Anti-Tumor Activity",
      "Decrease in BRAF V600E allele fraction measured in ctDNA using WES"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "melanoma",
      "colorectal cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "well-tolerated safety profile",
      "preliminary proof of mechanism",
      "increased drug exposure with dose escalation",
      "degradation of BRAF V600E protein",
      "evidence of anti-tumor activity"
    ],
    "safety": [
      "only one Grade \u22653 treatment-related adverse event",
      "no drug interruptions, reductions, or discontinuations due to treatment-related adverse events",
      "no Grade \u22653 wild-type adverse events common to BRAFi"
    ],
    "year": null,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CFT1946 ESMO Oral Presentation_FINAL 9.13.24.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "Mutant BRAF"
    ],
    "modality": "Degrader",
    "e3_ligase": null,
    "indications": [
      "BRAF-driven Cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF-V600X"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600X"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Specifically target mutant BRAF-V600X over wildtype BRAF",
      "Prevent mutant BRAF-V600X incorporation into RAF dimers",
      "Avoid paradoxical activation of RAF dimers",
      "Address failures in inhibitor-based therapy due to resistance mechanisms",
      "Effect deep elimination of mutant BRAF signaling and create durable responses"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "BRAF",
      "CRBN"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600E"
    ],
    "modality": "BiDAC",
    "e3_ligase": "CRBN",
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT1946 Degrades BRAF-V600E in a Dose Dependent Manner",
      "HiBiT assay shows BRAF-V600E degradation with CFT1946 treatment in dose-dependent manner",
      "pERK loss aligns with loss of BRAF-V600E protein demonstrating MAPK pathway inhibition"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600E"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Causes BRAF-V600E Degradation",
      "Potent Inhibition of MAPK Signaling",
      "Loss of Viability in BRAF-V600E Cells"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600E",
      "NRAS-Q61K"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Active in BRAF-V600E/NRAS-Q61K, a model of clinical resistance to BRAF inhibitors",
      "Combination treatment of BRAFi resistant xenograft model with CFT1946 and MEKi shows tumor growth inhibition/regression",
      "CFT1946 as a single agent and in combination with MEKi is effective in MAPK pathway inhibition, superior to BRAFi"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF-V600E"
    ],
    "modality": "BiDACTM degrader",
    "e3_ligase": null,
    "indications": [
      "BRAF-V600X\u2013driven cancers",
      "inhibitor-resistant BRAF-V600X\u2013driven cancers"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "potent and mutant-selective",
      "superior to inhibitors in in vitro and in vivo models"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "AACR-2023_CFT1946_presentation_FINAL.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "class-leading efficacy",
      "differentiated safety & tolerability profile",
      "$2.5B-$4B peak revenue potential"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Relapsed/Refractory Multiple Myeloma"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 3"
    ],
    "claims": [
      "Potential to be best-in-class",
      "Class-leading anti-myeloma activity with 50% ORR",
      "Median DOR of 9.3 months",
      "Differentiated safety & tolerability profile"
    ],
    "safety": [
      "Differentiated safety & tolerability profile"
    ],
    "year": 2025,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Relapsed Refractory Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "First-in-Human"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degrading IKZF1/3 leads to myeloma cell death",
      "Degrading IKZF1/3 supports T-cell activation"
    ],
    "safety": [
      "On-target neutropenia"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "RRMM",
      "R/R MM",
      "4L+ RRMM",
      "2L+ RRMM"
    ],
    "therapeutic_areas": [
      "multiple myeloma"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1B",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Potential accelerated approval",
      "Potential accelerated and full approval (2L+)",
      "Potential full approval (4L+)"
    ],
    "safety": [
      "differentiated safety & tolerability profile"
    ],
    "year": 2025,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "3 DLTs at 100 \u00b5g QD",
      "1 DLT at 62.5 \u00b5g QD due to Grade 4 neutropenia lasting >7 days",
      "5 DLT events at 100 \u00b5g QD (G4 neutropenia, G3 pneumonia in 2 patients, G3 ALT increase, G3 febrile neutropenia)"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Cemsidomide + Dexamethasone"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Favorable safety profile with no discontinuations related to safety",
      "No discontinuations related to cemsidomide and minimal dose reductions",
      "No unexpected safety signals",
      "TEAEs leading to dose reductions: 4/72 (6%)",
      "Well-tolerated profile, including at the two highest dose levels evaluated",
      "1 TEAE leading to discontinuation, unrelated to cemsidomide",
      "Low incidence of neutropenic complications",
      "Differentiated safety profile with manageable neutropenia",
      "Across all dose levels, Grade 3 neutropenia was 24% and Grade 4 neutropenia was 33%",
      "Low rates of febrile neutropenia across all dose levels, with only 4% at Grade 3 and 1% at Grade 4",
      "Risk of neutropenia does not increase over time; limited G-CSF use highlights minimal impact of neutropenia on patient experience",
      "Few neutropenic events occurred in later cycles coupled with low rates of G-CSF observed"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "TEAEs leading to dose reductions: 4/72 (6%)",
      "No Discontinuations Related to Cemsidomide",
      "1 TEAE led to discontinuation, unrelated to cemsidomide",
      "Common (>20% All Grades) TEAEs: Neutropenia, Infections, Pneumonia, Upper Respiratory Tract Infection, Septic Shock, Sepsis, Anemia, Fatigue, Diarrhea, Leukopenia, Thrombocytopenia, Lymphopenia, Febrile Neutropenia"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "adverse_event": "Neutropenia",
        "grade": "\u22653",
        "percentage": "50"
      },
      {
        "adverse_event": "Anemia",
        "grade": "\u22653",
        "percentage": "17"
      },
      {
        "adverse_event": "Upper respiratory tract infection",
        "grade": "\u22653",
        "percentage": "0"
      },
      {
        "adverse_event": "Pneumonia",
        "grade": "\u22653",
        "percentage": "0"
      },
      {
        "adverse_event": "Septic shock",
        "grade": "\u22653",
        "percentage": "0"
      },
      {
        "adverse_event": "Sepsis",
        "grade": "\u22653",
        "percentage": "0"
      },
      {
        "adverse_event": "Thrombocytopenia",
        "grade": "\u22653",
        "percentage": "0"
      },
      {
        "adverse_event": "Lymphopenia",
        "grade": "\u22653",
        "percentage": "0"
      },
      {
        "adverse_event": "Febrile neutropenia",
        "grade": "\u22653",
        "percentage": "0"
      }
    ],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Class-leading anti-myeloma activity",
      "40% ORR at the 75 \u00b5g dose level",
      "50% ORR at the 100 \u00b5g dose level",
      "MRD negativity achieved in 1 patient with a CR at the 100 \u00b5g dose level"
    ],
    "safety": [
      "Favorable safety profile with no discontinuations related to safety",
      "No unexpected safety signals",
      "Well-tolerated profile, including at the two highest dose levels evaluated",
      "Low incidence of neutropenic complications"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "50% of Multiple Myeloma Patients With Elevated Light Chains Achieved at Least a 50% Decrease in dFLC",
      "Cemsidomide 14/14 + dex induced dFLC decrease in 73% of patients"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 23
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 24
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Grade 3 neutropenia",
      "Grade 4 neutropenia",
      "Grade > 3 infections",
      "Febrile neutropenia",
      "Dose reductions due to TEAEs"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 26
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 28
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Very good partial response"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 29
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Class-leading anti-myeloma activity in heavily pre-treated patient population",
      "40% ORR at the 75 \u00b5g dose level and 50% ORR at 100 \u00b5g dose level",
      "1 patient at 100 \u00b5g dose level achieved MRD negativity",
      "Median duration of response is 9.3 months across all doses",
      "67% of efficacy evaluable patients who achieved a PR or better at the 75 \u00b5g and 100 \u00b5g dose levels remain on treatment",
      "Favorable safety profile with no discontinuations related to safety",
      "Well-tolerated profile, including at the two highest dose levels evaluated",
      "Manageable neutropenia supported by low G-CSF use"
    ],
    "safety": [
      "No unexpected safety signals",
      "Low incidence of neutropenic complications"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 30
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 31
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 32
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 33
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 34
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "4L or later",
      "2L or later"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Accelerated Approval",
      "Full Approval"
    ],
    "safety": [
      "Characterize safety and tolerability"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 35
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [],
    "safety": [
      "Characterize the safety and tolerability of cemsidomide in combination with a BCMA BiTE"
    ],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 37
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b",
      "Phase 2"
    ],
    "claims": [
      "best-in-class profile",
      "differentiated safety & tolerability profile with class-leading anti-myeloma activity",
      "de-risked development plan with two distinct opportunities for accelerated approval"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 38
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "CEMSI_IMS Investor Presentation_FINAL_9.16.25.pdf",
      "slide": 39
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "MonoDAC\u00ae Degrader",
    "e3_ligase": "cereblon",
    "indications": [
      "Relapsed/Refractory Multiple Myeloma"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Cemsidomide is a novel, potent, cereblon-based IKZF1/3 MonoDAC\u00ae degrader",
      "Class-leading catalytic activity to enable rapid and deep target degradation",
      "High binding affinity to overcome low cereblon levels that drive resistance to lenalidomide and pomalidomide",
      "Improved pharmacologic profile to promote tumor residence time and sustained IKZF1/3 degradation",
      "Cemsidomide + Dex demonstrated compelling anti-myeloma activity across a broad range of doses"
    ],
    "safety": [
      "Only 1 DLT occurred as of the data cutoff date",
      "38% of patients experienced Grade 3/4 neutropenia, which was manageable",
      "No cases resulted in discontinuation or dose reductions"
    ],
    "year": 2024,
    "source": {
      "document": "FINAL_CEMSIDOMIDE_POSTER_MM_11.13.24.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8634",
    "targets": [
      "BRD9"
    ],
    "modality": "bifunctional degradation activating compound",
    "e3_ligase": "cereblon",
    "indications": [
      "synovial sarcoma",
      "SMARCB1-null tumors"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "CFT8634 is an orally bioavailable selective bifunctional degrader of BRD9",
      "CFT8634 demonstrated a manageable safety profile",
      "CFT8634 has shown preliminary evidence of anti-tumor activity"
    ],
    "safety": [
      "Majority of AEs reported were considered mild to moderate in severity",
      "No clear dose dependent relationship to incidence/severity of TEAEs was observed"
    ],
    "year": 2023,
    "source": {
      "document": "CFT8634-CTOS 2023 Poster_Final_11.1.23[3].pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "Monofunctional Degradation Activating Compound (MonoDAC)",
    "e3_ligase": "CRBN",
    "indications": [
      "Multiple Myeloma",
      "Non-Hodgkin\u2019s Lymphoma"
    ],
    "therapeutic_areas": [
      "Hematology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Significant potency advantage over other IKZF1/3 degraders",
      "Differentiated pharmacokinetic profile",
      "Sustained IKZF1/3 degradation"
    ],
    "safety": [
      "Neutropenia",
      "Thrombocytopenia",
      "Anemia",
      "Leukopenia"
    ],
    "year": null,
    "source": {
      "document": "AACR_Poster_Presentation_CFT7455_Phase_1_2_Cohort_A_Data.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT1946",
    "targets": [
      "BRAF V600X"
    ],
    "modality": "BiDAC degrader",
    "e3_ligase": "cereblon",
    "indications": [
      "melanoma",
      "colorectal cancer (CRC)",
      "non-small cell lung cancer (NSCLC)",
      "brain metastasis"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase I"
    ],
    "claims": [
      "superior activity to clinically approved BRAF inhibitors",
      "abrogates resistance and paradoxical activation associated with RAF dimerization",
      "demonstrates efficacy in multiple models of BRAF V600X-driven cancers"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "C4_2024_AACR_CFT1946 _FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma",
      "Non-Hodgkin\u2019s Lymphoma"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [
      "Discovery",
      "Pre-clinical"
    ],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "CDK7",
      "CDK12"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 22
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [
      "POI-31_CysX",
      "POI-73_CysX"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 23
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 24
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "Final_TPD_2023_C4T_Covalent Binders_10.27.23.pdf",
      "slide": 25
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR L858R"
    ],
    "modality": "oral",
    "e3_ligase": null,
    "indications": [
      "EGFR inhibitor-resistant non-small cell lung cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR L858R"
    ],
    "modality": "Oral, CNS-Active, Allosteric Degrader",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Orally bioavailable, selective, allosteric degrader of EGFR L858R",
      "Active in vitro and in vivo in models with secondary mutations",
      "Demonstrates intracranial activity",
      "Potential to be active as single agent in the frontline setting"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR-L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Selectively targets EGFR-L858R in human cancer cell lines",
      "Not impacted by EGFR T790M or C797S"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR-L861Q",
      "EGFR-L858R"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR",
      "CCND1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT8919",
    "targets": [
      "EGFR L858R"
    ],
    "modality": "Oral, Allosteric, Mutant-selective Degrader",
    "e3_ligase": null,
    "indications": [
      "NSCLC"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Active in vitro and in vivo in models with secondary mutations",
      "Demonstrates intracranial activity",
      "Clinical evaluation is warranted",
      "May combine with approved EGFR inhibitors",
      "Potential for single agent activity in the front-line setting"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_CFT8919_TPD_Summit_Presentation.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "multiple myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "potent tumor regression in IMiD-resistant multiple myeloma xenograft models"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "Small Molecule",
    "e3_ligase": "CRBN",
    "indications": [
      "myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Potent, rapid, and deep target degradation",
      "High binding affinity to overcome IMiD resistance",
      "Selective to reduce off-target liabilities",
      "Optimized pharmacologic profile to enable sustained IKZF1/3 degradation"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Demonstrates High Potency in MM Cell Lines and Xenografts",
      "Has Broad Antiproliferative Activity",
      "Promotes Durable Tumor Regression"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Demonstrates High Potency in MM Cell Lines and Xenografts",
      "Has Broad Antiproliferative Activity",
      "Promotes Durable Tumor Regression"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Durable single-agent activity",
      "Lower disease burden",
      "Early and stable regression of disease"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF3",
      "IKZF1",
      "IRF-4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "CRBN",
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Multiple Myeloma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT7455 is efficacious in MM models resistant or insensitive to IMiDs",
      "CFT7455 retains activity in Len- & Pom-resistant MM cells",
      "CFT7455 promotes regression in tumors insensitive to Pom"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "CFT7455 yields robust efficacy as monotherapy and in combination with dexamethasone",
      "Significant improvement in survival with CFT7455 + dexamethasone combination"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": "CRBN",
    "indications": [
      "R/R MM",
      "non-Hodgkin lymphoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "first-in-human"
    ],
    "claims": [
      "High CRBN binding affinity (Kd = 0.9 nM)",
      "Rapid, deep degradation of IKZF1/3 that is associated with apoptosis",
      "Broad, potent antiproliferative activity in a panel of MM cell lines",
      "Regression in multiple treatment-na\u00efve MM tumor models at doses \u226510 \u00b5g/kg/day",
      "Durable antitumor responses consistent with long-lived pharmacodynamic activity",
      "Efficacy in models unresponsive to approved IMiDs",
      "Expected efficacy and survival outcomes when combined with dexamethasone"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "C4_AACR_Slides_030421_Final_for_posting.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": "MonoDAC\u00ae Degrader",
    "e3_ligase": null,
    "indications": [
      "Non-Hodgkin\u2019s Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide (CFT7455)",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": "MonoDAC\u00ae degrader",
    "e3_ligase": "cereblon",
    "indications": [
      "non-Hodgkin lymphoma",
      "multiple myeloma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Catalytic activity enabling rapid and deep target degradation",
      "High binding affinity to overcome resistance due to low cereblon levels",
      "Pharmacologic profile to promote tumor residence time and sustained IKZF1/3 degradation"
    ],
    "safety": [
      "On-target neutropenia"
    ],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 2
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "CFT7455",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "non-Hodgkin lymphoma",
      "peripheral T-cell lymphoma",
      "anaplastic large cell lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [
      "2 DLTs occurred at 100 \u00b5g due to grade 4 thrombocytopenia"
    ],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 3
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 4
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "1 death reported was considered unrelated to cemsidomide"
    ],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 5
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Cemsidomide monotherapy was well tolerated with 2 DLTs observed at 100 \u00b5g",
      "Discontinuation rates due to AEs were low",
      "2 patients had a DLT at 100 \u00b5g QD due to grade 4 thrombocytopenia with one also having grade 3 febrile neutropenia",
      "3 patients dose reduced in the 100 \u00b5g cohort to 62.5 \u00b5g: 2 DLT patients and 1 patient due to nausea and vomiting"
    ],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 6
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Grade 3/4 neutropenia",
      "Grade 5 AE (hip fracture resulting in transfer to hospice)"
    ],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 7
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 8
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 9
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 10
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 11
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 12
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 13
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 14
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 15
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 16
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 17
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 18
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 19
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 20
    }
  },
  {
    "company": "c4_therapeutics",
    "program": "Cemsidomide",
    "targets": [
      "IKZF1",
      "IKZF3"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "peripheral T-cell lymphoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "differentiated PK profile",
      "rapid and potent degradation of IKZF1/3",
      "well tolerated",
      "compelling anti-lymphoma activity",
      "wide therapeutic index",
      "44% ORR",
      "25% CR rates"
    ],
    "safety": [
      "2 DLTs at 100 \u00b5g (grade 4 thrombocytopenia)",
      "manageable grade 3/4 neutropenia cases"
    ],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 21
    }
  },
  {
    "company": "c4_therapeutics",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "CFT7455-ASH 2024 NHL Oral_FINAL.pdf",
      "slide": 22
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "oncology",
      "neuroscience"
    ],
    "clinical_phases": [
      "Phase 3",
      "Phase 2",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- Breast Cancer",
      "Prostate Cancer",
      "Solid and Haematological Malignancies",
      "Neurodegenerative Disorders"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Neurodegenerative Disorders"
    ],
    "clinical_phases": [
      "Preclinical",
      "Phase 1/1b",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "Estrogen Receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "advanced breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "first-in-class",
      "superior ER degradation (>90%)",
      "superior tumor regression versus fulvestrant",
      "potent degrader of ER",
      "complete ER antagonist",
      "promising efficacy and tolerability profile"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Excellent tolerability and signals of efficacy in the most heavily pretreated patients of any ER-targeting therapy",
      "demonstrated strong signals of efficacy in the VERITAC Phase 2 trial",
      "Clinical Benefit Rate: 38% (All patients), 51% (Patients with ESR1 mutant tumors)",
      "Progression-Free Survival: 3.7 Months (All patients), 5.7 Months (Patients with ESR1 mutant tumors)",
      "ARV-471 has been well tolerated"
    ],
    "safety": [
      "Grade 3/4 TRAE reported in 6% (2/35) patients at 200 mg",
      "In 35 patients treated at the recommended Phase 3 dose (200 mg), no dose reduction and 1 discontinuation"
    ],
    "year": 2022,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "ESR1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER-positive breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [
      "ARV-471 degrades ESR1mut and ESR1wt equally",
      "demonstrated signals of efficacy in both ESR1 mutant and wild-type patients"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Ph1B",
      "Ph2",
      "Ph3"
    ],
    "claims": [],
    "safety": [],
    "year": "2023",
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "androgen receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Metastatic Castrate Resistant Prostate Cancer (mCRPC)"
    ],
    "therapeutic_areas": [
      "Prostate Cancer"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "46% PSA50 response rate in patients with AR T878X/H875Y-positive tumors",
      "0% Grade \u22654 TRAEs",
      "Low rates of discontinuation and dose reduction"
    ],
    "safety": [
      "manageable tolerability"
    ],
    "year": 2022,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": "BCL6 PROTAC\u00ae degrader",
    "targets": [
      "BCL6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Diffuse Large B-Cell Lymphoma (DLBCL)"
    ],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "first-in-class potential therapy"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 15
    }
  },
  {
    "company": "arvinas",
    "program": "BCL-057",
    "targets": [
      "BCL6"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "Diffuse Large B-Cell Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "GLP toxicity studies"
    ],
    "claims": [
      "inhibits tumor growth by nearly 100%",
      "Complete tumor stasis at low, oral daily doses",
      "Tumor stasis correlates with 95-100% degradation of measurable BCL6"
    ],
    "safety": [],
    "year": "2023",
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 16
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "neurological diseases"
    ],
    "clinical_phases": [],
    "claims": [
      "Cross the blood-brain barrier",
      "Reach targets in 'deep brain' regions",
      "Degrade disease-causing proteins inside cells",
      "Differentiate between mutant and wild-type proteins, e.g., mutant huntingtin",
      "Be delivered orally"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 17
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 18
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "GLP toxicity studies"
    ],
    "claims": [
      ">85% LRRK2 degradation in deep brain regions of cynomolgus monkeys after oral dosing"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 19
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 20
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "JPM Presentation_Final_01.11.23.pdf",
      "slide": 21
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": "vepdegestrant",
    "targets": [
      "ESR1"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- advanced breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "2L"
    ],
    "claims": [
      "best-in-class treatment",
      "5-month median PFS",
      "2.9-month improvement over fulvestrant"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": "Vepdegestrant",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- advanced or metastatic breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": "Vepdegestrant",
    "targets": [
      "ESR1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "met the primary endpoint with a ~3-month improvement in mPFS in patients with tumors harboring ESR1 mutations"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": "Vepdegestrant",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": "Vepdegestrant",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": "Vepdegestrant",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": "vepdegestrant",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "TEAE": "Fatigue",
        "Any Grade": 27,
        "Grade 3/4": 14
      },
      {
        "TEAE": "ALT increased",
        "Any Grade": 14,
        "Grade 3/4": 1
      },
      {
        "TEAE": "AST increased",
        "Any Grade": 13,
        "Grade 3/4": 1
      },
      {
        "TEAE": "Nausea",
        "Any Grade": 12,
        "Grade 3/4": 0
      },
      {
        "TEAE": "Anemia",
        "Any Grade": 12,
        "Grade 3/4": 1
      },
      {
        "TEAE": "Neutropenia",
        "Any Grade": 11,
        "Grade 3/4": 1
      },
      {
        "TEAE": "Back pain",
        "Any Grade": 11,
        "Grade 3/4": 0
      },
      {
        "TEAE": "Arthralgia",
        "Any Grade": 11,
        "Grade 3/4": 0
      },
      {
        "TEAE": "Decreased appetite",
        "Any Grade": 11,
        "Grade 3/4": 0
      }
    ],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 15
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 16
    }
  },
  {
    "company": "arvinas",
    "program": "Vepdegestrant",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "2L+",
      "ESR1 mutant setting"
    ],
    "therapeutic_areas": [
      "metastatic breast cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "best-in-class treatment without tradeoffs between efficacy, tolerability, and patient reported outcomes",
      "favorable safety/tolerability",
      "low rates and severity of GI-related events",
      "2.5x improvement in mPFS over SoC",
      "improvement in mPFS (5.0m vs. 2.1m) vs. fulvestrant"
    ],
    "safety": [
      "favorable safety/tolerability",
      "low rates and severity of GI-related events"
    ],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 17
    }
  },
  {
    "company": "arvinas",
    "program": "Vepdegestrant",
    "targets": [],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "tumors harboring an ESR1 mutation"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [
      "demonstrate clinical benefit",
      "clinically meaningful median PFS benefit over fulvestrant",
      "potential best-in-class profile"
    ],
    "safety": [
      "safety and tolerability provide further evidence"
    ],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 18
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2",
      "BCL6",
      "KRAS G12D"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Parkinson's disease",
      "non-Hodgkin\u2019s lymphoma",
      "diffuse large B-cell lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 19
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "VERITAC-2 Trial Results - ASCO 2025.pdf",
      "slide": 20
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [
      "androgen receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "first PROTAC degrader with an efficacy signal in humans",
      "first evidence for androgen receptor degradation in patients"
    ],
    "safety": [
      "generally well tolerated",
      "dose escalation continues"
    ],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [
      "AR",
      "T878A",
      "H875Y",
      "F877L",
      "M895V"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Degrades >90% AR protein in vivo",
      "In vivo activity in multiple xenograft models"
    ],
    "safety": [
      "Does not degrade L702H or AR-V7",
      "ARV-110 is not blood-brain barrier penetrant"
    ],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "No dose limiting toxicities (DLTs)",
      "No treatment related Adverse Events (AEs)",
      "No DLTs",
      "No grade 2/3/4 treatment related AEs"
    ],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metastatic castration-resistant prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "adverse_event": "Nausea",
        "grade": "Gr \u22642",
        "count": 13,
        "percentage": 59
      },
      {
        "adverse_event": "Diarrhea",
        "grade": "Gr \u22642",
        "count": 6,
        "percentage": 27
      },
      {
        "adverse_event": "Fatigue",
        "grade": "Gr \u22642",
        "count": 6,
        "percentage": 27
      },
      {
        "adverse_event": "ALT increased",
        "grade": "Gr \u22642",
        "count": 5,
        "percentage": 23
      },
      {
        "adverse_event": "AST increased",
        "grade": "Gr \u22642",
        "count": 4,
        "percentage": 18
      },
      {
        "adverse_event": "Lymphocyte count decreased",
        "grade": "Gr \u22642",
        "count": 4,
        "percentage": 18
      },
      {
        "adverse_event": "Vomiting",
        "grade": "Gr \u22642",
        "count": 4,
        "percentage": 18
      }
    ],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "First patient with DLT: Grade 3/4 ALT/AST and renal failure",
      "Second patient with Grade 3 ALT/AST; re\u2010challenge off rosuvastatin supported contribution of rosuvastatin",
      "Patient continues on ARV\u2010110 with no further toxicity",
      "Following introduction of rosuvastatin restriction, no further elevation in LFTs observed",
      "6 patients on other statins, including 3 on atorvastatin (Lipitor\u00ae) and no ALT/AST adverse events"
    ],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 15
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 16
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [
      "AR"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "degrades AR in tumor tissue",
      "first proof of mechanism for PROTAC\u00ae protein degraders"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 17
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 18
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 19
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 20
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 21
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed RECIST partial response in a patient with a PCWG3",
      "RECIST: 80% reduction in tumor measurements",
      "Duration of ARV\u2010110: 18 weeks and ongoing",
      "PSA: 97% decline",
      "Near complete regression of adenopathy after 4 cycles"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 22
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Unequivocal efficacy signal in first-in-human dose escalation study",
      "Deep, durable, and ongoing responses",
      "Favorable safety profile",
      "Tolerability consistent with 2nd generation AR therapies",
      "Manageable drug-drug interaction with breast cancer resistant pump substrates"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 23
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 24
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Prostate Cancer",
      "Breast Cancer",
      "FTLD-Tau",
      "PSP",
      "Alzheimer\u2019s",
      "MSA",
      "Parkinson\u2019s"
    ],
    "therapeutic_areas": [
      "cancer",
      "neuroscience"
    ],
    "clinical_phases": [
      "Discovery",
      "Lead Optimization",
      "IND Enabling",
      "Phase 1",
      "Phase 2/3"
    ],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 25
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Proving the concept of PROTAC protein degradation",
      "Preclinical profile translating into clinical benefit",
      "Signals of efficacy in a heavily pretreated patient population with high unmet need, where traditional inhibitors have failed",
      "Proves the concept of PROTAC targeted protein degradation, validating our confidence in our pipeline of degraders"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 26
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 27
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 28
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 29
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN ASCO 2020_VF.pdf",
      "slide": 30
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "estrogen receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "breast cancer",
      "metastatic castrate-resistant prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "best-in-class estrogen receptor-targeting therapy",
      "demonstrated safety and efficacy in men with late-line metastatic castrate-resistant prostate cancer"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ Breast Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "breast cancer"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "2L",
      "3L"
    ],
    "claims": [
      "Compelling efficacy signal in heavily pretreated patients",
      "Well tolerated, with manageable adverse events",
      "Superior ER degradation compared to SERDs"
    ],
    "safety": [
      "Well tolerated, with manageable adverse events"
    ],
    "year": 2020,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "ARV-110",
      "ARV-766",
      "AR-V7",
      "ARV-471",
      "BCL6",
      "KRAS G12D/V",
      "Myc",
      "HPK1",
      "Alpha Synuclein",
      "mHTT"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "ER+/HER2- Breast Cancer",
      "B-cell Malignancies",
      "NSCLC",
      "CRC",
      "Pancreatic",
      "Solid Malignancies",
      "FTLD-TAU",
      "PSP",
      "AD",
      "MSA",
      "Parkinson\u2019s",
      "Neurodegeneration",
      "Huntington\u2019s"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Immuno-oncology",
      "Neuroscience"
    ],
    "clinical_phases": [
      "Exploratory",
      "Research",
      "IND Enabling",
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV-471 Collaboration Presentation_vF.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "estrogen receptor"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Potential best-in-class estrogen receptor-targeting therapy",
      "Outstanding tolerability profile",
      "Better ER degradation than fulvestrant",
      "Robust signals of efficacy"
    ],
    "safety": [
      "Outstanding tolerability profile observed"
    ],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "well tolerated at all dose levels",
      "no Grade 3 adverse events",
      "adverse events were primarily Grade 1",
      "no dose limiting toxicities"
    ],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "Estrogen receptor"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "ER",
      "ESR1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Degraded ER up to 90%",
      "Degradation superior to fulvestrant"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 15
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 16
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 17
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 18
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 19
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-471 has the potential to be a best-in-class ER-directed therapy"
    ],
    "safety": [
      "Diarrhea",
      "Nausea",
      "Vomiting",
      "Bradycardia",
      "Visual disturbance"
    ],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 20
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Superior degradation to fulvestrant and SERDs",
      "Strong efficacy signal in a predominantly ER-independent population",
      "Well tolerated",
      "Potential for 2L/3L approval as monotherapy or in combination",
      "Planned combinations with CDK4/6 inhibitors in adjuvant or early metastatic cancers"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 22
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 23
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "40% PSA50 in a molecularly defined subgroup",
      "well tolerated",
      "potential best-in-class therapy"
    ],
    "safety": [
      "well tolerated",
      "escalating through the current dose of 700 mg"
    ],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 24
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 25
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 26
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "showing early clinical benefit in highly refractory patients"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 27
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Promising antitumor activity in heavily pre-treated patients with limited treatment options",
      "PSA reduction is associated with plasma exposure",
      "Activity in wild-type AR patients supports broader use",
      "ARV-110 is well tolerated, allowing continued dose escalation up to current dose of 700 mg daily, and potentially supporting use in earlier lines of therapy"
    ],
    "safety": [
      "Safety cut-off date: October 2, 2020"
    ],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 28
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 29
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 30
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 31
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 32
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 33
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [
      "AR"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "refractory mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Best PSA Change In Patients with Wild-Type AR (N=15)",
      "PSA50 13% (2/15)"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 34
    }
  },
  {
    "company": "arvinas",
    "program": "ARDENT",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Well tolerated; no TRAEs Gr >2",
      "Strong signal in molecularly defined patient populations",
      "High potential for patient benefit in earlier-line, more AR-dependent patients"
    ],
    "safety": [
      "Safety cut-off date: October 2, 2020"
    ],
    "year": 2021,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 35
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "late-line mCRPC",
      "early-line mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Potential for accelerated approval"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 36
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metastatic castrate resistant prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 3",
      "Phase 2"
    ],
    "claims": [
      "planned registrational path aligns with unmet need",
      "potential label expansion into earlier settings"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 37
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "molecularly defined, late-line mCRPC",
      "CSPC"
    ],
    "therapeutic_areas": [
      "prostate cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "Driving tumor responses and PSA reductions",
      "Well tolerated",
      "Two potential registrational paths",
      "Accelerated approval in molecularly defined mCRPC",
      "Broader 1L/2L mCRPC",
      "High unmet need across all stages of prostate cancer"
    ],
    "safety": [
      "Well tolerated"
    ],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 38
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 39
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "ARV-110",
      "ARV-766",
      "AR-V7",
      "BCL6",
      "KRAS",
      "Myc",
      "HPK1",
      "Tau",
      "Alpha Synuclein",
      "mHTT"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "Other AR indications",
      "ER+/HER2- Breast Cancer",
      "B-cell Malignancies",
      "NSCLC",
      "CRC",
      "Pancreatic",
      "Solid Malignancies",
      "FTLD-TAU",
      "PSP",
      "AD",
      "MSA",
      "Parkinson\u2019s",
      "Huntington\u2019s",
      "Neurodegeneration"
    ],
    "therapeutic_areas": [
      "oncology",
      "I-O",
      "neuroscience"
    ],
    "clinical_phases": [
      "Exploratory",
      "Research",
      "IND Enabling",
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 40
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 41
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 42
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARVN_Clinical Program Update ARV-110 .pdf",
      "slide": 43
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide (ARV-110)",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Robust signals of efficacy",
      "manageable tolerability",
      "potential path to accelerated approval"
    ],
    "safety": [
      "The majority of TRAEs are Grade 1 or 2",
      "no Grade \u22654 TRAEs",
      "Low rates of discontinuation or dose reduction from the RP2D due to TRAEs"
    ],
    "year": 2022,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [
      "androgen receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "promising efficacy profile",
      "first-in-class",
      "degrades wild-type AR and clinically relevant mutants"
    ],
    "safety": [
      "heavily pretreated patient population",
      "76% of patients received prior chemotherapy",
      "82% received both abiraterone and enzalutamide",
      "84% had non-AR gene mutations"
    ],
    "year": 2020,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "post-NHA mCRPC"
    ],
    "therapeutic_areas": [
      "prostate cancer"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "safety and tolerability acceptable",
      "efficacy signal sufficiently robust (>25% PSA50)",
      "higher PSA response rate in less pretreated population"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metastatic castration resistant prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [
      "acceptable for use in a post-NHA patient population"
    ],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [
      {
        "TRAE": "Any TRAE",
        "Grade 1": 39,
        "Grade 2": 53,
        "Grade 3": 22,
        "Total": 115
      },
      {
        "TRAE": "Nausea",
        "Grade 1": 42,
        "Grade 2": 16,
        "Grade 3": 7,
        "Total": 66
      },
      {
        "TRAE": "Fatigue",
        "Grade 1": 32,
        "Grade 2": 36,
        "Grade 3": 5,
        "Total": 73
      },
      {
        "TRAE": "Vomiting",
        "Grade 1": 28,
        "Grade 2": 35,
        "Grade 3": 2,
        "Total": 65
      },
      {
        "TRAE": "Decreased appetite",
        "Grade 1": 19,
        "Grade 2": 28,
        "Grade 3": 1,
        "Total": 48
      },
      {
        "TRAE": "Diarrhea",
        "Grade 1": 19,
        "Grade 2": 20,
        "Grade 3": 3,
        "Total": 42
      },
      {
        "TRAE": "Alopecia",
        "Grade 1": 18,
        "Grade 2": 17,
        "Grade 3": 1,
        "Total": 36
      },
      {
        "TRAE": "AST increased",
        "Grade 1": 12,
        "Grade 2": 16,
        "Grade 3": 1,
        "Total": 29
      },
      {
        "TRAE": "Weight decreased",
        "Grade 1": 9,
        "Grade 2": 15,
        "Grade 3": 0,
        "Total": 24
      },
      {
        "TRAE": "Anemia",
        "Grade 1": 6,
        "Grade 2": 11,
        "Grade 3": 1,
        "Total": 18
      }
    ],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "post-NHA mCRPC"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [
      "acceptable for use in a post-NHA mCRPC patient population"
    ],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": "AR-advanced prostate cancer",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "PSA50=75% in T878X/H875Y mutant tumors",
      "PSA50=11% in WT/Other",
      "PSA50=4% in L702H/AR-V7",
      "PSA50=22% in Less Pretreated"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "46% PSA50 in all patients with AR T878X/H875Y tumor mutations",
      "PSA30=57%"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [
      "AR T878X",
      "AR H875Y"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "robust duration of treatment"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": "AR T878X/H875Y",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [
      "Durable partial responses in 2 of 7 RECIST-evaluable patients",
      "Activity was durable; patients with confirmed partial responses (PR) remained on treatment for approximately 9 (ongoing) and 10 months",
      "6 of 7 patients had tumor reductions"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": "AR T878X/875Y",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "46% PSA50 rate",
      "Durable partial responses",
      "Tumor regression"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 15
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 16
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [
      "acceptable for use in a post-NHA mCRPC patient population"
    ],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 17
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metastatic castration resistant prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 18
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 19
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 20
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "CRPC",
      "CSPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "pivotal trial"
    ],
    "claims": [
      "potential path to accelerated approval",
      "unmet need expected to increase as NHAs move earlier"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 21
    }
  },
  {
    "company": "arvinas",
    "program": "bavdegalutamide",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metastatic castration resistant prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "46% PSA50 rate",
      "2 of 7 RECIST-evaluable patients with durable partial responses",
      "6 of 7 patients with tumor reductions",
      "43% of patients remained on treatment for 24 weeks or more"
    ],
    "safety": [
      "Manageable tolerability profile"
    ],
    "year": 2022,
    "source": {
      "document": "ASCO_GU IR presentation_FINAL_draft 021722.pdf",
      "slide": 22
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "breast cancer",
      "neuroscience",
      "oncology"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "AR",
      "ER"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "2L, ESR1m, ER+/HER2- advanced or metastatic BC",
      "late-line prostate cancer"
    ],
    "therapeutic_areas": [
      "breast cancer",
      "prostate cancer"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Positive efficacy and well-tolerated in Phase 1, 2 and 3 clinical trials",
      "First positive Phase 3 trial and first new drug application (NDA) submitted to U.S. FDA with a PROTAC",
      "Potential to be a best-in-class treatment monotherapy option",
      "Demonstrated signals of efficacy in late-line prostate cancer"
    ],
    "safety": [
      "well-tolerated"
    ],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2",
      "polyQ-AR",
      "BCL6",
      "KRAS G12D",
      "HPK1",
      "ER",
      "AR"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Parkinson\u2019s disease",
      "Spinal Bulbar Muscular Atrophy",
      "non-Hodgkin lymphoma",
      "Solid tumors harboring KRAS G12D mutations",
      "mHSPC",
      "mCRPC"
    ],
    "therapeutic_areas": [
      "neurology",
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 1 monotherapy",
      "Phase 1",
      "Phase 3",
      "Phase 1/2",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": "vepdegestrant",
    "targets": [],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "pivotal"
    ],
    "claims": [
      "first-in-class oral PROTAC estrogen receptor degrader"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Neurology"
    ],
    "clinical_phases": [],
    "claims": [
      "Investigational compound. Its safety and effectiveness have not been established."
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "neurodegenerative diseases"
    ],
    "clinical_phases": [
      "preclinical",
      "clinical"
    ],
    "claims": [
      "dose-dependent increases in exposure in cerebral spinal fluid after single and multiple doses indicated brain penetration"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Parkinson's Disease",
      "Progressive Supranuclear Palsy"
    ],
    "therapeutic_areas": [
      "Neurodegenerative disorders"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "idiopathic Parkinson\u2019s disease",
      "progressive supranuclear palsy"
    ],
    "therapeutic_areas": [
      "neurology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 15
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 16
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Parkinson's disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Increases lysosome functional degradative capacity and number in cells",
      "Dose-dependently increased degradation efficiency and lysosome number vs kinase inhibitors",
      "Increases lysosome degradation in A549 cells",
      "Increases lysosome number in A549 cells"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 17
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 18
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "better target engagement",
      "enhanced potency",
      "pathway engagement versus a LRRK2 inhibitor",
      "50x greater target engagement with ARV-102",
      "50x greater pathway engagement with ARV-102"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 19
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-102 degrades LRRK2 in NHP deep-brain regions",
      "CSF levels of LRRK2 track cortex LRRK2",
      "Orally dosed ARV-102 reaches multiple deep brain regions in NHPs and degrades LRRK2 up to 94%"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 20
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 21
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2",
      "IBA1",
      "Cathepsin B",
      "GPNMB"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Parkinson\u2019s disease"
    ],
    "clinical_phases": [],
    "claims": [
      "Putative LRRK2 biomarkers associated with disease are reduced in non-human primate CSF after dosing with ARV-102",
      "IBA1 is reduced by ARV-102",
      "Cathepsin B is reduced by ARV-102",
      "GPNMB is reduced by ARV-102"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 22
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "dose-dependent increases in LRRK2 reductions in CSF indicate brain penetration and target engagement",
      "ARV-102 induced dose-dependent reductions in LRRK2 levels in CSF, with >50% LRRK2 reduction at single doses \u226560 mg and repeated doses \u226520 mg"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 23
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "reductions in downstream LRRK2 pathway biomarkers in blood cells and urine",
      ">50% decreases in phospho-Rab10T73 and BMP in urine"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 24
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2",
      "C1QTNF1",
      "ENTPD1",
      "CTSH",
      "TMEM106A",
      "GRN",
      "GPNMB",
      "CD68"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "neurodegeneration",
      "Parkinson's disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "significant reductions in lysosomal pathway markers",
      "reduced lysosomal markers reflecting effects on proteolysis, lysosomal integrity, and microglial activation",
      "normalization of cytokine and purinergic signaling"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 25
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Parkinson's"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 26
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Parkinson's"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Decreased LRRK2 protein levels in PBMCs after a single oral dose"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 27
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Parkinson\u2019s disease",
      "progressive supranuclear palsy"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b"
    ],
    "claims": [
      "First-in-human data presented during oral presentation at AD/PD",
      "Final data from HV SAD/MAD cohorts presented at MDS",
      "Enrollment complete",
      "Presenting initial single ascending dose data"
    ],
    "safety": [
      "Safety",
      "Tolerability"
    ],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 28
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-027",
    "targets": [
      "polyQ-AR"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Neurology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 29
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 30
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 31
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-027",
    "targets": [
      "polyQ-AR"
    ],
    "modality": "PROTAC",
    "e3_ligase": true,
    "indications": [
      "spinal bulbar muscular atrophy"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 32
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-027",
    "targets": [
      "polyQ-AR"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "spinal bulbar muscular atrophy"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "induced polyQ-AR degradation in muscle tissues",
      "rescued strength and endurance"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 33
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [
      "BCL6"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Hematology-Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "investigational compound",
      "safety and effectiveness have not been established"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 34
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 35
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 36
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [
      "BCL6"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "non-Hodgkin lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Potent, orally bioavailable PROTAC small molecule degrader of BCL6",
      "Demonstrated significant anti-tumor single-agent activity",
      "Broad combinability with complete tumor regressions in combination with SOC biologics and investigational small molecule agents"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 37
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [
      "BCL6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "DLBCL"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "potently degrades BCL6",
      "exhibits picomolar degradation potency",
      "degradation is mediated by PROTAC mechanism"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 38
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [
      "BCL6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-393 rapidly degrades >90% of BCL6 within 2 hours",
      "overcomes BCL6 high resynthesis rate"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 39
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Diffuse Large B-Cell Lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "induces dose-dependent and sustained tumor growth inhibition",
      "demonstrated >90% TGI",
      "tumor regression at 30 mg/kg dosed once per day",
      "no adverse impact on animal health/body weight"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 40
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [
      "PTPN6",
      "IRF4",
      "CDKN1B"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 41
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "non-Hodgkin lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "induces tumor growth inhibition in PDX models of various non-Hodgkin lymphoma subtypes",
      "breadth of efficacy beyond DLBCL demonstrated in multiple patient-derived xenograft (PDX) models with no body weight loss"
    ],
    "safety": [
      "no body weight loss"
    ],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 42
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [
      "BCL6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "T-cell lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "preclinical"
    ],
    "claims": [
      "evidence of significant efficacy comparable to SOC romidepsin"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 43
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "non-Hodgkin lymphoma"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "potential to be an attractive combination partner for development of novel treatment options"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 44
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "diffuse large B-cell lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "demonstrates activity in combination with SOC chemotherapy/biologics",
      "drives tumor regressions, including complete responses"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 45
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "DLBCL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "demonstrates activity in combination with small molecule inhibitors",
      "drives tumor regressions, including complete responses, in preclinical models"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 46
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-393",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed/refractory non-Hodgkin lymphoma",
      "relapsed/refractory mature B-cell NHL",
      "nTFHL-AI"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 47
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-806",
    "targets": [
      "KRAS G12D"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Investigational compound. Safety and effectiveness have not been established."
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 48
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-806",
    "targets": [
      "KRAS G12D"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "pancreatic cancer",
      "colorectal cancer",
      "non-small cell lung cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Catalytic activity (overcomes upregulation, a common mechanism of resistance to inhibitor treatment)",
      ">40-fold higher potency in degrading KRAS G12D protein vs the comparable clinical-stage G12D degrader",
      ">25-fold greater potency in reducing cancer cell proliferation compared with clinical-stage KRAS G12D ON and OFF inhibitors and a clinical-stage G12D degrader"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 49
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 50
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 51
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-806",
    "targets": [
      "KRAS G12D"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-806 forms a ternary complex with both OFF (GDP-bound) and ON (GTP-bound) KRAS G12D",
      "Targeting both OFF and ON KRAS G12D allows ARV-806 to eliminate this oncogenic protein from the cell",
      "ARV-806 treatment directly leads to ubiquitination of KRAS G12D protein"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 52
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-806",
    "targets": [
      "KRAS G12D"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-806 is a highly potent, selective degrader of KRAS G12D",
      "ARV-806 degrades KRAS G12D with picomolar potency",
      "ARV-806 is selective for KRAS G12D",
      "ARV-806 effectively eliminates KRAS G12D from cancer cells",
      "ARV-806 demonstrates exquisite selectivity for KRAS G12D, indicating a robust therapeutic index"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 53
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-806",
    "targets": [
      "KRAS G12D"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Pancreatic Cancer",
      "Colorectal Cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Demonstrates anti-proliferative activity approximately 25 times greater than KRAS inhibitors and the leading clinical-stage degrader",
      ">40-fold more potent than KRAS G12D levels",
      ">25-fold more potent than all G12D-targeting competitors"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 54
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-806",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "pancreatic cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "more potently induces pancreatic cancer cell death in vitro relative to clinical-stage inhibitors and degrader",
      "more potently increases apoptosis (cell death)"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 55
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-806",
    "targets": [
      "KRAS G12D"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "leads to robust and extended degradation and signaling suppression in vivo",
      "KRAS G12D reduced >90% for 7 days",
      "Proliferative marker (c-MYC) suppressed and pro-apoptotic marker (BIM) increased for 5 days"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 56
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-806",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "colorectal cancer",
      "pancreatic cancer",
      "non-small cell lung cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "\u226530% tumor volume reductions in pancreatic and colorectal CDX models",
      "\u226530% tumor volume reductions in a patient-derived xenograft (PDX) model of lung cancer"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 57
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-806",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "KRAS G12D mutated advanced solid tumors",
      "previously treated KRAS G12D mutated advanced PDAC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [
      "safety",
      "tolerability",
      "pharmacokinetics (PK)",
      "preliminary antitumor activity"
    ],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 58
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "estrogen receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "Oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Its safety and effectiveness have not been established."
    ],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 59
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 60
    }
  },
  {
    "company": "arvinas",
    "program": "VEPDEGESTRANT",
    "targets": [
      "estrogen receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "ESR1 mutant ER+/HER2- advanced breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [
      "Vepdegestrant was well tolerated, with low rates of discontinuation",
      "Vepdegestrant met its primary endpoint of improvement in progression-free survival versus the standard of care, fulvestrant",
      "Patient reported outcomes data demonstrate that vepdegestrant significantly reduced risk of deterioration in measures of overall health status compared to fulvestrant"
    ],
    "safety": [
      "well tolerated",
      "low rates of discontinuation"
    ],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 61
    }
  },
  {
    "company": "arvinas",
    "program": "vepdegestrant",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "2L+",
      "ESR1 mutant setting"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "BEST-IN-CLASS TREATMENT without tradeoffs between efficacy, tolerability, and patient reported outcomes"
    ],
    "safety": [
      "Favorable safety/tolerability profile",
      "Low rates and severity of GI-related events",
      "Low rate of discontinuation (2.9%)"
    ],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 62
    }
  },
  {
    "company": "arvinas",
    "program": "vepdegestrant",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- advanced or metastatic breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 63
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 64
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 65
    }
  },
  {
    "company": "arvinas",
    "program": "Vepdegestrant",
    "targets": [
      "ESR1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "statistically significant improvements in CBR and ORR in the ESR1 mutant population"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 66
    }
  },
  {
    "company": "arvinas",
    "program": "Vepdegestrant",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "TEAE": "Any grade",
        "Vepdegestrant": 87,
        "Fulvestrant": 81
      },
      {
        "TEAE": "Grade \u22653",
        "Vepdegestrant": 23,
        "Fulvestrant": 18
      },
      {
        "TEAE": "Serious",
        "Vepdegestrant": 10,
        "Fulvestrant": 9
      },
      {
        "TEAE": "Leading to treatment discontinuation",
        "Vepdegestrant": 3,
        "Fulvestrant": 1
      },
      {
        "TEAE": "Leading to dose reduction",
        "Vepdegestrant": 2,
        "Fulvestrant": 0
      },
      {
        "TEAE": "QT prolongation",
        "Vepdegestrant": 10,
        "Fulvestrant": 1
      },
      {
        "TEAE": "Fatigue",
        "Vepdegestrant": 27,
        "Fulvestrant": 16
      },
      {
        "TEAE": "ALT increased",
        "Vepdegestrant": 14,
        "Fulvestrant": 10
      },
      {
        "TEAE": "AST increased",
        "Vepdegestrant": 12,
        "Fulvestrant": 10
      },
      {
        "TEAE": "Nausea",
        "Vepdegestrant": 12,
        "Fulvestrant": 9
      },
      {
        "TEAE": "Anemia",
        "Vepdegestrant": 11,
        "Fulvestrant": 8
      },
      {
        "TEAE": "Neutropenia",
        "Vepdegestrant": 11,
        "Fulvestrant": 5
      },
      {
        "TEAE": "Back pain",
        "Vepdegestrant": 11,
        "Fulvestrant": 7
      },
      {
        "TEAE": "Arthralgia",
        "Vepdegestrant": 1,
        "Fulvestrant": 1
      },
      {
        "TEAE": "Decreased appetite",
        "Vepdegestrant": 1,
        "Fulvestrant": 5
      }
    ],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 67
    }
  },
  {
    "company": "arvinas",
    "program": "Vepdegestrant",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ESR1 mutations"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "significantly reduced risk of clinically meaningful definitive deterioration in measures of overall health status compared to fulvestrant"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 68
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 69
    }
  },
  {
    "company": "arvinas",
    "program": "vepdegestrant",
    "targets": [
      "ESR1"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- advanced or metastatic breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "2L+"
    ],
    "claims": [
      "best-in-class treatment",
      "5-month median PFS",
      "2.9-month improvement over fulvestrant"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 70
    }
  },
  {
    "company": "arvinas",
    "program": "vepdegestrant",
    "targets": [
      "ESR1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "tumors harboring an ESR1 mutation"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [
      "clinically meaningful median PFS benefit over fulvestrant",
      "potential best-in-class profile"
    ],
    "safety": [
      "safety and tolerability provide further evidence"
    ],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 71
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2",
      "BCL6",
      "KRAS G12D"
    ],
    "modality": "PROTAC degraders",
    "e3_ligase": null,
    "indications": [
      "oncology",
      "neurology",
      "Parkinson\u2019s disease",
      "progressive supranuclear palsy",
      "advanced solid tumors",
      "spinal bulbar muscular atrophy"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Pre-Clinical",
      "Phase 1",
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 72
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ARVINAS Corporate Presentation 2025_Nov_5 Final.pdf",
      "slide": 73
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "ER"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "ER+ metastatic breast cancer"
    ],
    "therapeutic_areas": [
      "breast cancer"
    ],
    "clinical_phases": [],
    "claims": [
      "First-in-class ER-degrading PROTAC",
      "potential to degrade ER better than fulvestrant",
      "oral, best-in-class ER-directed therapy"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "ER"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "degraded ER up to 90% through the 120 mg dose level",
      "average degradation of 62%",
      "68% Reduction in ER after treatment with 60 mg ARV-471"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "Target 1",
      "Target 2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Confirmed RECIST Partial Response in a patient with extensive prior therapy and an ESR1 mutation at 120 mg"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- Breast Cancer"
    ],
    "therapeutic_areas": [
      "Breast Cancer"
    ],
    "clinical_phases": [
      "Phase 1b",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [
      "androgen receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "may overcome point mutations and other drivers of resistance"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "ARV-110 has shown clinical benefit in Phase 1 in a highly refractory patient population",
      "ARV-110 is well tolerated, allowing continued dose escalation up to 700 mg daily",
      "AR degradation and late-line activity suggest strong potential across multiple disease states",
      "AR molecular profiling identifies a molecularly defined, late line population that may offer a possible path to accelerated approval"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 15
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "encouraging efficacy signals",
      "substantially exceeded expectations for PSA50 responses",
      "suggests potential in early prostate cancer",
      "suggests potential for accelerated approval"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 16
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 17
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 18
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "ARV-110",
      "ARV-766",
      "ARV-471",
      "BCL6",
      "KRAS G12D/V",
      "Myc",
      "HPK1",
      "e Tau",
      "Alpha Synuclein",
      "mHTT"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "ER+/HER2- Breast Cancer",
      "B-cell Malignancies",
      "NSCLC",
      "CRC",
      "Pancreatic",
      "Solid Malignancies",
      "FTLD-TAU",
      "PSP",
      "AD",
      "MSA",
      "Parkinson\u2019s",
      "Neurodegeneration",
      "Huntington\u2019s"
    ],
    "therapeutic_areas": [
      "oncology",
      "immuno-oncology",
      "neuroscience"
    ],
    "clinical_phases": [
      "Exploratory",
      "Research",
      "IND Enabling",
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 19
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 1b",
      "Phase 1b",
      "Phase 2"
    ],
    "claims": [
      "Share completed Phase 1 data",
      "Initiate Phase 1b combination study with everolimus",
      "Begin early breast cancer study (neoadjuvant setting)"
    ],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 20
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 21
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 22
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 23
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 24
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "2021 TPD Summit - Arvinas Presentation.pdf",
      "slide": 25
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-766",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "interim Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-766",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metastatic castrate-resistant prostate cancer",
      "castrate-sensitive prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "promising efficacy signals in late-line mCRPC",
      "well-tolerated",
      "promising efficacy signals in heavily pretreated patients",
      "42% of patients with AR LBD mutations achieved PSA50",
      "3 of 3 patients with co-occurring AR T878/H875/L702H mutations achieved PSA50",
      "RECIST partial responses observed",
      "majority of TRAEs are Grade 1 or 2",
      "no Grade \u22654 TRAEs",
      "low rates of discontinuation or dose reduction"
    ],
    "safety": [
      "well tolerated to date",
      "majority of TRAEs are Grade 1 or 2",
      "no Grade \u22654 TRAEs",
      "low rates of discontinuation or dose reduction"
    ],
    "year": 2023,
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-766",
    "targets": [
      "AR L702H",
      "T878X",
      "H875Y"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metastatic castrate-resistant prostate cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-766",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-766",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [
      {
        "grade": 1,
        "total": 9,
        "fatigue": 3,
        "nausea": 2,
        "diarrhea": 3,
        "vomiting": 2,
        "dry_mouth": 2,
        "AST_increased": 2,
        "Cr_increased": 2,
        "hypophosphataemia": 2
      },
      {
        "grade": 2,
        "total": 7,
        "fatigue": 3,
        "nausea": 2,
        "diarrhea": 1,
        "dry_mouth": 0,
        "AST_increased": 0,
        "Cr_increased": 1,
        "hypophosphataemia": 0
      },
      {
        "grade": 3,
        "total": 2,
        "fatigue": 1,
        "AST_increased": 1,
        "Cr_increased": 0
      }
    ],
    "year": 2023,
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-766",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "CSPC"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1/2",
      "Phase 3"
    ],
    "claims": [
      "promising efficacy signals",
      "good tolerability profile",
      "precision medicine opportunity",
      "addresses an unmet need for durable and tolerable treatments"
    ],
    "safety": [],
    "year": 2023,
    "source": {
      "document": "June 2023 ARV-766 Disclosure_FINAL.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "First-in-human Safety Data"
    ],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [
      "androgen receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "clinical stage"
    ],
    "claims": [
      "early clinical proof-of-concept (safety, AR degradation, efficacy) demonstrated"
    ],
    "safety": [
      "early clinical safety data presented"
    ],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "prostate cancer",
      "mCRPC",
      "mCSPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "potentially first- and best-in-class AR-targeted therapy",
      "clear initial efficacy signal in dose escalation",
      "safety profile acceptable for potential use in frontline settings",
      "potential to address unmet patient need in 1L mCRPC and mCSPC"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ locally advanced or metastatic breast cancer",
      "2L+ ER+/HER2- mBC",
      "1L ER+ breast cancer"
    ],
    "therapeutic_areas": [
      "breast cancer"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "potential first- and best-in-class ER degrader",
      "early evidence of ER degradation",
      "no DLTs; dose escalation continues",
      "dose-proportional pharmacokinetics",
      "superior ER degradation and tumor inhibition in preclinical studies",
      "fast-to-market strategy"
    ],
    "safety": [
      "no DLTs"
    ],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-110 and ARV-471 have provided clinical proof-of-concept for PROTAC\u00ae degraders",
      "Degradation of AR and ER demonstrates proof-of-mechanism in human patients",
      "ARV-110 overcame prior resistance to AR therapy, showing the translation of ARV-110\u2019s preclinical profile into patient benefit"
    ],
    "safety": [
      "Safety initially observed in two different programs in two different patient populations"
    ],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 15
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "ER+/HER2- Breast Cancer",
      "FTLD-Tau",
      "PSP",
      "Alzheimer\u2019s",
      "MSA",
      "Parkinson\u2019s"
    ],
    "therapeutic_areas": [
      "oncology",
      "neuroscience"
    ],
    "clinical_phases": [
      "Exploratory",
      "Research",
      "IND Enabling",
      "Phase 1",
      "Phase 2/3"
    ],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 16
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "BCL6",
      "KRAS",
      "Myc",
      "HPK1",
      "mHTT"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 17
    }
  },
  {
    "company": "arvinas",
    "program": "BCL6",
    "targets": [
      "BCL6"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      ">95% degradation of BCL6 in vivo"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 18
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "KRAS"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "degraded >80% of KRAS G12C in vivo"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 19
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "mCRPC",
      "ER+/HER2- Breast Cancer",
      "B-cell Malignancies",
      "NSCLC",
      "CRC",
      "Pancreatic",
      "Solid Malignancies",
      "FTLD-TAU",
      "PSP",
      "AD",
      "MSA",
      "Parkinson\u2019s",
      "Huntington\u2019s",
      "Neurodegeneration"
    ],
    "therapeutic_areas": [
      "oncology",
      "I-O",
      "neuroscience"
    ],
    "clinical_phases": [
      "Exploratory",
      "Research",
      "IND Enabling",
      "Phase 1",
      "Phase 2/3"
    ],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 20
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 21
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 22
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "2020 TPD Summit_John H Presentation_Final-10.13.2020-V2.pdf",
      "slide": 23
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "Androgen Receptor",
      "AR-V7",
      "Estrogen Receptor",
      "Tau",
      "\u03b1-synuclein"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Prostate Cancer",
      "Breast Cancer",
      "FTLD-Tau",
      "PSP",
      "Alzheimer\u2019s",
      "MSA",
      "Parkinson\u2019s"
    ],
    "therapeutic_areas": [
      "cancer",
      "neurology"
    ],
    "clinical_phases": [
      "Discovery",
      "Lead Optimization",
      "IND Enabling",
      "Phase 1",
      "Phase 2/3"
    ],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [
      "Androgen Receptor"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "metastatic castration-resistant prostate cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "overcomes known resistance mechanisms to enzalutamide and abiraterone",
      "highly selective degradation of AR"
    ],
    "safety": [
      "initial safety/pharmacokinetic data shared Oct. 2019"
    ],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-110 inhibits tumor growth in an in vivo model of acquired enzalutamide resistance",
      "Daily and orally delivered ARV-110 significantly inhibited tumor growth",
      "10 mpk ARV-110: 70% tumor growth inhibition"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-110 demonstrates efficacy and plasma PSA reduction in an enzalutamide-insensitive patient derived xenograft model",
      "Orally delivered ARV-110 significantly inhibited tumor growth in these intrinsically enza-insensitive tumors (TGI: 100%)",
      "Plasma PSA levels following ARV-110 treatment significantly decreased vs. mice treated with vehicle or enzalutamide"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "favorable safety profile observed in the first 3 cohorts"
    ],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "locally advanced breast cancer",
      "metastatic breast cancer"
    ],
    "therapeutic_areas": [
      "breast cancer"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "80% of breast cancers are estrogen receptor (ER) positive",
      "Fulvestrant has demonstrated the value of ER degradation in breast cancer"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Superior tumor growth inhibition versus fulvestrant in a Y537S (ER gene mutation) PDX model",
      "Oral, daily dose of ARV-471 inhibited tumor growth by 99% at 10 mpk and 106% at 30 mpk in an ESR1 mutant PDX model",
      "Superior inhibitor of tumor growth compared to fulvestrant",
      "In corresponding quantitative western blots, ER is reduced by 79% and 88% in the 10 mpk and 30 mpk arms, respectively, vs. 63% for fulvestrant"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Achieved significant tumor shrinkage in combination with palbociclib (131% TGI) in an MCF-7 xenograft mouse model",
      "In all 10 mice in experiment, tumors reduced by >80%",
      "Superior tumor shrinkage (in combination with palbociclib) compared to fulvestrant (108% TGI)"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 15
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 16
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "No treatment-related AEs or DLTs were observed in the first cohort of ARV-471"
    ],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 17
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 18
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "neuroscience"
    ],
    "clinical_phases": [],
    "claims": [
      "Reduce intra\u2010 and extracellular pathologic tau",
      "Discriminate between wild type and pathologic tau",
      "Oral administration with BBB biodistribution"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 19
    }
  },
  {
    "company": "arvinas",
    "program": "Tg25081",
    "targets": [
      "tau"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [
      "tauopathy"
    ],
    "clinical_phases": [],
    "claims": [
      "Dose-Dependently Reduce tau in the Brain of Tauopathy Mice Following Parenteral Administration"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 20
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 21
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "human \u03b1-synuclein"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Oligomer\u2010specific PROTAC\u00ae molecules degrade human \u03b1\u2010synuclein aggregates in primary rat neurons",
      "PROTAC molecules degrade oligomeric \u03b1\u2010synuclein species",
      "PROTAC\u20101 and PROTAC\u20102 degrade \u03b1\u2010synuclein aggregates in primary rat neurons expressing human \u03b1\u2010synuclein",
      "PROTAC degraders were identified that specifically remove oligomeric \u03b1\u2010synuclein"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 22
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "Tau",
      "\u03b1-synuclein"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "FTDP",
      "Progressive supranuclear palsy",
      "ApoE4 AD risk allele carriers",
      "Synuclein mutations",
      "Multiple systems atrophy",
      "GBA PD risk allele carriers",
      "Alzheimer\u2019s",
      "Parkinson\u2019s"
    ],
    "therapeutic_areas": [
      "neuroscience"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 23
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 24
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 25
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 26
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 27
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 28
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "HER2",
      "BRAF"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "PROTAC degraders can disable target protein overexpression",
      "PROTAC degraders can differentiate between mutant and wild type proteins"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 29
    }
  },
  {
    "company": "arvinas",
    "program": "PROTAC 1",
    "targets": [
      "p38\u03b1"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 30
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [
      "AR"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "mCRPC"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "selectively degrades AR",
      "overcomes mechanisms of resistance to current standards of care"
    ],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 31
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-110",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "men with mCRPC"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Maximum Tolerated Dose/Recommended Phase 2 Dose/Safety",
      "Pharmacokinetics",
      "Anti-Tumor Activity (PSA, RECIST)",
      "Biomarkers"
    ],
    "safety": [
      "Dose increases dependent on toxicities: range 25% (if 1 DLT in 6 pts) to 100% (\u2264Grade 1 Adverse Events)"
    ],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 32
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2\u2010 advanced breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [
      "Maximum Tolerated Dose/Recommended Phase 2 Dose/Safety"
    ],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 33
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 34
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2020,
    "source": {
      "document": "NAPDC 2020-Arvinas-Berlin.pdf",
      "slide": 35
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": 2021,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Potential to be the endocrine backbone of choice for ER+/HER2- breast cancer treatment",
      "Designed to be an oral, high-potency ER degrader with favorable safety profile"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "estrogen receptor"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "clinical trial"
    ],
    "claims": [
      "Potential best-in-class estrogen receptor-targeting therapy",
      "clinical benefit rate of 42% (5 of 12 evaluable patients)",
      "clinical benefit rate of 40% (19 of 47 evaluable patients)",
      "ER degradation up to 89% continues to exceed reported degradation in fulvestrant and clinical-stage SERDs"
    ],
    "safety": [
      "Well-tolerated across all dose levels with no dose limiting toxicities up to 700mg",
      "Majority (89%) of AEs reported were grade 1/2"
    ],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- advanced breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Well tolerated at all dose levels",
      "No dose limiting toxicities",
      "MTD not reached",
      "Discontinuation rate <2% (1 out of 60)",
      "Dose reductions <2% (1 out of 60)",
      "Four patients experienced Gr 3 events potentially related to ARV-471 (headache lasting 1-day, single occurrence of asymptomatic increased amylase and lipase, nausea and asymptomatic QTc prolongation, and venous embolism after a minor procedure)"
    ],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": "AVR-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "40% clinical benefit rate (CBR) in 47 evaluable patients",
      "3 patients had confirmed PRs",
      "14 patients were ongoing at the time of data cutoff, including 2 who have been on treatment for >18 months"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "ARV-471 demonstrates promising anti-tumor activity in late-line patients"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "ER",
      "ESR1 mutant",
      "ESR1 wild-type"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Degradation up to 89%",
      "median 67%",
      "mean of 64%",
      "Degradation exceeds reported data for fulvestrant"
    ],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": "oral, high-potency ER degrader",
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "robust signals of efficacy",
      "early clinical benefit",
      "clinical benefit rate (CBR) of 40%",
      "confirmed partial responses",
      "maximum ER degradation of 89%",
      "89% of TRAEs were grade 1/2 in severity with no DLTs"
    ],
    "safety": [
      "favorable safety profile"
    ],
    "year": 2021,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1b",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "1L",
      "2L",
      "3L"
    ],
    "claims": [
      "Superior degradation to published fulvestrant and SERD data",
      "Strong efficacy signal in a predominantly ER-independent population",
      "Well tolerated"
    ],
    "safety": [
      "Well tolerated"
    ],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 15
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": null,
    "source": {
      "document": "ARV_SABCS_Clinical Program Update ARV-471.pdf",
      "slide": 16
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Potential best-in-class estrogen receptor-targeting therapy",
      "Favorable tolerability at both 200 mg qd and 500 mg qd",
      "No single TRAE in more than ~20% of patients",
      "In 35 patients treated at 200mg (RP3D), no dose reductions and only 1 discontinuation",
      "No signal for bradycardia or visual disturbance"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "favorable safety profile"
    ],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+ and HER2- advanced breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Median ER degradation was 69%",
      "Mean ER degradation was 71%"
    ],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "ALT increased (n=1)",
      "Neutropenia (n=1)",
      "Fatigue (n=1)",
      "QT prolongation (n=1)",
      "ECG T-wave abnormality (n=1)",
      "Back pain/spinal cord compression (n=1)"
    ],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "TRAEs": "Any TRAE",
        "200 mg QD": {
          "Grade 1": 13,
          "Grade 2": 13,
          "Grade 3/4": 2
        },
        "500 mg QD": {
          "Grade 1": 11,
          "Grade 2": 9,
          "Grade 3/4": 3
        },
        "Total": {
          "Grade 1": 24,
          "Grade 2": 22,
          "Grade 3/4": 5
        }
      },
      {
        "TRAEs": "Fatigue",
        "200 mg QD": {
          "Grade 1": 8,
          "Grade 2": 6,
          "Grade 3/4": 2
        },
        "500 mg QD": {
          "Grade 1": 3,
          "Grade 2": 4,
          "Grade 3/4": 0
        },
        "Total": {
          "Grade 1": 15,
          "Grade 2": 8,
          "Grade 3/4": 1
        }
      },
      {
        "TRAEs": "Nausea",
        "200 mg QD": {
          "Grade 1": 0,
          "Grade 2": 0,
          "Grade 3/4": 0
        },
        "500 mg QD": {
          "Grade 1": 0,
          "Grade 2": 0,
          "Grade 3/4": 0
        },
        "Total": {
          "Grade 1": 0,
          "Grade 2": 0,
          "Grade 3/4": 0
        }
      },
      {
        "TRAEs": "Arthralgia",
        "200 mg QD": {
          "Grade 1": 0,
          "Grade 2": 0,
          "Grade 3/4": 0
        },
        "500 mg QD": {
          "Grade 1": 0,
          "Grade 2": 0,
          "Grade 3/4": 0
        },
        "Total": {
          "Grade 1": 0,
          "Grade 2": 0,
          "Grade 3/4": 0
        }
      },
      {
        "TRAEs": "Hot flush",
        "200 mg QD": {
          "Grade 1": 0,
          "Grade 2": 0,
          "Grade 3/4": 0
        },
        "500 mg QD": {
          "Grade 1": 0,
          "Grade 2": 0,
          "Grade 3/4": 0
        },
        "Total": {
          "Grade 1": 0,
          "Grade 2": 0,
          "Grade 3/4": 0
        }
      },
      {
        "TRAEs": "AST increased",
        "200 mg QD": {
          "Grade 1": 3,
          "Grade 2": 1,
          "Grade 3/4": 0
        },
        "500 mg QD": {
          "Grade 1": 0,
          "Grade 2": 0,
          "Grade 3/4": 0
        },
        "Total": {
          "Grade 1": 7,
          "Grade 2": 2,
          "Grade 3/4": 1
        }
      }
    ],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 15
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- advanced breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 16
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 17
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 18
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [
      "Continued efficacy and favorable tolerability",
      "Strong CBR and mPFS in heavily treatment-resistant patients",
      "Favorable tolerability profile at 200 and 500 mg qd"
    ],
    "safety": [
      "No dose reductions and one discontinuation at 200 mg phase 3 dose"
    ],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 19
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "metastatic breast cancer"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "best-in-class ER-targeting therapy",
      "validated PROTAC protein degrader"
    ],
    "safety": [
      "favorable tolerability profile"
    ],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 20
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2022,
    "source": {
      "document": "SABCS IR deck December 8 2022.pdf",
      "slide": 21
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC\u00ae Degrader",
    "e3_ligase": null,
    "indications": [
      "neurodegenerative disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 1
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "neurodegenerative diseases",
      "idiopathic Parkinson\u2019s Disease",
      "Progressive Supranuclear Palsy"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "potential advantages and therapeutic benefits of ARV-102",
      "potential for ARV-102 to change the treatment paradigm in neurodegenerative diseases",
      "potential benefits of Arvinas' PROTAC\u00ae protein degraders",
      "potential of PROTAC\u00ae-induced LRRK2 degradation as a treatment for idiopathic Parkinson\u2019s Disease and Progressive Supranuclear Palsy"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 2
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Eliminate (rather than inhibit) disease-causing proteins",
      "Disrupt scaffolding functions of target proteins",
      "Bind and degrade classically 'undrugged' proteins",
      "Act iteratively (catalytically)",
      "Potential for oral delivery and achieve broad tissue distribution, including across the blood-brain-barrier"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 3
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "ER+/HER2- Breast Cancer",
      "Prostate Cancer"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Hematology",
      "Neuroscience"
    ],
    "clinical_phases": [
      "Preclinical",
      "Phase 1/1b",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 4
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "Parkinson\u2019s",
      "PSP"
    ],
    "therapeutic_areas": [
      "neurodegenerative diseases"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Potential to cross the blood brain barrier and degrade disease-causing proteins inside cells",
      "Specifically target pathogenic proteins in the brain",
      "Potential for oral therapies"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 5
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "idiopathic Parkinson\u2019s Disease",
      "Progressive Supranuclear Palsy"
    ],
    "therapeutic_areas": [
      "neurology"
    ],
    "clinical_phases": [
      "clinical trials"
    ],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 6
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 7
    }
  },
  {
    "company": "arvinas",
    "program": "LRRK2 PROTAC",
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Parkinson\u2019s disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 8
    }
  },
  {
    "company": "arvinas",
    "program": "LRRK2 PROTAC",
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "neurodegeneration"
    ],
    "therapeutic_areas": [
      "neurology"
    ],
    "clinical_phases": [],
    "claims": [
      "enhances lysosome-based degradation",
      "induces enhanced lysosomal clearance"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 9
    }
  },
  {
    "company": "arvinas",
    "program": "LRRK2 PROTAC",
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "PSP",
      "tauopathy"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "LRRK2 PROTAC degraders induce reduction of pathologic tau",
      "Reduction of pathologic (AT8) Tau induced by LRRK2 PROTAC"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 10
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-471",
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      ">85% LRRK2 degradation in deep brain regions of cynomolgus monkeys after oral dosing"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 11
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [
      "LRRK2"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Parkinson\u2019s Disease"
    ],
    "therapeutic_areas": [
      "Neurodegeneration"
    ],
    "clinical_phases": [],
    "claims": [
      "better target engagement",
      "enhanced potency",
      "pathway engagement"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 12
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 13
    }
  },
  {
    "company": "arvinas",
    "program": "ARV-102",
    "targets": [
      "LRRK2"
    ],
    "modality": "PROTAC",
    "e3_ligase": null,
    "indications": [
      "Parkinson's",
      "PSP"
    ],
    "therapeutic_areas": [
      "neurodegenerative diseases"
    ],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "Potential to cross the blood brain barrier and degrade disease-causing proteins inside cells",
      "Specifically target pathogenic proteins in the brain",
      "Potential for oral therapies"
    ],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 14
    }
  },
  {
    "company": "arvinas",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2024,
    "source": {
      "document": "Stifel_Neuro_2-14-2024final.pdf",
      "slide": 15
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 1
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 2
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 3
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 4
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed/refractory CLL"
    ],
    "therapeutic_areas": [
      "I&I"
    ],
    "clinical_phases": [
      "Phase 2",
      "Phase 1",
      "IND-enabling studies"
    ],
    "claims": [
      "83% ORR",
      "22.1-month median PFS"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 5
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [
      "BTK",
      "IKZF",
      "CBL-B",
      "BRAF",
      "IRAK4",
      "STAT6"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies",
      "Immuno-oncology",
      "Solid tumors",
      "Autoimmune cytopenia in CLL patients",
      "Rheumatoid arthritis and other inflammatory diseases",
      "Type 2 inflammatory diseases",
      "Inflammation / autoimmune"
    ],
    "therapeutic_areas": [
      "Oncology",
      "Inflammation & Immunology"
    ],
    "clinical_phases": [
      "Discovery",
      "IND-Enabling",
      "Phase 1A",
      "Phase 1B",
      "Phase 2/3"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 6
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "advanced CNS disease",
      "B-cell malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Removes both BTK enzymatic activity and scaffolding functions",
      "Degradation removes all functions of BTK unlike BTK inhibitors",
      "Acts catalytically with unprecedented potency",
      "Exquisitely selective degrader of BTK",
      "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
      "Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 7
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "advanced CNS disease",
      "B-cell malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Degradation removes all functions of BTK unlike BTK inhibitors",
      "Acts catalytically with unprecedented potency",
      "Exquisitely selective degrader of BTK",
      "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
      "Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 8
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies",
      "advanced CNS disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "First 'deg' with a potential best-in-class profile",
      "Selectively degrades BTK with no off-target degradation",
      "Degradation removes all functions of BTK unlike BTK inhibitors",
      "Acts catalytically with unprecedented potency",
      "Exquisitely selective degrader of BTK",
      "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
      "Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 9
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies",
      "advanced CNS disease"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "First 'deg' with a potential best-in-class profile",
      "Superior mutational coverage compared to BTK inhibitors",
      "Degradation removes all functions of BTK",
      "Acts catalytically with unprecedented potency",
      "Most potent cell killing",
      "Exquisitely selective degrader of BTK",
      "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
      "Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 10
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CNS disease",
      "B-cell malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Only BTK degrader to demonstrate clinical activity in patients with CNS disease including complete responses",
      "Degradation removes all functions of BTK unlike BTK inhibitors",
      "Acts catalytically with unprecedented potency",
      "Exquisitely selective degrader of BTK",
      "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
      "Crosses the blood brain barrier with clinical responses in patients with advanced CNS disease",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 11
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "relapsed or refractory chronic lymphocytic leukemia",
      "advanced CNS disease",
      "B-cell malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a"
    ],
    "claims": [
      "High objective response rate",
      "Prolonged PFS",
      "Degradation removes all functions of BTK",
      "Efficacy across all doses (50mg \u2013 600mg)",
      "Objective response rate (ORR) 83.0%",
      "Median progression-free survival (PFS) 22.1 months",
      "Acts catalytically with unprecedented potency",
      "Exquisitely selective degrader of BTK",
      "Active against wildtype BTK and overcomes BTK inhibitor resistance mutations",
      "Crosses the blood brain barrier with clinical responses",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 12
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 13
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a"
    ],
    "claims": [
      "Robust Response Rate",
      "Long-term Disease Control"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 14
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Relapsed/Refractory CLL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "Tolerable safety profile",
      "No dose-limiting toxicities",
      "No systemic fungal infections or Grade 4 infections of any kind reported"
    ],
    "safety": [
      "Comparable AE profile for patients overall and at the 600 mg dose selected per Project Optimus",
      "Single event of new onset atrial fibrillation consistent with the rate in the age-matched general population",
      "Three Grade 5 AEs (all deemed not related to bexobrutideg)"
    ],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 15
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 16
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 17
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "R/R CLL",
      "SLL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Accelerated Approval"
    ],
    "safety": [
      "Safety follow-up"
    ],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 18
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed or refractory chronic lymphocytic leukemia"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [
      "Designed to evaluate superiority to latest approved BTKi, pirtobrutinib"
    ],
    "safety": [
      "Safety follow-up"
    ],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 19
    }
  },
  {
    "company": "nurix",
    "program": "NX-5948-203",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL",
      "SLL"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1b",
      "Phase 2"
    ],
    "claims": [
      "ORR per iwCLL as assessed by IRC"
    ],
    "safety": [
      "Safety run-in",
      "Safety follow-up"
    ],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 20
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 21
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "r/r CLL",
      "2L+ CLL",
      "WM",
      "NHL",
      "I&I"
    ],
    "therapeutic_areas": [
      "oncology",
      "inflammatory"
    ],
    "clinical_phases": [
      "Phase 1b/2",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Accelerated Approval"
    ],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 22
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [
      "BTK",
      "STAT6",
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CSU",
      "HS",
      "MS",
      "wAIHA",
      "asthma",
      "AD",
      "BP",
      "COPD",
      "CRwNP",
      "EoE",
      "PN",
      "PsO",
      "PsA",
      "RA",
      "SLE",
      "CLE",
      "CD",
      "UC"
    ],
    "therapeutic_areas": [
      "inflammation",
      "autoimmune diseases"
    ],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 23
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [
      "BTK",
      "STAT6",
      "IRAK4"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "B-cell & myeloid cell-driven inflammation",
      "Type 2 inflammation",
      "IL-1R/TLR-driven inflammation"
    ],
    "therapeutic_areas": [
      "inflammation",
      "autoimmune diseases"
    ],
    "clinical_phases": [
      "Phase 1 SAD/MAD study",
      "IND-enabling studies ongoing"
    ],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 24
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 25
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 26
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2026,
    "source": {
      "document": "JPM 2026 Investor Presentation FINAL.pdf",
      "slide": 27
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL",
      "WM"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 1
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 2
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 3
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Potent and exquisitely selective degrader of BTK",
      "Active against wildtype BTK and demonstrated ability to overcome treatment-emergent resistance mutations",
      "Addresses BTK scaffolding function unlike current BTK inhibitors",
      "Acts catalytically driving degradation at low free-plasma concentrations",
      "Crosses the blood brain barrier and demonstrated clinical activity in the CNS",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 4
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Potent and exquisitely selective degrader of BTK",
      "Active against wildtype BTK and demonstrated ability to overcome treatment-emergent resistance mutations",
      "Addresses BTK scaffolding function unlike current BTK inhibitors",
      "Acts catalytically driving degradation at low free-plasma concentrations",
      "Crosses the blood brain barrier and demonstrated clinical activity in the CNS",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 5
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Potent and exquisitely selective degrader of BTK",
      "Active against wildtype BTK and demonstrated ability to overcome treatment-emergent resistance mutations",
      "Addresses BTK scaffolding function unlike current BTK inhibitors",
      "Acts catalytically driving degradation at low free-plasma concentrations",
      "Crosses the blood brain barrier and demonstrated clinical activity in the CNS",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 6
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [],
    "claims": [
      "Potent and exquisitely selective degrader of BTK",
      "Active against wildtype BTK and demonstrated ability to overcome treatment-emergent resistance mutations",
      "Addresses BTK scaffolding function unlike current BTK inhibitors",
      "Acts catalytically driving degradation at low free-plasma concentrations",
      "Crosses the blood brain barrier and demonstrated clinical activity in the CNS",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 7
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL",
      "NHL"
    ],
    "therapeutic_areas": [
      "central nervous system",
      "B-cell malignancies"
    ],
    "clinical_phases": [],
    "claims": [
      "Potent and exquisitely selective degrader of BTK",
      "Active against wildtype BTK and demonstrated ability to overcome treatment-emergent resistance mutations",
      "Addresses BTK scaffolding function unlike current BTK inhibitors",
      "Acts catalytically driving degradation at low free-plasma concentrations",
      "Crosses the blood brain barrier and demonstrated clinical activity in the CNS",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 8
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed or refractory chronic lymphocytic leukemia"
    ],
    "therapeutic_areas": [
      "B-cell malignancies"
    ],
    "clinical_phases": [
      "Phase 1a"
    ],
    "claims": [
      "High objective response rate and prolonged PFS in r/r CLL patients",
      "Objective response rate (ORR) 83.0%",
      "Median progression-free survival (PFS) 22.1 months",
      "Potent and exquisitely selective degrader of BTK",
      "Active against wildtype BTK and demonstrated ability to overcome treatment-emergent resistance mutations",
      "Addresses BTK scaffolding function unlike current BTK inhibitors",
      "Acts catalytically driving degradation at low free-plasma concentrations",
      "Crosses the blood brain barrier and demonstrated clinical activity in the CNS",
      "Demonstrates robust clinical activity in difficult to treat B-cell malignancies"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 9
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed/refractory CLL",
      "2L+ CLL",
      "1L+ CLL",
      "WM",
      "NHL"
    ],
    "therapeutic_areas": [
      "BTK mediated diseases"
    ],
    "clinical_phases": [
      "Phase 1/2",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "Accelerated Approval"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 10
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 11
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg (NX-5948)",
    "targets": [
      "Bruton\u2019s Tyrosine Kinase (BTK)"
    ],
    "modality": "Degrader",
    "e3_ligase": null,
    "indications": [
      "Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL)",
      "Waldenstr\u00f6m Macroglobulinemia"
    ],
    "therapeutic_areas": [
      "Chronic Lymphocytic Leukemia",
      "B Cell Lymphomas"
    ],
    "clinical_phases": [
      "Phase 1a/b"
    ],
    "claims": [
      "Demonstrates Rapid and Durable Clinical Responses",
      "Shows High Clinical Activity and Tolerable Safety"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 12
    }
  },
  {
    "company": "nurix",
    "program": "NX-5948",
    "targets": [
      "Bruton\u2019s Tyrosine Kinase (BTK)"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL)",
      "Waldenstr\u00f6m Macroglobulinemia"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a/b"
    ],
    "claims": [
      "Demonstrates Rapid and Durable Clinical Responses",
      "Shows High Clinical Activity and Tolerable Safety"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 13
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg (NX-5948)",
    "targets": [
      "Bruton\u2019s tyrosine kinase (BTK)"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "relapsed/refractory chronic lymphocytic leukemia (CLL)"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a/b"
    ],
    "claims": [
      "demonstrates rapid and durable clinical responses"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 14
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed/refractory B-cell malignancies",
      "CLL/SLL",
      "WM/NHL",
      "MZL",
      "FL",
      "WM",
      "MCL",
      "DLBCL",
      "PCNSL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 15
    }
  },
  {
    "company": "nurix",
    "program": "NX-5948-301",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL",
      "SLL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [],
    "safety": [
      {
        "discontinued_treatment": 22,
        "reasons": {
          "radiographic_progression": 9,
          "clinical_progression": 5,
          "adverse_event": 4,
          "death": 1,
          "physician_decision": 1,
          "prohibited_medication_procedure": 1,
          "patient_withdrew_consent": 1
        }
      },
      {
        "discontinued_treatment": 13,
        "reasons": {
          "clinical_progression": 5,
          "adverse_event": 4,
          "radiographic_progression": 2,
          "death": 1,
          "physician_decision": 1
        }
      }
    ],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 16
    }
  },
  {
    "company": "nurix",
    "program": "NX-5948-301",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL",
      "SLL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 17
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 18
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 19
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      {
        "any_teae": {
          "all_patients": {
            "n": 126,
            "percentage": 90.5
          },
          "600_mg": {
            "n": 70,
            "percentage": 85.7
          }
        }
      },
      {
        "treatment_related": {
          "all_patients": {
            "n": 95,
            "percentage": 75.4
          },
          "600_mg": {
            "n": 51,
            "percentage": 72.9
          }
        }
      },
      {
        "grade_3_or_higher": {
          "all_patients": {
            "n": 62,
            "percentage": 49.2
          },
          "600_mg": {
            "n": 31,
            "percentage": 44.3
          }
        }
      },
      {
        "treatment_related_sae": {
          "all_patients": {
            "n": 31,
            "percentage": 24.6
          },
          "600_mg": {
            "n": 18,
            "percentage": 25.7
          }
        }
      },
      {
        "treatment_related_grade_5": {
          "all_patients": {
            "n": 7,
            "percentage": 5.6
          },
          "600_mg": {
            "n": 3,
            "percentage": 4.3
          }
        }
      },
      {
        "treatment_related_discontinuation": {
          "all_patients": {
            "n": 27,
            "percentage": 21.4
          },
          "600_mg": {
            "n": 10,
            "percentage": 14.3
          }
        }
      },
      {
        "treatment_related_dlt": {
          "all_patients": {
            "n": 3,
            "percentage": 2.4
          },
          "600_mg": {
            "n": 1,
            "percentage": 1.4
          }
        }
      }
    ],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 20
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Tolerable safety profile consistent with prior disclosures",
      "No dose-limiting toxicities",
      "No systemic fungal infections or Grade 4 infections of any kind reported",
      "Single event of new onset atrial fibrillation consistent with the rate in the age-matched general population",
      "3 Grade 5 AEs (death not otherwise specified; pulmonary embolism; pneumonia; all deemed not related to bexobrutide)"
    ],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 21
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 22
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 23
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 24
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 25
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 26
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg (NX-5948)",
    "targets": [
      "BTK"
    ],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed/refractory CLL",
      "SLL"
    ],
    "therapeutic_areas": [
      "oncology"
    ],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "well tolerated in a heavily pretreated population",
      "ORR of 83%",
      "CR rate of 4.3%",
      "Median DOR of 20.1 months",
      "Median PFS of 22.1 months",
      "higher ORR and superior PFS at the 600 mg dose"
    ],
    "safety": [
      "tolerable safety profile consistent with prior disclosures"
    ],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 27
    }
  },
  {
    "company": "nurix",
    "program": "NX-5948",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Ph1a/b"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 28
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg (NX-5948)",
    "targets": [
      "Bruton\u2019s Tyrosine Kinase (BTK)"
    ],
    "modality": "degrader",
    "e3_ligase": null,
    "indications": [
      "Waldenstr\u00f6m Macroglobulinemia"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a/b"
    ],
    "claims": [
      "High Clinical Activity",
      "Tolerable Safety"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 29
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "relapsed/refractory B-cell malignancies"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a/b"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 30
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 31
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [
      "Neutropenia",
      "Petechiae",
      "Diarrhea",
      "Anemia",
      "Purpura/contusion",
      "Thrombocytopenia",
      "Fall",
      "Upper respiratory tract infection",
      "Cough",
      "Dizziness",
      "Hematoma",
      "Pain in extremity",
      "Post-procedural hemorrhage"
    ],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 32
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "WM"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a",
      "Phase 1b"
    ],
    "claims": [
      "High Overall Response Rate"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 33
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 34
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": "small molecule",
    "e3_ligase": null,
    "indications": [
      "Waldenstr\u00f6m macroglobulinemia"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1"
    ],
    "claims": [
      "can overcome treatment-emergent BTKi resistance mutations",
      "disrupt BTK scaffolding"
    ],
    "safety": [
      "well tolerated",
      "AEs predominantly low grade",
      "most common AEs were neutropenia, petechiae, diarrhea, anemia, purpura/contusion, and thrombocytopenia",
      "No atrial fibrillation observed",
      "No DLTs noted",
      "two TEAEs led to drug discontinuation",
      "no Grade 5 AEs"
    ],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 35
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 36
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a",
      "Phase 2",
      "Phase 3"
    ],
    "claims": [
      "ORR of 83.0%",
      "median DOR of 20.1 months",
      "median PFS of 22.1 months"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 37
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1a"
    ],
    "claims": [
      "ORR of 83.0%",
      "median DOR of 20.1 months",
      "median PFS of 22.1 months"
    ],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 38
    }
  },
  {
    "company": "nurix",
    "program": "Bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "Relapsed/refractory CLL",
      "SLL"
    ],
    "therapeutic_areas": [
      "chronic lymphocytic leukemia"
    ],
    "clinical_phases": [
      "Phase 2"
    ],
    "claims": [
      "Potential to address a current and anticipated future unmet medical need"
    ],
    "safety": [
      "600 mg cleared for pivotal studies in r/r CLL"
    ],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 39
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "chronic lymphocytic leukemia",
      "small lymphocytic lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 3"
    ],
    "claims": [
      "will outperform all components of the investigator\u2019s choice arm"
    ],
    "safety": [
      "safety follow-up"
    ],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 40
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "chronic lymphocytic leukemia",
      "small lymphocytic lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b",
      "Phase 2"
    ],
    "claims": [
      "maximizes 2L market share opportunity",
      "provides potential path to 1L CLL"
    ],
    "safety": [
      "Safety Run-in"
    ],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 41
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "B-cell malignancies",
      "chronic lymphocytic leukemia",
      "Waldenstr\u00f6m macroglobulinemia",
      "non-Hodgkin lymphoma"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [
      "83% ORR with a 20.1 month median duration of response in CLL",
      "Well tolerated with low rate of discontinuation in CLL",
      "Progression free survival tracking well above standard of care with a current estimate of 22.1 months in CLL",
      "75% ORR in WM with responses deepening over time including 3 VGPRs",
      "Median duration of response was not reached in WM",
      "130 NHL patients treated to date in NX-5948-301",
      "Multiple CR/CMRs observed in all cohorts (DLBCL, MCL, FL, MZL, PCNSL)"
    ],
    "safety": [
      "Well tolerated with low rate of discontinuation in CLL"
    ],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 42
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 43
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 44
    }
  },
  {
    "company": "nurix",
    "program": "bexobrutideg",
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [
      "CLL",
      "NHL",
      "I&I"
    ],
    "therapeutic_areas": [],
    "clinical_phases": [
      "Phase 1b",
      "Phase 1a/b",
      "Phase 1 SAD/MAD",
      "Phase 1",
      "Phase 3"
    ],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 45
    }
  },
  {
    "company": "nurix",
    "program": null,
    "targets": [],
    "modality": null,
    "e3_ligase": null,
    "indications": [],
    "therapeutic_areas": [],
    "clinical_phases": [],
    "claims": [],
    "safety": [],
    "year": 2025,
    "source": {
      "document": "ASH 2025 Investor conference call - FINAL On site.pdf",
      "slide": 46
    }
  }
]